A translational approach to the genetics of renal disease by Doorenbos, Carolina Roelfiena Cornelia,
A translational approach to
the genetics of renal diseaseDoorenbos, C.R.C.
A translational approach to the genetics of renal disease
PhD thesis, The University Medical Center Groningen (UMCG),
University of Groningen, the Netherlands
with summary in Dutch
First published 2012
Cover: H. Doorenbos
Lay-out: C.R.C. Doorenbos
Printing: CPI W ohrmann Print Service
Typeset from a TEX/L ATEX le prepared by Vibor Jeli c and adapted by C.R.C. Doorenbos
ISBN 978-90-367-5808-6
ISBN 978-90-367-5809-3 (electronic version)A translational approach to
the genetics of renal disease
Proefschrift
ter verkrijging van het doctoraat in de
Medische Wetenschappen
aan de Rijksuniversiteit Groningen
op gezag van de
Rector Magnicus, dr. E. Sterken,
in het openbaar te verdedigen op
maandag 12 november 2012
om 16.15 uur
door
Carolina Roelena Cornelia Doorenbos
geboren op 8 december 1982
te VoorschotenPromotor: Prof. dr. G.J. Navis
Copromotor: Dr. M.H. de Borst
Beoordelingscommissie: Prof. dr. T.P. Links
Prof. dr. H. Snieder
Prof. dr. P. HeeringaContents
Abbreviations iii
1 Introduction 1
2 Urinary Albumin Loci in Mice and Apoe 15
3 Possible renoprotection by vitamin D in chronic renal disease 31
4 Vitamin D pathway SNPs in renal transplantation 55
5 Creatinine-Based Renal function Equations in Renal Transplant Recip-
ients 73
6 Antiproteinuric treatment reduces urinary loss of vitamin D 93
7 VDBP as a tubulointerstitial damage marker 107
8 Summary and general discussion 123
Nederlandse samenvatting 134
Dankwoord 141
List of publications 145
iCONTENTS
iiAbbreviations
-SMA Alpha-smooth muscle actin, a marker for interstitial myobroblast transforma-
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ltration rate, regarded as the renal function
LD Linkage disequilibrium, association of alleles in a frequency dierent from what is
expected based on random recombination
NMD Nonsense mediated decay, degradation of mRNA transcripts caused by genetic
variation
QTL Quantitative trait locus/loci, area in the genome associated with a certain pheno-
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Introduction
Chronic kidney disease (CKD) is a major global health problem. In the Netherlands 12% of
the population has an estimated glomerular ltration rate (eGRF) of < 60 ml/min and/or
microalbuminuria or proteinuria (1). The prevalence in the United States of America is
similar, with 13% of the adult population aected by CKD (2). CKD is the common
denominator of a wide variety of diseases aecting the kidney with dierent etiologies
and courses. Whereas in some patients mild renal disease may rapidly progress to end
stage renal disease requiring dialysis and ultimately a renal transplant, in others renal
disease will remain mild or worsen only slowly with aging. Dierentiating between pa-
tients with dierent prognoses may help to allocate treatment and preventive measures
more eciently. Considering the relentlessly progressive course in many patients, better
identication of mechanisms, and of novel targets for intervention might be even more
rewarding. The rapid development of genetics in medicine over the last decades has re-
sulted in a rapidly expanding body of data and resources that have allowed important
progress in understanding the pathophysiology of several kidney disorders. Studying the
genetics of renal disease could potentially uncover novel pathways involved in renal dis-
ease progression and deepen our understanding of previously identied pathways to allow
for more reliable risk stratication and better suited treatment. It is a major challenge
however, to translate the ndings from genetic studies into insights that are of benet to
renal patients. This thesis introduction oers some background in the genetic approach to
studying disease mechanisms and discovering novel treatment options and continues with
highlighting several renal disease phenotypes and their importance in genetic studies.
Genetics of renal damage
Many types of renal disease are considered to be at least in part genetically determined
(3). The classical example of genetically determined diseases are Mendelian diseases:
these disorders are typically caused by one mutation in a single gene, with a large eect
on occurrence or severity of the disease. Over the last decades, progress in genetics has
allowed for the identication of a large number of such Mendelian disorders, many very
rare, some somewhat more common. In nephrology, such genetic variants are for instance
those in the CTNS gene in cystinosis (4), the COL4A3, COL4A4 and COL4A5 genes
encoding the alpha-3, alpha-4, and alpha-5 chains of type IV collagen in Alport syndrome
(5) and the PKD1, PKD2 and PKHD1 genes in autosomal dominant and autosomal
recessive polycystic kidney disease (6{8).
Common complex diseases on the other hand, are determined by a combination of mul-
tiple genetic and multiple environmental factors that each in itself exert just a small eect
on the occurrence of the disease phenotype. This applies to more common nephropathies
like diabetic nephropathy, IgA nephropathy and renal vascular disease. Whereas their
cause is not a single genetic mutation, a relevant genetic component is likely to be present.
Since the eect size of genetic variants contributing to common complex diseases is gener-
ally very modest, establishing the genetic basis of common complex diseases is considerably
more complicated than of Mendelian disorders.
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Gene discovery strategies
Several approaches are available to elucidate which genes may be involved in multifactorial
diseases, as summarized in Table 1.1. Linkage analysis and association analysis aim to
identify genetic markers such as single nucleotide polymorphisms (SNPs) or copy number
variations that are associated with disease. In linkage analysis both aected and unaected
individuals of the same families are studied. This strategy is suitable to identify genetic
regions with a large eect on a phenotype. Association analysis is usually done in a case-
control study design and does not require inclusion of family members, making it easier
to recruit large numbers of study participants. Association analysis is used to identify
common variants with a small eect on phenotype (9).
A general distinction between genetic discovery strategies is the division between
hypothesis-free and hypothesis-driven approaches. In hypothesis-free studies genetic vari-
ation in the whole genome is studied, allowing for unbiased discovery of both known and
novel variants, not restricted by prior assumptions or prior knowledge. This in princi-
ple allows for the discovery of truly novel genes and pathways. Hypothesis-driven stud-
ies focus on a part of the genome, depending on the hypothesis, that can be based on
prior pathophysiological knowledge or on ndings from hypothesis-free studies. Usually
a combination of hypothesis-free and hypothesis-driven approaches is used, to enable the
identication of novel variants in a hypothesis-free approach, followed by testing of the
resulting hypothesis in a hypothesis-driven study design.
Hypothesis-free gene discovery
The Genome Wide Association Study (GWAS) is a subtype of association study that
covers variation in the whole genome. This kind of study does not require prior knowledge
of disease etiology and can therefore be described as hypothesis-free. The same applies to
Mapping by Admixture Linkage Disequilibrium (MALD). This analysis can be regarded as
positioned between linkage analysis and association analysis because it uses non-random
association of genetic variations due to admixture. Admixture is the forming of a new
population out of individuals from genetically very dierent parental populations. In
their ospring many more genetic variants are in linkage disequilibrium, because little
recombination has taken place since the combination of the ancestral populations. This
means that when a genetic variant on a chromosome is found to originate from one parental
population, many more surrounding markers are expected to originate from the same
parental population than in a genetically stable population. Instead of using 300,000-
1,000,000 markers to assess the whole genome, 2,000-3,000 markers suce in an admixed
population (10).
The principle of an admixed population study can be applied in a controlled form
in animal models, because their genome is usually well characterized and mating can be
controlled. Through mating of closely related individuals for many generations animal
strains have become homozygous for almost all loci. When two strains are intercrossed,
genetic variation in the whole genome can be covered with relatively few markers.
In chapter 2 the renal phenotype albuminuria, a hallmark of progressive renal disease,
is studied in an intercross of the progeny of albuminuric A/J mice and non-albuminuric
B6 mice. The genome of the study population was manipulated to create a group of Apoe
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knockout mice and a group not knocked out for Apoe to study the eect of the presence
or absence of APOE on the development of albuminuria. An area of the genome that
is associated with a quantitative trait like albuminuria is referred to as a quantitative
trait locus (QTL). A QTL usually spans such a large area of a chromosome, that it is
not possible to attribute the association to a specic gene. In order to narrow the QTL,
concordance between the genomes of species is taken into account. Species like mice,
rats and humans have many genes in common, but concordant genes may be located
on dierent chromosomes. The concordant regions of a specic QTL identied in one
species may therefore be scattered over several chromosomes in a second species. When
a QTL for that same trait is found on one of these chromosomes of the second species,
the concordant regions of the original QTL on other chromosomes can likely be ruled out.
Using QTL from several species therefore narrows down the number of genes, making it
easier to identify the gene that is associated with the phenotype. Figure 1.1 illustrates
the principle of concordance of QTL between species and the use of several QTL studies
to narrow the locus of interest. This approach is reviewed in detail elsewhere (11).
Another hypothesis-free approach to candidate gene discovery is the measurement of
gene expression by means of a microarray. RNAs, microRNAs and proteins can be used
as readout parameters (12). Furthermore, to identify the eects of genetic variation in
regulatory regions on gene expression, expression quantitative trait loci (eQTL) can be
studied. Instead of a disease phenotype the expression of a gene related to the disease of
interest is chosen as a phenotype (9). The loci identied using hypothesis-free candidate
gene discovery can be studied in closer detail using hypothesis-driven gene discovery.
Hypothesis-driven gene discovery
Hypothesis-driven gene discovery is a more focused approach to study and identify can-
didate genes. This strategy requires a hypothesis about genes or pathways that may
be involved in the disease of interest, either based on prior knowledge about biological
plausibility or on results from hypothesis-free gene discovery studies. This thesis contains
several studies addressing the role of the vitamin D pathway, which was recently identied
as a pathway that could be involved in the progression of renal disease.
Vitamin D
Alterations in the vitamin D metabolism are well-established to be a consequence of re-
nal disease, aecting bone and mineral metabolism. Moreover, population studies have
shown that a considerable part of the Dutch population is vitamin D decient (13). In
patients with renal disease vitamin D deciency is more prevalent, and proportionate
to the decrease of GFR (14). This may have clinically relevant consequences, as vita-
min D deciency has been associated with worse cardiovascular outcome and mortality.
In CKD patients, several mechanisms are proposed to explain lower vitamin D levels.
The activity of 24-hydroxylase, the enzyme that metabolizes both 25-hydroxyvitamin D
and 1,25-dihydroxyvitamin D to inactive metabolites, may be increased. Conversely,
1alpha-hydroxylase, which metabolizes 25-hydroxyvitamin D to the active 1,25-dihydroxy-
vitamin D may be suppressed in CKD by broblast growth factor 23 (15). The latter
would explain lower levels of 1,25-dihydroxyvitamin D, but would not explain low lev-
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Figure 1.1: Concordance of kidney disease loci in rats, mice, and humans. The
numbered bars with ticks represent rat chromosomes, the kidney disease loci are shown as colored
bars for rat, red stars for mouse and explosions for human. FHH, fawn-hooded hypertensive rat;
ACI, August-Copenhagen-Irish rat; MWF, Munich-Wistar-Fromter rat; LEW, Lewis rat; SHR,
spontaneously hypertensive rat; SS, Dahl salt-sensitive rat; BUF, Bualo rat; WKY, Wistar-
Kyoto rat. Distances are shown in megabases according to the Ensembl database (release 21.3b.1).
Quantitative trait loci (QTL) intervals were estimated using the Ensembl positions of the reported
markers closest to the edges of the QTL. Adapted from Korstanje et al. (11).
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els of 25-hydroxyvitamin D which are also very common in CKD. Reduced exposure to
sunlight and poor intake of vitamin D could at least in part explain lower availability
of vitamin D or its precursors in the circulation. The association of impaired vitamin
D status with a wide range of outcomes, be it renal, cardiovascular and psychological,
has fueled renewed interest, and discovery of several novel potential pathways involved in
the impact of vitamin D deciency on health status, including suppression of the renin-
angiotensin-aldosterone system, and anti-in
ammatory and immunomodulatory eects.
The novel insights in the diverse roles of the vitamin D pathway are reviewed in chapter
3.
Hypothesis-driven gene discovery: focus on the vitamin D pathway
In chapter 4 the pathway of interest is the vitamin D pathway, which was studied using a
case-control design. SNPs in four genes of this pathway were genotyped in renal transplant
recipients and their donors under the assumption that vitamin D plays a modulating role
in the development of end stage renal disease (ESRD). Results of a hypothesis-driven
study like this identify variations in specic genes or their regulatory region(s). Genetic
variations that are identied in this way are not necessarily causative. The causative
variation may also be closely linked to the identied SNP and be inherited together, a
phenomenon called linkage disequilibrium. Regardless of the gene discovery strategy the
denition of the phenotype is essential. With a cleaner phenotype, nding a signicant
association with a relevant gene becomes more likely.
Dening the renal phenotype: diagnosis and monitoring
of renal disease
Renal function
Renal disease can be studied and monitored in dierent ways. Studying the urine is
probably the oldest way: the ancient Egyptians already described polyuria as a disease
symptom, possibly referring to diabetes mellitus. Besides analysis of the urine, doctors
can nowadays also rely on serum measurements, kidney biopsies and imaging techniques
for diagnosis and monitoring of renal disease. In larger studies and in the absence of a
clinical reason for a kidney biopsy, however, the available data for renal disease classi-
cation are much more limited. The current classication for chronic kidney disease is
based on estimated GFR in combination with albuminuria. For estimation of GFR serum
creatinine is the currently recommended assessment parameter. Obviously, shortcomings
in GFR estimates will impact on the quality of studies using this phenotype. Since serum
creatinine levels are not only in
uenced by renal function but also by amongst others
muscle mass and diet, the 24-hour creatinine clearance is found to be a better marker
to estimate renal function than serum creatinine itself. However, creatinine clearance is
the result of both glomerular ltration and tubular handling. Measuring the clearance of
infused radioactive markers that are not excreted or reabsorbed by the tubules is therefore
more accurate than creatinine clearance and is considered the gold standard of glomerular
ltration measurements.
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Though very precise, measuring the clearance of an infused radioactive marker like 125I-
iothalamate is time consuming, expensive and burdensome for the patient, and therefore
impractical for routine clinical practice. To approximate the glomerular ltration rate
(GFR), renal function equations have been developed. However, most equations are based
on serum creatinine levels and are therefore subject to its limitations. This can be adjusted
by adding biometrical data like gender, age, weight, height or body mass index to the
equations. Because serum creatinine and the biometric data that are required for renal
function equations are relatively easily available in large populations, these equations are
often used as the renal phenotype in population studies. Still, equations perform modest
at best in predicting the true GFR. Improvement of renal function equations could benet
both population studies as well as individual patients. In renal transplant recipients for
example renal function equations are used to monitor graft function and to predict graft
failure. An analysis of bias of renal function equations in a cohort of renal transplant
recipients can be found in chapter 5.
Urinary protein loss
Besides a decreased glomerular ltration rate, the presence of proteinuria is also associated
with adverse outcome in renal disease (1). Proteinuria is both a symptom of glomerular
damage and a causal factor in the development of tubulointerstitial damage (16). Albumin
is the most prevalent protein in the urine of proteinuric patients. In the healthy kidney
small amounts of albumin are ltered by the glomerulus, and subsequently reabsorbed in
the proximal tubule. In the proteinuric kidney more albumin is ltered by the glomerulus
than is absorbed by the tubules resulting in urinary loss of albumin. This is illustrated
in Figure 1.2 . Whether albuminuria is mainly caused by glomerular damage resulting in
increased permeability for albumin (17) or by tubular damage preventing full reuptake of
albumin (18), or a combination of these two, is a matter of debate. Nevertheless, albu-
minuria is associated with mortality in the general population (19) and with ESRD and
mortality in CKD patients (20). Given its relatively robust performance as a predictive
marker of clinical outcome in CKD, albuminuria was chosen as the read-out parameter
for renal damage in the genetic study in mice in chapter 2.
Tubulointerstitial brosis and proximal tubular function
Whereas albuminuria is considered to be an acceptable marker associated with renal dis-
ease progression, a stronger predictor of subsequent progressive renal function loss in
chronic kidney disease is provided by the severity of renal interstitial scarring (brosis),
a form of tubular damage (21). However, the assessment of renal interstitial brosis re-
quires a renal biopsy, which hampers its use in clinical practice and study populations.
Reliable, non-invasive assessment of tubulointerstitial damage would therefore be of great
value in the development and monitoring of renoprotective therapy. Also it would be
very useful to identify biomarkers of tubular damage that may re
ect interstitial brosis
in an early stage, since early pro-brotic changes might still be reversible (22). Among
tubular damage markers currently being investigated for clinical utility are kidney injury
molecule 1 (KIM-1) (23), N-acetyl--d-glucosaminidase (NAG) (24), beta-2-microglobulin
(25), neutrophil gelatinase-associated lipocalin (NGAL) (26) and vitamin D-binding pro-
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Albumin Albumin
Complete reuptake of albumin
in renal proximal tubule
Partial reuptake of albumin
in renal proximal tubule
No albuminuria Albuminuria
Glomerulus Glomerulus
Healthy kidney Proteinuric kidney
Figure 1.2: Mechanism of proteinuria illustrated with the ltration and reuptake
of albumin. Under normal conditions, absorption of ltered (low-molecular weight) proteins
and albumin is complete, and accordingly virtually no proteins are present in urine. In condi-
tions of proteinuria, glomerular ltration is inappropriately increased, and exceeds the tubular
reabsorptive capacity, even if the latter is normal.
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tein. Vitamin D-binding protein (VDBP) is a 58 kDa protein, which has the transport of
vitamin D metabolites through the circulation as its main function. VDBP is ltered by
the glomerulus and subsequently reabsorbed by proximal tubular cells through receptor-
mediated uptake. Tubular reabsorption of VDBP is mediated by megalin and cubulin
receptors (27, 28), and is energy-consuming. Therefore relatively mild tubular injury
would already be expected to result in urinary VDBP loss. Such urinary VDBP loss has
been suggested to aect vitamin D status in patients with nephrotic range proteinuria
(29). Therefore, we studied urinary VDBP from two dierent perspectives. First, in
chapter 6, we investigated its possible contribution to vitamin D deciency in proteinuric
renal patients, and second, in chapter 7, we investigated whether urinary VDBP could be
used as a tubulointerstitial damage marker.
Thesis outline
The thesis outline, demonstrating the link between the dierent chapters is illustrated in
Figure 1.3 .
Chapter 2 describes the discovery of quantitative trait loci in a mouse cross between
albuminuric and non-albuminuric mice. The results in Apoe knock-out mice and
mice with Apoe are compared.
Chapter 3 reviews the renoprotective roles of vitamin D beyond the classical mineral
metabolism.
Chapter 4 compares common genetic variants in the vitamin D pathway in human renal
transplant recipients and their donors.
Chapter 5 studies the performance of renal function equations in renal transplant recip-
ients.
Chapter 6 tests the hypothesis that low vitamin D levels in proteinuric patients are
caused by urinary loss of vitamin D bound to vitamin D-binding protein.
Chapter 7 describes vitamin D-binding protein as a potential novel marker of early
interstitial brosis and tubular damage in both animals and humans.
Chapter 8 summarizes all results of this thesis and puts them in a broader perspective.
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Renal phenotype
Hypothesis free approach Hypothesis driven 
approach
eGFR
Fibrosis
Chapter 2
Quantitative trait loci for urinary albumin in 
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Chapter 3
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Chapter 4
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Chapter 7
Possible renoprotection by vitamin D in chronic 
renal disease: beyond mineral metabolism
Chapter 6
Antiproteinuric  treatment  reduces  urinary  loss  of 
vitamin D-binding protein but does not affect vitamin 
D status in patients with chronic kidney disease
Chapter 5
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Renal 
function
VDBP
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Figure 1.3: Thesis outline.
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Abstract
We investigated the eect of apolipoprotein E (Apoe) on albuminuria in the males of
two independent F2 intercrosses between C57BL/6J and A/J mice, using wild-type
inbred strains in the rst cross and B6-Apoe
-/- animals in the second cross. In the rst
cross, we identied three quantitative trait loci (QTL): chromosome (Chr) 2 [LOD 3.5,
peak at 70 cM, condence interval (C.I.) 28 88 cM]; Chr 9 (LOD 2.0, peak 5 cM, C.I.
5 25 cM); and Chr 19 (LOD 1.9, peak 49 cM, C.I. 23 54 cM). The Chr 2 and Chr 19
QTL were concordant with previously found QTL for renal damage in rat and human.
The Chr 9 QTL was concordant with a locus found in rat. The second cross, testing
only Apoe
-/- progeny, did not identify any of these loci, but detected two other loci on
Chr 4 (LOD 3.2, peak 54 cM, C.I. 29 73 cM) and Chr 6 (LOD 2.6, peak 33 cM, C.I.
11 61 cM), one of which was concordant with a QTL found in rat. The dependence of
QTL detection on the presence of Apoe and the concordance of these QTL with rat and
human kidney disease QTL suggest that Apoe plays a role in renal damage.
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Introduction
Chronic kidney disease is a growing medical problem caused by various environmental
and genetic factors. Identifying genes underlying common forms of kidney disease in
humans has proven dicult, expensive, and time consuming. However, quantitative trait
loci (QTL) for several complex traits are concordant among mice, rats, and humans,
suggesting that genetic ndings from animal models are relevant to human disease (1{
4). This has been supported by the discovery of human disease genes from candidates
identied in mouse (5, 6). With respect to chronic kidney disease, QTL analysis using
mice is likely to contribute new ndings in the near future (7).
The gene encoding apolipoprotein E (APOE) has been implicated in chronic kidney
disease. Several human association studies have shown an association of APOE with
renal damage parameters in dierent groups of patients (8{10). Additionally, we found
an association between serum APOE levels and albuminuria in the general population
(R. Korstanje, unpublished data). Recently, a direct, lipid independent role for APOE in
the kidney and involvement in renal disease has been suggested. Chen et al. (11) showed
that APOE regulates mesangial cell proliferation in a dose-dependent fashion. APOE
has an antiproliferative eect specic for mesangial cells (not endothelial cells) through
the induction of matrix heparin sulfate proteoglycan (HSPG) (11). Thus, varying APOE
levels or genetic variation in the APOE receptors involved in this mechanism could be
expected to have an important eect on renal function and disease.
Studies of kidney disease involving Apoe-/- mice have led to contrasting results. In the
study by Wen et al. (12), Apoe-/- mice developed spontaneous glomerular lesions with
macrophage accumulation, commonly with foam cell appearance, deposition of extracel-
lular matrix, glomerular hyperplasia, and foci of mesangiolysis associated with capillary
microaneurysms. On the other hand, in studies using uninephrectomy (UNX) and subto-
tal nephrectomy (SNX) on wild-type and Apoe-/- mice, Buzello et al. (13) did not observe
a dierence in renal or glomerular injury after reduction of renal mass.
The aim of the current study is to investigate whether presence or absence of APOE
would have an eect on the genetic susceptibility to albuminuria in mice. To this purpose
we performed two independent F2 intercrosses between C57BL/6J mice, which do not
develop albuminuria, and A/J mice, which do develop albuminuria (14). In the rst cross
only wild-type inbred strains B6 and A/J were used; in the second cross B6. Apoe-/-
animals were crossed to A/J mice and only the Apoe-/- F2 animals were analyzed. We
expected that the combination of Apoe deciency and alleles from the susceptible A/J
strain would allow us to map loci involved in the dierence in susceptibility to kidney
disease between B6 and A/J mice, as well as the eect of APOE on these alleles.
Materials and methods
Mice and phenotype characterization
A/J, C57BL/6J (B6), and B6-129P2-Apoetm1Unc/J (B6-Apoe-/-) mice, which were back-
crossed at least 12 times to B6 and are now at N12F13, were obtained from The Jackson
Laboratory (Bar Harbor, ME). A/J females were mated to B6 (cross 1) or B6-Apoe-/-
(cross 2) males to produce the F1 progeny; F1 mice were intercrossed to produce 381 male
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F2 (cross 1) and 145 male F2-Apoe-/- (cross 2) progeny. Mice were housed in a climate-
controlled facility with a 14-hour:10-hour light dark cycle with free access to food and
water throughout the experiment. After weaning, mice were maintained on a chow diet
(Old Guilford 234A, Guilford, CT). Spot urine samples were taken between 8 and 10
weeks, and albumin and creatinine concentrations were measured on a Beckman Syn-
chron CX5 chemistry analyzer. Actual mouse albumin concentrations were calculated by
linear regression from a standard curve generated with mouse albumin standards (Kamiya
Biomedical, Seattle) (15). All experiments were approved by The Jackson Laboratory's
Animal Care and Use Committee.
Genotyping
DNA was isolated as described previously (16). Each F2 animal was genotyped using 98
SNPs (cross 1) or 140 SNPs (cross 2) polymorphic between A/J and B6 covering the whole
genome (supplemental Tables 2.4 and 2.5). Genotyping was performed by KBiosciences
(Hoddesdon, UK) using the Ampli
uor chemistry (Serologicals, Norcross, GA).
QTL mapping and statistics
QTL analysis and genome scans were carried out using the scanone and bayesint functions
of the R/qtl package (17). Urinary albumin presents a highly skewed, two-part distribution
in which many individuals have a score of zero (Figure 2.1). Broman (18) studied the
problem of mapping such phenotypes and concluded that the nonparametric procedure
(19) provides the most reliable analysis. Thus, we used the nonparametric method to
analyze urinary albumin as a binary trait (Alb = 0 vs. Alb > 0). Signicance of QTL
LOD scores was assessed using 1000 permutations of the phenotypic data (20). Signicant
QTL are reported at the genomewide adjusted 0.05 level (LOD 2.97 in cross 1 and LOD
3.35 in cross 2) and suggestive QTL at genomewide 0.63 level (LOD 1.93 in cross 1 and
LOD 2.01 in cross 2) (21). Bayesian credible intervals for particular chromosomes are
computed and reported as condence intervals. The 10LOD is taken, rescaled to have area
1, and followed by calculating the connected interval with density above threshold having
coverage matching the target probability at 0.96. The nonparametric analysis presents
some limitations. It is dicult to estimate eect sizes of the QTL, multiple QTL modeling
is not available, and adjustment for covariates such as sex cannot be made. Nonetheless,
it is justied in the case of such an extreme phenotype distribution. Due to the extreme
skew in the distribution of albumin levels, the pairscans, to test for epistasis, were highly
unstable. A number of transformations were tried but did not lead to reliable results.
The mode of inheritance was determined by performing an ANOVA on the mean values
for the three genotypes.
Results
Renal parameters in parental and F2 animals
Table 2.1 shows the values for the male parental and F2 animals. In each group, the males
were more susceptible to albuminuria than the females, which had almost no detectable
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Table 2.1: Renal parameters of male parental and F2 animals from both crosses.
N Albumin/creatinine (mg/g  SD)
B6 4 12.5  7.2
B6-Apoe
-/- 18 11.6  4.4
A/J 4 118.2  66.4
F2 (wild type) 381 8.9  35.1
F2-Apoe
-/- 145 13.2  2.4
albuminuria (data not shown) and therefore were not analyzed in the F2. In inbred B6
mice, the presence or absence of Apoe did not aect albuminuria.
Nonparametric analyses of albuminuria
Because most F2 animals did not have detectable urinary albumin concentrations, the trait
was not normally distributed (Figure 2.1). Therefore, we used the presence or absence of
detectable urinary albumin as a binary phenotype and performed nonparametric analyses
to identify loci involved in the phenotype. An overview of the QTL found in both crosses
is given in Table 2.2, which provides the QTL peak, 95% condence interval, locus name,
LOD score, allele conferring the high value, and nearest SNP marker. The QTL were
named if they were signicant (LOD 2.97 in cross 1 and LOD 3.35 in cross 2) or if they
were suggestive (LOD 1.93 in cross 1 and LOD 2.01 in cross 2) and found previously
as homologous QTL in rat crosses. In the analysis of cross 1 we detected three loci
(Figure 2.2 A). A signicant locus was found on chromosome (Chr) 2 (LOD = 3.5), while
two suggestive loci were found on Chr 9 (LOD = 2.0) and Chr 19 (LOD = 1.9). The
allele-eect plots of the three loci (Figure 2.3) show a recessive high allele from A/J at
the Chr 2 locus, while for both the Chr 9 and 19 loci the heterozygotes represent the
respectively susceptible and resistant phenotype. We found weak statistical evidence for
a second QTL on Chr 2 (1-QTL LOD = 3.46 and 2-QTL LOD = 4.95, dierence = 1.49,
nominal P-value for 2 = 0.03). However, the tests for linked QTL were underpowered
and, although we cannot provide strong evidence to support a second QTL, we cannot
rule it out. In the analysis of cross 2 none of these three loci was detected. Instead, two
suggestive loci on Chr 4 (LOD = 3.2) and Chr 6 (LOD = 2.6) were found (Figure 2.2
B). For both loci the A/J allele represents the susceptible phenotype but the allele is
dominant at the Chr 4 locus and recessive at the Chr 6 locus (Figure 2.4). We reduced
the interval of Albq1 by applying the bioinformatics strategy described by DiPetrillo et
al. (22). First we reduced the 95% C.I. by comparative mapping with the rat and human
genome using albuminuria as the kidney disease phenotype in all three species (Figure 2.5).
The locus is concordant with the rat Renal failure 3 (Rf3 ) locus on rat Chr 3 described
by Shiozawa et al. (23) and a locus on 20p13 associated with albuminuria in humans (24).
This approach reduced the 95% C.I. of the mouse locus from 124 Mb [containing 1570
genes according to the Ensembl database (release 42)], to 51 Mb (661 genes). Second, we
used the Jackson Laboratory's SNP databases (http://www.jax.org/phenome) to compare
B6 and A/J haplotypes. When we exclude the regions that are identical by descent
between the two strains, we can reduce the interval to three small regions with dierent
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Figure 2.1: Distribution of the albumin/creatinine ratio (ACR) in cross 1 (A) and
cross 2 (B).
haplotypes, which are 2, 9, and 24 Mb, respectively. Together, these regions contain
343 genes according to the Ensembl database (release 42, December 2006). As a QTL
for albuminuria was previously reported in a backcross between BALB/c and KK/Ta
(25), we investigated the possiblity of further narrowing the region using SNP data on
BALB/cByJ and KK/HiJ. Although this cross conrmed our mapping results, it did not
improve resolution.
Discussion
The gene encoding apolipoprotein E (APOE ) has been implicated in chronic kidney dis-
ease. Therefore, the aim of this study was to investigate whether the presence or absence
of APOE would have an eect on the genes involved in kidney damage in mice. To achieve
this, we crossed two strains, B6 and A/J, which are known to be near the extremes of
the urinary albumin spectrum for inbred strains (14) (K. DiPetrillo, unpublished results).
We used wild-type B6 and A/J mice, which have identical Apoe alleles according to their
genome sequence, for the rst cross, whereas we used the B6-Apoe-/- knockout mice for
the second cross and selected only the homozygous knockout mice in the F2 population.
Analysis of cross 1 between A/J and B6 mice identied one signicant locus and two
suggestive loci; in cross 2 between A/J and B6-Apoe-/- mice, these loci did not reach the
suggestive level and two dierent loci were identied. The signicant Chr 2 locus maps to
the same region as the previously reported albuminuria QTL that was found in a KK/Ta
 (BALB/c  KK/Ta) F1 backcross (25) with a similar LOD score (3.5). In a review, we
previously discussed concordance of renal damage loci between mouse, rat, and human
(7). Most of the loci found in the current crosses are concordant with rat loci for renal
parameters (Table 2.3). The Chr 2 region is homologous with the distal part of rat Chr 3
containing QTL for kidney mass and renal function (23). The homologous human region
(20p13) is also associated with albuminuria (24). Using this concordance to narrow the
interval region by comparative mapping signicantly reduces the number of candidate
20Urinary Albumin Loci in Mice and Apoe
T
a
b
l
e
2
.
2
:
Q
T
L
i
d
e
n
t
i

e
d
f
o
r
s
i
n
g
l
e
g
e
n
e
g
e
n
o
m
e
w
i
d
e
s
c
a
n
s
o
f
t
h
e
t
w
o
c
r
o
s
s
e
s
.
C
r
o
s
s
C
h
r
a
P
e
a
k
(
c
M
)
9
5
%
C
.
I
.
(
c
M
)
L
o
c
u
s
n
a
m
e
L
O
D
b
S
u
s
c
.
a
l
l
e
l
e
,
(
i
n
h
e
r
i
t
a
n
c
e
)
c
N
e
a
r
e
s
t
m
a
r
k
e
r
1
2
7
0
2
8
-
8
8
A
l
b
q
1
3
.
5
A
(
r
e
c
)
0
2
-
1
3
9
6
0
3
5
9
9
-
M
9
5
5
 
2
5
A
l
b
q
2
2
.
0
H
e
t
0
9
-
0
1
3
3
9
6
0
6
0
-
N
1
9
2
4
1
2
 
2
7
A
l
b
q
3
2
.
1
A
a
n
d
B
6
1
9
-
0
5
9
0
8
9
0
8
6
-
M
2
4
5
4
2
9
 
7
3
A
l
b
q
4
3
.
2
A
(
d
o
m
)
0
4
-
1
0
7
2
0
4
5
4
5
-
N
6
2
9
1
1
 
6
1
2
.
6
A
(
r
e
c
)
0
6
-
0
7
6
2
8
5
7
3
8
-
M
a
C
h
r
o
m
o
s
o
m
e
b
S
i
g
n
i

c
a
n
c
e
o
f
Q
T
L
L
O
D
s
c
o
r
e
s
w
a
s
a
s
s
e
s
s
e
d
u
s
i
n
g
1
0
0
0
p
e
r
m
u
t
a
t
i
o
n
s
o
f
t
h
e
p
h
e
n
o
t
y
p
i
c
d
a
t
a
(
2
0
)
.
S
i
g
n
i

c
a
n
t
Q
T
L
a
r
e
r
e
p
o
r
t
e
d
a
t
t
h
e
g
e
n
o
m
e
w
i
d
e
a
d
j
u
s
t
e
d
0
.
0
5
l
e
v
e
l
(
L
O
D
2
.
9
7
i
n
c
r
o
s
s
1
a
n
d
L
O
D
3
.
3
5
i
n
c
r
o
s
s
2
)
a
n
d
s
u
g
g
e
s
t
i
v
e
Q
T
L
a
t
g
e
n
o
m
e
w
i
d
e
0
.
6
3
l
e
v
e
l
(
L
O
D
1
.
9
3
i
n
c
r
o
s
s
1
a
n
d
L
O
D
2
.
0
1
i
n
c
r
o
s
s
2
)
(
2
1
)
c
S
u
s
c
e
p
t
i
b
l
e
a
l
l
e
l
e
a
n
d
l
i
k
e
l
y
m
o
d
e
o
f
i
n
h
e
r
i
t
a
n
c
e
:
r
e
c
,
r
e
c
e
s
s
i
v
e
;
d
o
m
,
d
o
m
i
n
a
n
t
.
21Chapter 2
Figure 2.2: Genomewide scans for albuminuria using nonparametric analysis for (A)
cross 1 and (B) cross 2. The dotted line at the top depicts a signicant LOD score (P < 0.05)
and the dotted line at the bottom a suggestive LOD score (P < 0.63).
Figure 2.3: Allele eects for the loci found in cross 1. Homozygosity for A/J alleles is
represented by AA, homozygosity for C57BL/6J alleles by BB, and heterozygosity by AB. The
SNP at which the allele eect is determined is shown under each graph.
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Figure 2.4: Allele eects for the loci found in cross 2. Homozygosity for A/J alleles is
represented by AA, homozygosity for C57BL/6J alleles by BB, and heterozygosity by AB. The
SNP at which the allele eect is determined is shown under each graph.
Figure 2.5: Using comparative genomics and interval-specic haplotype analysis to
narrow the chromosome 2 QTL. Comparing the C.I. of our cross with the interval on rat Chr
3 found in the (FHH  ACI) F2 intercross and the human chromosome 20 interval narrowed the
region to 51 Mb. Interval-specic haplotype analysis of this region, comparing SNPs between B6
and A, resulted in three regions that have dierent haplotypes between the strains and contain
343 genes according to the Ensembl database (release 42).
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genes (Figure 2.5). The Chr 9 locus is homologous to a part of rat Chr 8 to which a QTL
for urinary albumin excretion was mapped in three independent crosses (26, 27). The
QTL mapped to Chr 19 is concordant with the rat Renal failure 1 (Rf1) locus on Chr
1, which was mapped in four independent rat crosses (23, 27{29) and is also concordant
with a human locus (19q13) aecting renal disease (30) and creatinine clearance (31).
Finally, the Chr 4 region found in cross 2 is concordant with QTL for renal function
(32), kidney mass (33), and renin concentration (34) mapped to the homologous region
on rat Chr 5. Because we performed the QTL analysis on two independent crosses, there
might be some confounders that could lead to dierences in the analysis. For this study,
confounders such as dierent mouse rooms (in the same building) and dierent seasonal
eects could in
uence the results. However, we do not believe that the variability caused
by these factors substantially aects the results. Evidence for this comes from comparing
published QTL crosses for blood pressure in B  A populations (2, 35). Although the
independent crosses were conducted at dierent institutions under dierent dietary and
environmental conditions-one cross used only males and the other used both sexes, the
population sizes diered by more than fourfold, and one cross was a backcross while the
other an intercross-the experiments produced similar results. The QTL with the highest
LOD scores identied by Woo and Kurtz (35) were also detected by Sugiyama et al. (2),
using one-quarter the population size. The dierences between the crosses in our study
were fewer than between these published crosses. Thus, we believe that the presence
or absence of Apoe is the primary reason for the dierent QTL identied in cross 1 vs.
cross 2, suggesting that the absence of APOE modies the QTL involved in albuminuria.
The strain that we used has been backcrossed 12 times, leaving a theoretical 0.05% of
the 129 genome in the mice. Although chances are small, it would be possible for a
129 allele to contribute to the susceptibility (or resistance) to albuminuria. We do not
have data of a cross between A/J and 129 to test this. However, we do have data from
a cross between B6 and 129 for albuminuria, in which a QTL was found on Chr18 (S.
Sheehan, unpublished results). This suggests that the only dierence between B6 and 129
with respect to albuminuria is on Chr 18; we did not observe this QTL in our crosses
(Figure 2.2).
APOE, a component of very low-density lipoprotein (VLDL) particles as they are se-
creted from the liver, is acquired by chylomicrons soon after their synthesis and secretion
by the small intestine (36). APOE accomplishes its lipid transport and delivery function
mainly through binding to several receptors like the LDL receptor (LDLR), VLDL re-
ceptor (VLDLR), and megalin (LRP2). This binding of lipoproteins to the receptors is
enhanced by lipoprotein lipase (LPL) (37). Both the receptors and LPL have been impli-
cated previously in renal damage (38, 39). In addition to its possible role in the kidney
through lipid metabolism, recent data show that APOE also has direct eects on mesan-
gial cell proliferation and extracellular matrix expansion. Mesangial expansion is a key
feature in the pathogenesis of renal diseases (40). Moreover, Apoe knockout mice show in-
creased mesangial cell proliferation and matrix formation compared with wild-type mice
or Apob-overexpressing mice, which have elevated plasma cholesterol and triglycerides.
This suggests that lack of APOE, rather than hyperlipidemia, contributes to mesangial
expansion (11). In line with these ndings, in vitro experiments show that APOE inhibits
mesangial cell proliferation and apoptosis induced by oxidized LDL. In addition, APOE
induces the mesangial matrix heparin sulfate proteoglycan (11). Loss of anionic heparin
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Table 2.3: Concordance between the mouse urinary albumin QTL and QTL found
for related phenotypes in rat and human.
QTL Chr Peak (cM) Concordance
in rat
Concordance
in human
Albq1 2 70 Chr 3 for UAE,
UPE
Chr 20p13 for
ACR
Albq2 9 5 Chr 8 for UAE,
UPE
Albq3 19 24 Chr 1 for UAE,
UPE
Chr 10q23 for
ESRD, CC
Albq4 4 54 Chr 5 for CC,
KM
UAE, urinary albumin excretion; UPE, urinary protein excretion; ACR, urinary albumin-to-
creatinine ratio; ESRD, end-stage renal disease; CC, creatinine clearance; KM, kidney mass.
sulfate proteoglycan in the basement membrane and mesangial matrix is associated with
disruption of the ltration barrier (41). Finding one signicant QTL in the presence of
Apoe and only two (dierent) suggestive QTL in the absence of Apoe suggests that the un-
derlying gene of the Chr 2 QTL is dependent on Apoe to cause increased albumin/creatine
ratio (ACR). When APOE is absent, this dependency gets lost and the Chr 2 locus no
longer contributes to the dierence in susceptibility. Instead, ACR is determined by other
(Apoe-independent) loci. In conclusion, we detected ve loci using nonparametric analy-
ses for albuminuria in a cross between A/J and either B6 or B6-Apoe-/- mice. However,
the loci detected depend on the presence or absence of APOE. Only one of the loci (Chr
2) was signicant, but all loci, except for the locus on Chr 6, are concordant with QTL
for renal damage in rat, and two of the loci (Chr 2 and Chr 19) are concordant with
associations found in human. The dependence on APOE suggests the involvement of this
pathway in renal disease.
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Table 2.4: SNP markers and map positions of Cross 1.
Marker cM Marker cM Marker cM
01-005230167-M 8.4 05-094897264-N 45.0 11-107678903-M 65.0
01-023061064-M 14.1 05-118031699-M 67.0 12-011234798-M 3.0
01-050041930-M 26.7 05-145143884-M 81.0 12-049281625-M 24.0
01-080181487-M 49.7 06-008951271-M 2.6 12-077362373-M 38.0
01-110152038-M 62.1 06-036801292-N 15.8 12-104222856-N 53.0
01-139952425-M 73.0 06-076285738-M 31.5 13-015609597-M 9.0
01-157000923-M 81.6 06-131929438-M 63.3 13-046957715-M 30.0
01-187052090-M 102 07-011167675-M 4.0 13-082184874-M 45.0
02-020414303-M 10.0 07-041032053-M 26.8 13-105849719-M 59.0
02-051174661-M 33.0 07-071043704-M 41.0 14-020426806-M 6.5
02-080232231-M 48.1 07-094312514-M 49.9 14-052865726-M 26.0
02-110955544-N 51.4 07-122982432-M 66.0 14-079218045-M 44.3
02-139603599-M 79.4 08-015199792-M 6.0 14-108203728-M 54.0
02-169619681-N 99.0 08-035000451-M 21.0 15-020953071-M 14.5
03-007561998-N 2.4 08-041947937-M 22.5 15-055206736-N 27.5
03-032431792-M 16.5 08-065245444-M 33.0 15-093195380-M 57.8
03-051281956-M 25.0 08-092730657-N 43.0 16-005644892-N 1.7
03-082192100-M 38.3 08-109943429-M 54.0 16-043075679-C 29.0
03-114106772-M 55.0 D8Mit280 72.0 16-093066825-C 66.8
03-138370314-M 68.3 09-013396060-N 5.0 17-013493244-M 8.1
03-155372777-M 84.9 09-044591533-N 26.0 17-050794277-N 31.5
04-004044733-M 0.0 09-074179540-M 40.0 17-086110517-N 55.7
04-034118412-M 10.6 09-110057634-M 61.0 18-010953833-N 4.0
04-061409675-M 31.4 10-014021037-M 7.0 18-047863056-M 24.0
04-093224754-M 44.5 10-053898997-M 30.0 18-086980249-M 57.0
04-124081318-M 58.0 10-086567143-M 48.0 19-007376322-N 5.0
04-145870512-M 71.0 10-120289167-M 77.0 19-036011794-M 34.0
05-021194830-M 9.0 11-014984030-M 3.3 19-059089086-M 54.0
05-045056991-M 26.0 11-044333996-M 20.0
05-065089744-M 41.0 11-077198334-M 44.7
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Table 2.5: SNP markers and map positions of Cross 2.
Marker cM Marker cM Marker cM
01-005230167-M 8.4 06-076285738-M 32.5 13-032546453-N 13.0
01-021004950-M 12.5 06-092583427-N 37.0 13-043995023-N 30.0
01-036208806-N 19.5 06-121280548-M 55.0 13-061943220-M 36.0
01-065042402-M 33.3 06-149052281-M 74.4 13-084819885-M 42.0
01-080181487-M 49.7 07-072051696-M 37.0 13-105849719-M 59.0
01-094081544-M 58.7 07-087073425-M 48.5 14-025184538-M 10.0
01-124147455-M 63.1 07-102009856-M 52.4 14-040017031-M 16.5
01-139952425-M 73.0 07-116120590-M 59.0 14-052865726-M 26.0
01-153183498-M 73.0 07-129989877-M 69.0 14-068060767-M 43.0
01-169425148-M 87.9 08-015199792-M 7.0 14-083150973-M 45.0
01-182325478-N 101 08-041043944-M 22.6 14-108203728-M 54.0
01-194803746-N 101.5 08-067470102-N 33.0 15-010120073-M 0.0
02-020551477-M 10.0 08-084965991-N 38.6 15-026132801-M 4.0
02-038092910-M 28.0 08-109943429-M 54.0 15-041919640-N 9.9
02-053087820-M 30.5 08-123825384-N 67.0 15-055206736-N 14.8
02-069853291-N 38.3 09-013396060-N 5.0 15-070911071-M 25.6
02-083047417-M 47.7 09-032867340-M 9.0 15-086076093-M 38.2
02-101074874-M 50.3 09-048062033-M 27.0 15-102788257-N 59.3
02-124063590-M 69.0 09-063923771-M 35.0 16-009050448-C 4.7
02-146910375-M 81.7 09-078935732-M 42.0 16-031026287-C 12.0
02-169619681-N 85.2 09-103190604-M 56.0 16-045665633-N 31.0
03-005501855-M 2.4 09-123708875-M 72.0 16-061226828-C 43.0
03-034069633-M 16.5 10-003233934-M 4.0 16-093066825-C 66.3
03-049202892-M 23.3 10-018064293-M 7.0 17-022861830-N 12.6
03-064203823-M 30.0 10-027070647-M 21.0 17-035364626-M 19.1
03-079175961-M 35.2 10-053898997-M 30.0 17-050794277-N 29.4
03-100489838-M 49.2 10-083144168-M 47.0 17-065004394-N 38.5
03-124103177-M 58.8 10-094049193-M 52.5 17-078140174-N 47.4
03-138370314-M 68.3 10-107333522-M 59.0 17-091151542-M 55.7
03-153429247-M 84.9 10-121549764-N 69.0 18-010953833-N 4.0
04-003163167-M 1.3 10-129117100-M 70.0 18-024982833-M 8.7
04-022875524-M 6.3 11-004367508-M 0.3 18-039129483-M 22.0
04-049893004-M 20.8 11-016263012-N 2.0 18-052783850-M 25.0
04-075869463-M 37.7 11-035421451-M 17.0 18-067972780-M 41.0
04-092052171-M 44.5 11-047224208-M 23.0 18-086980249-M 58.0
04-107204545-N 53.6 11-061500282-N 33.9 19-005091208-M 0.5
04-122948823-M 58.0 11-076223449-M 44.2 19-015117261-M 9.0
04-135262063-N 67.0 11-091287860-M 52.0 19-036011794-M 24.0
04-150152643-M 79.4 11-107678903-N 65.0 19-051918908-M 49.0
05-021194830-M 9.0 11-118804416-N 77.0 19-060823449-N 50.0
05-037101849-M 24.0 12-005458738-M 1.0
05-065089744-M 41.0 12-020194907-M 6.0
05-094897264-N 45.0 12-031214248-M 17.0
05-107871207-M 59.0 12-048364436-M 24.0
05-123262990-M 68.0 12-061271925-M 29.0
05-149044358-M 85.0 12-077362373-M 38.0
06-003167392-M 0.7 12-094386176-N 46.0
06-017592278-N 3.2 12-110259850-M 59.0
06-032993330-M 6.6 13-003003286-M 4.0
06-046967317-M 19.1 13-015609597-M 4.0
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Abstract
Vitamin D is typically viewed as a key player in the regulation of calcium and
phosphate levels and the control of bone metabolism; however, growing evidence
suggests that vitamin D deciency may also have an important role in the progressive
loss of renal function. Vitamin D deciency is particularly frequent in patients with
chronic kidney disease, in whom it is associated with increased mortality. Studies
indicate that treatment with vitamin D analogues reduces proteinuria, suppresses
the renin-angiotensin-aldosterone system (RAAS), and exerts anti-in
ammatory and
immunomodulatory eects. These pleiotropic eects render vitamin D a potentially
interesting treatment modality for renoprotection in patients with chronic kidney
disease. Whether vitamin D has clinically relevant renoprotective eects in addition to
RAAS blockade is currently under investigation.
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Introduction
Vitamin D has been recognized for decades as a key player in the control of bone metabolism
through the regulation of calcium and phosphate homeostasis. This hormone regulates
serum concentrations of calcium and phosphate by stimulating the absorption of these
minerals in the intestine and their reabsorption by the kidney. Vitamin D deciency
results in increased circulating levels of parathyroid hormone (PTH), which has several
disadvantageous eects on bone metabolism. PTH activates osteoblasts to stimulate the
maturation of osteoclasts. Mature osteoclasts degrade the mineralized collagen matrix
in bone, resulting in osteopenia, osteoporosis, and increased risk of fracture. Another
important consequence of high circulating levels of PTH levels is phosphaturia, which can
result in low levels of serum phosphate. Consequently, the calcium-phosphorus product
decreases, which results in decreased mineralization of the collagen matrix and can lead
to the development of rickets in children and osteomalacia in adults (1).
The decline in the incidence of rickets that was observed following the fortication of
food products with vitamin D indicated that the key problems associated with vitamin
D deciency were solved. Over the past decade, however, two important ndings have
questioned this assumption. First, despite fortication of foods with vitamin D in West-
ern countries, a considerable proportion of the population remained insucient or even
decient in vitamin D. Certain subpopulations such as elderly individuals and patients
with chronic kidney disease (CKD) are at particular risk of vitamin D deciency. Second
is the increasing awareness that vitamin D not only has a role in the regulation of bone
metabolism, but also aects several other organ systems. For example, kidneys express
functional vitamin D receptors (VDRs) and respond to treatment with active vitamin D.
A growing number of experimental studies suggest the vitamin D axis has a renoprotective
role. Maintenance of adequate serum vitamin D levels might, therefore, be of particular
importance for patients with renal disease, not only for the prevention of bone disease,
but also for the protection of renal function.
This Review rst outlines the physiology of vitamin D and discusses the physiological
processes that might be aected in patients with CKD. The epidemiology of vitamin
D deciency as well as its implications in both the general population and in patients
with renal disease is also described. The main focus is on the pathogenic consequence of
vitamin D deciency in the kidney and on the renoprotective potential of pharmacological
strategies that use vitamin D analogues.
Vitamin D physiology
In the presence of solar ultraviolet B radiation, vitamin D3 is photochemically produced
in the skin from 7-dehydrocholesterol (Figure 3.1). Alternatively, vitamin D3 can be
absorbed through the intestine from food sources such as oily sh, fortied dairy products
and mushrooms. Ingested or photosynthesized vitamin D3 is converted to active vitamin
D (1,25(OH)2 vitamin D3 or calcitriol, subsequently referred to in this Review as active
vitamin D), via two hydroxylation steps. First, vitamin D3 is converted by 25-hydroxylase
in the liver to form 25(OH) vitamin D3 (calcidiol). Calcidiol is subsequently converted to
active vitamin D in the proximal tubular epithelial cells of the kidney. Transport of the
dierent vitamin D metabolites to the liver, kidney, and target organs is facilitated by
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the plasma vitamin D-binding protein (DBP) (2). The calcidiol-DBP complex is ltered
by the glomerulus before it enters the proximal tubule cells via megalin-mediated uptake
at the brush border (2). In tubular epithelial cells, the conversion of calcidiol into active
vitamin D is regulated by 25(OH) vitamin D3 1-hydroxylase (CYP27B1). This enzyme
has an important role in the regulation of circulating concentrations of active vitamin D,
and is controlled by several peptide hormones and regulatory feedback loops. PTH is the
main inducer of 1-hydroxylase activity. PTH is produced by calcium-sensing cells of the
parathyroid gland, mainly under hypocalcemic conditions. In addition, 1-hydroxylase
activity is induced by calcitonin (3), a hormone that is produced by the C cells of the
thyroid gland under normocalcemic conditions when the PTH system is downregulated.
Circulating levels of active vitamin D are negatively regulated by several feedback
mechanisms (Figure 3.1). First, vitamin D can be directly inactivated by the enzyme
1,25-dihydroxyvitamin D3 24-hydroxylase (CYP24A1) by the addition of another hydroxyl
(OH) group at position 24. This step results in the generation of 1,24,25(OH)3 vitamin D3
and ultimately produces the water-soluble calcitroic acid (1-hydroxy-23-carboxy-24,25,-
26,27-tetranorvitamin D3), which is excreted by the kidney. Second, 1-hydroxylase ex-
pression is downregulated by active vitamin D itself via vitamin D-responsive elements
in the promoter region of 1-hydroxylase (4). Third, active vitamin D stimulates the
production of broblast growth factor (FGF)23 in osteocytes (5). This growth factor acts
via the FGF receptor 1 (FGFR-1)-Klotho complex, which functions as an FGF23 receptor
(6) to negatively regulate renal synthesis of 1-hydroxylase (Figure 3.1) (7).
Several factors also in
uence circulating levels of active vitamin D. The eects of
seasonal changes (8) and sunlight exposure (9) on levels of active vitamin D have been
recognized for decades. Circulating vitamin D levels also dier with ethnicity, being lowest
in non-Hispanic blacks (10). Diet is also a contributing factor, but the contribution of diet
to overall levels of active vitamin D is limited because much higher amounts are produced
in the skin (1).
The actions of active vitamin D are mediated by the VDR. This receptor is part of
the nuclear receptor superfamily and is predominantly located in the nucleus, although
in some cells it can be associated with caveolae in the plasma membrane. Following
the recruitment of transcriptional coactivators, the activated VDR binds to vitamin D-
response elements in the promoter region of target genes. An overview of the diverse VDR
target genes that have been identied in several cell types has been published elsewhere
(9{15).
The VDR also exerts nongenomic actions. For example, the VDR can form a com-
plex with the p65 subunit of NFB to produce anti-in
ammatory actions (16). Another
nongenomic mechanism of action of VDR is achieved by so-called rapid responses. This
mechanism has been reviewed elsewhere (17). Brie
y, binding of active vitamin D to
caveolae-associated VDRs activates second messenger systems, which may force the open-
ing of voltage-gated calcium or chloride channels, and facilitate cross-talk with the nucleus
to modulate the expression of target genes. The VDR is expressed by more than 30 or-
gan systems and tissues (18{20), including the kidney. Available data on the expression
pattern of VDRs in the normal kidney are limited, but immunohistochemically detectable
levels are expressed by proximal and distal tubular epithelial cells, glomerular parietal
epithelial cells, and collecting duct cells (21). Treatment of cultured tubular epithelial
cells (16), mesangial cells (22), podocytes (23), and juxtaglomerular cells (23), with ac-
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Figure 3.1: Vitamin D physiology. Vitamin D3 is generated from 7-dehydrocholesterol in
the skin under the in
uence of UV-B radiation or is obtained from dietary sources by absorption
through the intestine. Circulating vitamin D3 is transported in conjugation with DBP. In the
liver, vitamin D3 is converted to 25(OH) vitamin D3 by 25-hydroxylase. 25(OH) vitamin D3
is then converted to the active vitamin D metabolite, 1,25(OH)2 vitamin D3 in the kidney
by the enzyme 1-hydroxylase. 1-hydroxylase is regulated by several mechanisms, including
PTH, calcitonin, and FGF23. Active vitamin D can be deactivated by addition of another
hydroxyl (OH) group at the position 24, after which the end product is excreted. Abbreviations:
24-OHase, 1,25-dihydroxyvitamin D3 24-hydroxylase; DBP, vitamin D-binding protein; FGF,
broblast growth factor; PTH, parathyroid hormone; UV, ultraviolet; vit, vitamin. Permission
obtained from Nature Publishing Group Ltd ' Deeb, K. K. et al. Vitamin D signalling pathways
in cancer: potential for anticancer therapeutics. Nat. Rev. Cancer 7, 684-700 (2007).
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tive vitamin D or vitamin D analogues such as paricalcitol, modulated the expression of
target genes, suggesting the presence of a functional VDR in these cells. Whether renal
VDR expression is modulated in patients with CKD, is unknown.
Epidemiology of vitamin D deciency
The denition of vitamin D deciency is still a matter of debate. Some consider serum
levels of 25(OH) vitamin D3 < 75 nmol/l (< 30 ng/ml) to be insucient, levels < 37
nmol/l (< 15 ng/ml) decient, and levels < 25 nmol/l (< 10 ng/ml) severely decient
(24). However, most experts dene vitamin D deciency as 25(OH) vitamin D3 levels <
50 nmol/l (< 20 ng/ml) (1, 25{27). A review of several reports of vitamin D intoxication
suggests that serum levels of 25(OH) vitamin D3 > 375-500 nmol/l (> 150-200 ng/ml)
are associated with a risk of hypercalcemia and should be considered toxic (1, 28).
Data from consecutive cohort studies of the general population from the National
Health and Nutrition Examination Survey (NHANES) suggested that changes had oc-
curred in levels of serum vitamin D in the US population between the periods of 1988-1994
(NHANES III) and 2001-2004 (10). This change might be related to the increased use
of sunscreen (29), decreased amounts of outdoor activity (30), and the increased preva-
lence of obesity (31), all of which are associated with reduced vitamin D levels. Although
these data raise considerable concerns, the validity of comparing dierent measurements
of 25(OH) vitamin D3 has been questioned because of methodological issues that can
arise due to calibration problems, lack of standard operating procedures and the use of
a variety of equipment (32{34). Adjusting for methodological changes in the measure-
ment of vitamin D levels demonstrated that much of the observed dierence in vitamin
D levels between the NHANES III and NHANES 2001-2004 studies could be accounted
for by changes unrelated to actual changes in vitamin D status (35). Until a reference
measurement procedure for 25(OH) vitamin D3 is available, caution must be taken with
the interpretation of epidemiological data on vitamin D (36).
Patients with CKD, in particular those on dialysis, generally have more severe vitamin
D deciency than the general population (10, 37{39). Vitamin D insuciency (dened
as levels < 75 nmol/l [< 30 ng/ml]) and severe vitamin D deciency (dened as levels
< 25 nmol/l [< 10 ng/ml]) are both more common in patients with predialysis CKD
than in the normal population (Figure 3.2) (37). Some, but not all, studies have found a
positive association between stage of CKD and prevalence of vitamin D deciency (40, 41).
Predialysis CKD patients who live in a sunny country are less likely to be vitamin D
insucient or decient than those who live in less sunny areas (42). In a cross-sectional
cohort of 825 dialysis patients in the US, only 22% had 25(OH) vitamin D3 levels of >
75 nmol/l (> 30 ng/ml), while 60% had levels between 25 and 75 nmol/l (10 and 30
ng/ml) (43). In a French study of dialysis patients, 42% had severe vitamin D deciency
(Figure 3.2) (38). An analysis of patients on peritoneal dialysis showed similar percentages
(44). Thus, in patients with end-stage renal disease, vitamin D deciency is an even
more prevalent and severe problem than it is in patients with mild to moderate renal
insuciency.
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Figure 3.2: Prevalence of vitamin D deciency in the general population and in pa-
tients with chronic kidney disease. Prevalence of vitamin D levels > 75 nmol/l (> 30 ng/ml)
(dened by some researchers as sucient), between 25 and 75 nmol/l (10 and 30 ng/ml), and <
25 nmol/l (< 10 ng/ml) (severely decient) in the a | general population (8), b,c | in patients
with preterminal chronic kidney disease (stages 3 and 4) (37), and d | hemodialysis patients
(stage 5) (38). Vitamin D insuciency is common in all categories of patients, whereas severe
deciency seems to be more prevalent in those with more severe renal disease. Abbreviations:
CKD, chronic kidney disease; GFR, glomerular ltration rate.
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Implications of vitamin D deciency
In the general population, vitamin D deciency has been independently associated with a
small but signicantly increased risk of all-cause mortality (45{47). Other studies found
that vitamin D deciency may be associated with cardiovascular morbidity (48) and mor-
tality (49). A subgroup analysis showed that the strongest associations between vitamin
D deciency and mortality occurred in patients without cardiovascular disease, hyperten-
sion, or diabetes. This nding may imply that vitamin D deciency exerts detrimental
actions before cardiovascular disease is established. Whether vitamin D treatment could
provide cardiovascular protection has been the subject of intense debate since the publica-
tion of negative ndings by Hsia et al. (50) in 2007. Of note, researchers have commented
that the vitamin D replacement dose used in that study may have been inadequate to
achieve an eect (51).
The relationship between vitamin D deciency and impaired bone metabolism is illus-
trated by the role of vitamin D deciency in the development of rickets and osteomalacia
(52). Several studies have documented benecial eects of vitamin D supplementation
(700-800 IU daily in combination with calcium) in patients with osteoporosis (53{56).
Lower doses of vitamin D3, or doses that do not lead to the restoration of adequate serum
25(OH) vitamin D3 levels, may not eectively lower fracture risk (25, 57).
In the NHANES III cohort, vitamin D deciency was associated with an increased
risk of albuminuria (58). Whether vitamin D deciency is the cause or consequence
(through reduced reuptake of the calcidiol-DBP complex in tubular cells under proteinuric
conditions, as is discussed below) of albuminuria, or whether it is an epiphenomenon, is
the subject of ongoing randomized, controlled trials (59). In patients with CKD, several
studies have demonstrated an independent inverse association between serum levels of
active vitamin D and the rate of renal function loss or mortality (41, 60, 61). Similarly,
Wolf et al. reported an association between vitamin D deciency and early mortality in
a cohort of patients on dialysis (43). Importantly, subsequent treatment of these patients
with active vitamin D was associated with increased survival.
Low serum vitamin D levels are more strongly associated with increased risk of coro-
nary atherosclerosis in patients with CKD than in individuals with normal renal function
(62). In a population of patients on peritoneal dialysis, the risk of cardiovascular morbidity
was higher in individuals with vitamin D deciency than in those without (44). In other
studies, vitamin D deciency was independently associated with several cardiovascular
risk factors such as hypertension, insulin resistance, diabetes, and dyslipidemia (63, 64).
These associations could at least in part explain the increased incidence of cardiovascular
morbidity and mortality in patients with CKD and vitamin D deciency. Osteoporosis
and osteopenia are common in patients with CKD (65, 66). This detrimental eect on
bone is most likely related to disturbed vitamin D and PTH metabolism in these patients.
The prevalence of vitamin D deciency in patients with CKD and the association of
vitamin D deciency with increased mortality, cardiovascular morbidity and bone disease,
warrants adequate correction of vitamin D levels well before these patients develop end-
stage renal disease. The Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines
advise vitamin D supplementation in patients with stages 3-4 CKD if serum 25(OH)
vitamin D3 level is < 75 nmol/l (< 30 ng/ml) to reduce the risk of low bone mineral
density and hip fracture (67). Increasing understanding of the potential renoprotective
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eects of active vitamin D might provide an additional reason for the early initiation of
vitamin D supplementation in patients with renal disease. Emerging data suggests that
correction of vitamin D may potentially slow the progression of renal disease in these
patients.
Vitamin D deciency in renal disease
Mechanisms of reduced vitamin D levels
After ltration by the glomerulus, the reuptake of 25(OH) vitamin D3 (bound to DBP),
takes place at the brush border of the proximal tubular epithelial cells (Figure 3.3). This
process is mediated by megalin, and can result in release of either active 1,25(OH)2 vi-
tamin D3 or inactive 25(OH) vitamin D3 into the circulation on the basolateral side.
Although reduced renal megalin expression has not been demonstrated in patients with
renal disease, studies in cultured tubular epithelial cells suggest that chronic exposure
to albumin reduces megalin expression (68). In addition, renal megalin messenger RNA
(mRNA) expression is reduced in models of experimental nephrotic syndrome in vivo
(69). Furthermore, megalin knockout mice develop low-molecular-weight proteinuria and
actually lose large amounts of vitamin D-DBP in their urine (70). These ndings are
supported by studies in a kidney-specic megalin knockout mouse-when fed a vitamin
D-depleted diet, these mice demonstrated lower circulating levels of 25(OH) vitamin D3
and strongly elevated 25(OH) vitamin D3-DBP excretion than did wildtype mice (71).
Furthermore, kidney-specic megalin knockout mice were hypocalcemic and had osteo-
malacia (softening of the bones) (71). In a rat model of nephrotic syndrome induced by
puromycin aminonucleoside, serum levels of 25(OH) vitamin D3 decreased concomitantly
with increased proteinuria (72). Since liver mRNA expression of both CYP2R1 (the pro-
tein product of which metabolizes vitamin D3 to 25(OH) vitamin D3) and the gene that
encodes DBP were unchanged, the decreased levels of 25(OH) vitamin D3 might not be
a result of dysfunctional hydroxylation or transport to the liver. Rather, these studies
indicate that 25(OH) vitamin D3-DBP might be lost into the urine in the nephrotic state.
Alternatively, the reduced serum levels of 25(OH) vitamin D3 in CKD patients might oc-
cur secondary to decreased photoproduction of pre-vitamin D3 from 7-dehydrocholesterol
in the skin because of uremia (73).
Reduced activity of 1-hydroxylase is widely accepted to be the main cause of reduced
circulating levels of 1,25(OH)2 vitamin D3 in patients with CKD (74). In a model of ex-
perimental nephrosis, renal mRNA expression of 1-hydroxylase is decreased and CYP24A1
is increased 3 days after induction of nephrosis, resulting in a reduction in serum levels
of 1,25(OH)2 vitamin D3 (72). Therefore, in patients with CKD, vitamin D deciency
probably results from multiple factors including urinary loss of 25(OH) vitamin D3-DBP
associated with proteinuria (72), reduced activity of 1-hydroxylase, and compromised
endogenous pre-vitamin D3 production in the skin (73).
Renoprotective potential of vitamin D
Growing evidence indicates that vitamin D analogues may have benecial eects in pa-
tients with CKD. Antibrotic eects of vitamin D analogues have been demonstrated in
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Figure 3.3: Possible mechanisms of vitamin D deciency in proteinuric renal disease.
a | In healthy individuals, 25(OH) vitamin D3 bound to DBP is ltered through the glomeru-
lus (1). In proximal tubular cells, uptake of 25(OH) vitamin D3-DBP is facilitated by megalin.
After uptake into lysosomes (2), 25(OH) vitamin D3-DBP is either returned to the circulation
(3), or converted to active vitamin D by hydroxylation by 1-hydroxylase (4), and released into
the circulation (5). b | In patients with proteinuria, megalin is occupied by an extensive pro-
tein load that consists mainly of albumin (1); thus, fewer receptors are available to reabsorb
25(OH) vitamin D3-DBP. In addition, as a consequence of proteinuria, proximal tubular cells are
damaged and express less megalin (2), which also reduces 25(OH) vitamin D3-DBP reabsorption.
1-hydroxylase expression is also reduced in patients with chronic kidney disease (3), which results
in decreased formation of active vitamin D. Abbreviation: DBP, vitamin D-binding protein; vit,
vitamin.
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Figure 3.4: Overview of the potential renoprotective eects of active vitamin D
in the damaged kidney. In the glomerulus, vitamin D protects podocytes by increasing the
expression of nephrin and podocin. Under nephrotic conditions, vitamin D reduces the expression
of desmin, a marker of podocyte injury. In juxtaglomerular apparatus cells, renin production is
inhibited by vitamin D. In macrophages, vitamin D reduces TNF and NFB expression. Similarly,
vitamin D has anti-in
ammatory eects in injured tubular epithelial cells, by reducing NFB
availability. Consequently, expression of chemokines such as CCL5 (RANTES), are reduced.
Vitamin D can also modify T-helper-cell responses and aect the maturation and dierentiation
of dendritic cells, which provides protection against in
ammatory damage in response to renal
injury. Abbreviations: CCL5, CC-chemokine ligand 5; NFB, nuclear factor B; TH, T-helper;
TNF, tumor necrosis factor.
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cultured renal cells (75) and in animal models of renal damage (76). Several mechanisms
could be involved in this renoprotective eect, including direct antiproteinuric eects
through the protection of podocytes, interactions with the renin-angiotensin-aldosterone
system (RAAS), and anti-in
ammatory eects (Figure 3.4).
Antiproteinuric eects
In experimental puromycin aminonucleoside-induced nephrotic syndrome, treatment with
active vitamin D or the vitamin D analogue 22-oxacalcitriol has demonstrated clear an-
tiproteinuric eects (72, 77). Administration of active vitamin D or 22-oxacalcitriol par-
tially restored glomerular expression of nephrin, an important structural slit diaphragm
protein that is inversely correlated with proteinuria. In podocytes, active vitamin D in-
duces nephrin gene expression (possibly in cooperation with the retinoic acid receptor
(78)), probably by binding of the activated VDR to vitamin D response elements in the
nephrin gene (79). In addition, vitamin D treatment restores expression of podocin, a
molecule associated with the slit diaphragm, and decreases expression of the podocyte
injury marker desmin (72). Together, these ndings indicate that active vitamin D has a
direct protective eect on podocytes, and possibly explains the antiproteinuric eects of
vitamin D that have been reported by other studies (80, 81). As proteinuria is a marker of
progressive renal dysfunction, these data support the potential of vitamin D administra-
tion for long-term renoprotection. Studies to assess the antiproteinuric eects of vitamin
D analogues in humans are currently underway. As RAAS blockade is rst method of
choice for reducing proteinuria, the eects of vitamin D administration together with
RAAS blockade are also under investigation (59).
RAAS-related eects
The antiproteinuric eects of vitamin D and its analogues could, at least in part, be
explained by actions on the RAAS. Two key publications demonstrated that active vitamin
D binds to the promoter region of the renin gene to downregulate renal mRNA expression
of renin (68, 82). In VDR knockout mice, inhibition of renin transcription by vitamin D
is reduced, which results in RAAS activation and renal injury (23, 82). VDR knockout
mice are hypertensive, probably as a consequence of RAAS activation (82). Whether this
nding implies that administration of vitamin D analogues could have antihypertensive
eects is currently a subject of controversy (83). In cultured juxtaglomerular-like cells,
the administration of active vitamin D reduces renin expression by 90% (82) by blocking
the cyclic adenosine monophosphate response element in the renin gene promoter (68) In
adipocytes, 1,25(OH)2 vitamin D3 dose-dependently decreases expression of the gene that
encodes the type I angiotensin II receptor (84). Whether VDR and type I angiotensin II
receptor interact in renal cells is unknown.
RAAS blockade is currently rst-line renoprotection therapy for patients with CKD,
but can be associated with a reactive rise in renin (85, 86). Both angiotensin-converting-
enzyme (ACE) inhibitors and type I angiotensin II antagonists require concomitant ad-
herence to a low sodium diet and administration of a diuretic to achieve optimal eects on
blood pressure and proteinuria (87, 88); however, the benets of these approaches come
at the expense of a potentiated reactive rise in levels of both renin and aldosterone. Data
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support direct probrotic eects of aldosterone (89) and renin by direct eects on the
(pro)-renin receptor (90). Thus, the eventual therapeutic benet of volume depletion by
RAAS blockade can be limited by the reactive rise in renin levels. Data from studies in
rats support the presence of probrotic renal eects associated with aggressive volume
depletion under RAAS blockade (91). These data, therefore, suggest that blocking the
reactive rise in renin during RAAS blockade could have therapeutic benets. In our opin-
ion, vitamin D is a potential candidate for this purpose. The addition of vitamin D to
RAAS blockade therapy might improve the ecacy of RAAS blockade by blunting the
reactive rise in renin (and the downstream rise in aldosterone). Indeed, treatment with a
combination of paricalcitol and enalapril reduced renal damage in the 5/6 nephrectomy
rat model more strongly than did paricalcitol or enalapril alone (92).
Direct inhibition of renin has long been known to have renoprotective potential (93)
and may suppress the reactive rise in renin activity. Studies over the past few years have
investigated the renoprotective eects achieved by combined treatment with conventional
RAAS blockers (that is, ACE inhibitors and angiotensin II receptor blockers) and the
direct renin inhibitor aliskiren (94{96). In patients with type 2 diabetes, hypertension,
and diabetic nephropathy, combination treatment with aliskiren and losartan for 6 months
reduced proteinuria to a greater extent than did losartan alone (94). The reduction in
proteinuria seemed to occur independently of blood pressure, which was not signicantly
aected by treatment. However, the long-term renoprotective eects of combined renin
and ACE inhibition or angiotensin II receptor blockade remain to be documented. For
the purpose of the current Review, it should be mentioned that direct renin inhibitors
aect the enzymatic activity of renin but not its production or its interaction with the
prorenin receptor (97). Therefore, inhibition of renin production by vitamin D may still
have therapeutic potential for patients with CKD (98).
The anti-in
ammatory properties of vitamin D might also add to the value of vitamin
D as an adjunct to RAAS blockade, as in
ammation is a determinant of RAAS blockade
resistance (99, 100). Vitamin D therapy could be particularly benecial in patients for
whom additional RAAS blockade therapy is contraindicated, such as those with hypoten-
sion or hyperkalemia.
Anti-in
ammatory and immunomodulatory eects
Several studies have demonstrated the anti-in
ammatory properties of active vitamin D
(16, 22, 101). The concept of vitamin D as an immunomodulatory molecule originated
over 25 years ago (102, 103), but the mechanisms involved, and the relevance of these
eects to the treatment of renal disease, have only now begun to be understood (104). A
study by Zehnder et al. reported that serum 1,25(OH)2 vitamin D3 levels were inversely
associated with renal in
ammation in several types of kidney disease (105). As mentioned
previously, treatment of cultured proximal tubular epithelial cells with the vitamin D
analogue paricalcitol induced the formation of a complex that consisted of VDR and the
NFB component p65 (16). The formation of this complex led to the reduced binding of
NFB to the promoter regions of genes involved in the in
ammatory response, resulting
in decreased activation of genes such as CCL5 (also known as RANTES). Similar results
were achieved in mesangial cells-administration of active vitamin D inhibited the activity
of CCL2 (also known as MCP-1) by stabilization of the NFB inhibitory unit IB (22).
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In macrophages, active vitamin D also suppressed NFB activity, leading to reduced
production of TNF (106). These ndings emphasize that VDR regulates the expression of
target genes both directly, and also by altering the activity of transcription factors such
as NFB.
Of interest, in addition to processing in the liver and the kidneys, vitamin D can also be
metabolized by cells of the immune system (107). Specically, activated T cells can convert
25(OH) vitamin D3 to active vitamin D (107). Moreover, macrophages and some dendritic
cells express enzymes required to convert vitamin D3 into active vitamin D (107{109).
The net eect of active vitamin D on T cells is to block the production of cytokines, in
particular interferon 
, by T-helper-1 cells, and to promote T-helper-2 cell responses (110).
Vitamin D also has inhibitory eects on dendritic cell maturation and dierentiation
in vitro, which results in a marked T-cell hyporesponsiveness (that is, reduced T-cell
proliferation and interferon 
 production) (111). Vitamin D may have an important
role in the maintenance of peripheral tolerance by expanding the pool of antigen-specic
regulatory T cells (112, 113). Together, these ndings justify studies that investigate
the potential of vitamin D analogues for the treatment of in
ammatory kidney diseases
such as autoimmune nephritis, and for tolerance induction in renal transplant recipients.
Preclinical studies in rats have shown improved graft survival following treatment with
active vitamin D after kidney transplantation (114). Although cholecalciferol treatment
(100,000 IU every 2 weeks for 2 months) in vitamin D-decient kidney transplant patients
has been shown to be safe (115), the dose required to induce renal allograft tolerance or
to prolong allograft or patient survival is not known.
Vitamin D could also have important immunomodulatory eects in individuals with
non-autoimmune chronic renal disease and in those who do not yet require kidney trans-
plantation. Of note, a recent study demonstrated the importance of renal dendritic cells in
the progression of glomerulonephritis after glomerular injury (116). Vitamin D-mediated
inhibition of dendritic cell maturation and dierentiation might reduce the in
ammatory
response associated with glomerular injury, which might slow or potentially even halt
progression of renal damage.
Conclusions
The kidney has a key role in the metabolism of vitamin D; consequently, renal disease
aects vitamin D metabolism. Epidemiological studies indicate that the prevalence of
vitamin D deciency in the general population is considerable, but is higher in patients
with CKD. This latter nding is important since low circulating levels of vitamin D have
been associated with increased morbidity and mortality, particularly in patients with
CKD; however, whether a causal relationship exists remains to be determined.
In addition to the classic eects of vitamin D on calcium and phosphate homeostasis,
several studies have revealed other important functions of this hormone. For example,
administration of vitamin D in experimental CKD reduces proteinuria, which may relate
to the eects of vitamin D on the RAAS and anti-in
ammatory actions. Vitamin D
decreases RAAS activity by downregulation of renin gene transcription in juxtaglomerular
cells. The inhibitory eect on renin is of particular interest, given the reactive rise in renin
during RAAS blockade, the cornerstone of current pharmacological treatment in patients
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with CKD. Vitamin D might, therefore, be a suitable add-on strategy to RAAS blockade in
these patients. Long-term, randomized, controlled trials should address the renoprotective
potential of this approach.
The relationship between vitamin D and the immune system is currently under intense
investigation. The role of vitamin D in macrophages, T cells and dendritic cells is of
particular interest, since these cells have a substantial role in the pathophysiology of renal
damage. Results from clinical trials that have used vitamin D analogues in patients with
CKD (59) and renal transplant recipients (117) are expected in the near future.
In conclusion, emerging data indicate that vitamin D deciency has greater clinical
consequences than the induction of osteomalacia in non-renal and renal populations. Al-
though the prevalence of rickets has decreased in Western countries, other disease entities
that are related to vitamin D deciency have been recognized. Clinical trials to investigate
the role of vitamin D supplementation for renal and cardiovascular protection are currently
underway, and will enable the role of vitamin D supplementation in the management of
CKD to be better dened.
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Abstract
End stage renal disease (ESRD) is a phenotype of severe irreversible renal dam-
age that can have a wide variety of etiologies. Genetic variants in vitamin D-related
genes may contribute to progression of renal disease towards ESRD. We genotyped 44
single nucleotide polymorphisms (SNPs) in four genes in the vitamin D pathway in
1271 renal transplant donor / recipient pairs. Minor allele frequencies of these SNPs
were compared between donors and recipients. In survival analysis, the eect of SNPs
in donors and recipients on the risk of mortality and death-censored graft failure was
investigated. Seven SNPs were identied with higher minor allele frequencies in ESRD
patients than in donors: in CYP24A1, rs8124792 (odds ratio [95% condence interval
(CI)] 2.2 [1.8-2.9]), in VDR, rs757343 (2.7 [2.1-3.5]) and rs11574143 (0.5 [0.3-0.6]),
and in GC, rs3755967 (1.5 [1.3-1.7]), rs4364228 (1.5 [1.2-1.9]), rs222017 (1.7 [1.4-2.0])
and rs3733359 (1.6 [1.3-2.0]) (all p < 0.0001). The cumulative risk of these SNPs on
ESRD expressed as a genetic risk score was highly signicant (odds ratio 1.57 [95% CI
1.44-1.70] per risk allele copy, p = 9  10
-28). At 5.4 [3.0-8.8] (median[interquartile
range]) years of follow-up, the minor allele of rs4809957 (CYP24A1) in recipients was
associated with an increased risk of mortality (hazard ratio 1.45 [95% CI 1.15-1.84], p
< 0.00001). No other recipient or donor SNP predicted graft failure or mortality. This
study observed association of seven common genetic variants in the vitamin D pathway
with ESRD, and of recipient rs4809957 with mortality in renal transplant recipients.
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Introduction
Vitamin D is a key regulator of calcium/phosphorus homeostasis. Studies over the past
decade have demonstrated additional roles for vitamin D, including modulation of the
renin-angiotensin-aldosterone system (RAAS) and the immune system (reviewed in (1)).
Both systems play a prominent role in the etiology and progression of chronic kidney dis-
ease. Accordingly, the renoprotective eect of vitamin D supplementation has been well
documented over the past years in animal models, along with reduction of RAAS activa-
tion and in
ammation (2{4). On the molecular level, direct modulation of the renin gene
(5), reduction of the bioactive TGF-beta/Smad3 pathway (6) and regulation of several
immune-modulatory genes through vitamin D response elements in their promoter regions
(7{9) are considered major determinants of the renoprotective properties of vitamin D.
In line with the accumulating preclinical data on renoprotective eects of vitamin D and
its analogues, vitamin D deciency has been associated with renal disease progression
in numerous clinical studies (10, 11). Together, these studies have led to randomized
controlled trials addressing the reno- and cardioprotective eects of vitamin D analogues
(12, 13). Unfortunately the results of these studies have been disappointing: only a bor-
derline signicant eect on albuminuria (20% reduction on top of standard treatment)
(12) and no eect on left ventricular hypertrophy (13) could be demonstrated. Genetic
heterogeneity in patients in contrast to the genetic homogeneity in animals could possibly
account for the discrepancy between ndings in animal studies and randomized clinical
trials. Furthermore, the presence of common genetic variants in vitamin D-related genes
has been linked to lower circulating vitamin D levels (14, 15).
Since vitamin D has a variety of renoprotective eects, our primary aim was to address
whether genetic variants in the vitamin D pathway are associated with an increased risk of
end stage renal disease (ESRD), requiring kidney transplantation. Furthermore, the prog-
nostic impact of genetic variants in the vitamin D pathway after kidney transplantation
is unclear, as previous studies have been con
icting and of limited sample size (16, 17).
Therefore our second aim was to relate common genetic variants in vitamin D-related
genes in donors and recipients to the risk of mortality and death-censored graft loss after
kidney transplantation.
Materials and Methods
Study population
Of all patients receiving a renal transplant between 1993 and 2008 in the University
Medical Center Groningen, The Netherlands, 1271 donor recipient pairs were included in
the study. We excluded patients who received a renal transplant combined with a liver or
pancreas transplant, donor/recipient pairs lacking material for genotyping and patients
lost to follow-up (Figure 4.1).
Selection of genes
We focused on four genes in the vitamin D pathway: CYP27B1 or 1-hydroxylase,
which hydroxylates 25-hydroxyvitamin D to active 1,25-dihydroxyvitamin D in the prox-
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imal tubular cells in the kidney, CYP24A1 or 24-hydroxylase, which hydroxylates both
25-hydroxyvitamin D and 1,25-dihydroxyvitamin D to inactive metabolites, VDR or vi-
tamin D receptor, which is the receptor for active vitamin D and GC, group specic
component or vitamin D binding protein, the main vitamin D carrier molecule in the
circulation.
Selection of SNPs
We considered all SNPs in the CYP27B1, CYP24A1, VDR and GC genes including 5 kb
around the coding region which are genotyped in both the CEU population, consisting of
Utah residents with Northern or Western European ancestry, and TSI population, con-
sisting of Tuscans in Italy, based on HapMap 3 version R2. Using HaploView (developed
at the Broad institute, MIT, Boston MA), tag SNPs were selected using the aggressive
method which allows for prediction of SNPs based on the genotypes of two or three other
SNPs, covering variation in the whole gene. All SNPs were analyzed prior to the actual
genotyping to maximize the success rate of genotyping with the Illumina kit. SNPs that
were predicted to fail were replaced by others. Some SNPs could not be replaced by
proxy SNPs and were therefore omitted. This resulted in 2 SNPs for CYP27B1, 18 for
CYP24A1, 13 for VDR and 11 for GC (Supplemental Table 4.5).
DNA analysis and genotyping
DNA was isolated from peripheral blood in recipients and living donors and from spleen
lymphocytes in deceased donors with a commercial kit following manufacturer's instruc-
tions. Genotyping of the selected SNPs was performed using the Illumina VeraCode
GoldenGate assay kit (Illumina, San Diego, CA, USA), according to the manufacturer's
instructions. Genotype clustering and calling were performed using BeadStudio Software
(Illumina). One donor/recipient pair was excluded because no genotype data was avail-
able. SNPs with a missing rate > 10% were excluded, this was true for rs1570669 in
CYP24A1.
Statistical analysis
Analyses were conducted with PASW Statistics 18.0.3 (SPSS: An IBM Company, Armonk,
NY) and PLINK v1.07 (S. Purcell, http://pngu.mgh.harvard.edu/purcell/plink/). The
analyses were divided in a case control analysis in which the association between genotype
and phenotype, i.e. being either renal transplant recipient (case) or kidney donor (control)
was addressed, and a survival analysis in which the eects of donor and recipient genotypes
on transplant outcome were studied. To test for Hardy Weinberg equilibrium, only donors
were considered. CYP24A1 rs6097807, CYP24A1 rs4809960, CYP27B1 rs1048691, VDR
rs2239179 and GC rs1155563 were below the threshold Chi square p value of 0.001 and
were excluded from all analyses.
Case control analysis
For the case control analysis, recipients were only included for their rst transplant, leaving
1142 cases. Subjects who donated two kidneys were included only once, leaving 1186
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Figure 4.1: Selection of patients and analysis groups.
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controls (Figure 4.1). Missingness (i.e. the fraction of missing data per group) diered
between donors and recipients in two SNPs (Chi squared test, p < 0.001): VDR rs2239179
and GC rs7041, possibly due to lesser quality of donor DNA. These SNPs were excluded
from analysis.
With logistic regression the eect of each single SNP was calculated after adjusting
for donor and recipient gender and age and for type of donation (living, heartbeating
or non-heartbeating). This analysis was repeated with additional adjustment for cold is-
chemia time, rst and second warm ischemia times, total number of HLA mismatches, and
the highest panel-reactive antibodies (PRA) percentage. To test whether all SNPs that
signicantly dier between donors and recipients independently contribute to the model,
linkage disequilibrium (LD) was calculated between SNPs on the same gene. Furthermore,
the eects of all SNPs in one gene that were identied as signicant when tested alone,
were analyzed in one logistic regression model for each gene.
To correct for multiple testing, an algorithm was used that is similar to the Bon-
ferroni correction, but takes into account that some SNPs are in LD and are therefore
not independent. It calculates the eective number of independent comparisons and a
corresponding signicance threshold that keeps the gene-wide Type I error rate at 5%
(18). For CYP24A1 the eective number of independent comparisons was 13.7, resulting
in a signicance threshold of 0.004. For CYP27B1, only one SNP was analyzed, so the
threshold was 0.05. For VDR and GC, the eective number of independent comparisons
was 10.1 and 7.9, resulting in a signicance threshold of 0.005 and 0.006 respectively.
Survival analysis
Since both donor and recipient genotype were considered possible predictors of death-
censored graft loss and mortality, donors were only included for their rst donation and
recipients only for their rst transplantation leading to 1068 donor/recipient pairs (Fig-
ure 4.1).
Cox regression analysis was used to test for dierences in time to death or time to
death-censored graft loss between SNPs. The eective number of independent comparisons
and corresponding p values were calculated per gene in both donors and recipients using
the same algorithm as in the case control analysis. Although the eective number of
independent comparisons in some cases diered from the ones in the case control analysis,
the adjusted p values were the same as in the case control analysis for both donors and
recipients.
Results
Kidney transplant donor and recipient characteristics are shown in Table 4.1. Gender
diered between donors (51% male) and recipients (58%, p=0.001), and donors were sig-
nicantly younger than recipients (44 and 48 years, respectively, p = 1  10-10). Median
follow-up was 5.4 years (interquartile range 3.0-8.8 years). During follow-up, 170 (16%)
renal transplant recipients lost their transplant due to graft failure, and 185 (17%) recip-
ients died with a functioning graft. All genotyped SNPs in CYP24A1, CYP27B1, VDR
and GC are shown in Supplemental Table 4.5.
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Case control analysis
In single SNP analysis the minor allele frequency of seven SNPs was signicantly dierent
between kidney transplant donors and recipients (ESRD patients), adjusted for donor and
recipient age and gender and type of transplantation (Table 4.2). The two SNPs in VDR
(rs11574143 and rs757343) were in moderate linkage disequilibrium (LD) (r2 0.59). All
other SNPs were not in LD (r2 < 0.2).
Next, for each gene, all signicant SNPs as indicated above were put in a multivariate
regression model per gene, as dierent SNPs in the same gene may be interrelated. When
adjusted for the other signicant SNPs in the same gene, odds ratios for SNPs in GC were
higher. This conrms the independent contribution of each SNP to the model. Table 4.2
shows the SNPs that were found to be signicant, their allele frequencies and the odds
ratios when tested separately and when tested with the other signicant SNPs in the gene.
In VDR the minor allele of rs11574143 was found to be protective instead of harmful when
adjusted for rs757343. Table 4.3 shows the interaction of these two SNPs.
We dened a risk score as the sum of risk alleles of the seven SNPs that signicantly
and independently dierentiated between donors and recipients. These were the minor
alleles of rs8124792, rs757343, rs3755967, rs4364228, rs222017 and rs3733359, and the
major allele of rs11574143. The risk score ranged from 1-8 in donors and 2-9 in recipients.
The risk of ESRD gradually increased when a higher number of risk allele copies was
present (odds ratio 1.57 [95% CI 1.44-1.70] per risk allele copy, p = 9  10-28). Figure 4.2
shows the odds ratio for recipient status with the number of risk alleles categorized.
Adjustment for cold ischemia time, rst and second warm ischemia times, total number
of HLA mismatches, and the highest PRA percentage yielded highly similar results (results
not shown).
Survival analysis
Univariate Cox regression analysis revealed that rs4809957 in CYP24A1 in recipients
predicted mortality (hazard ratio [95% condence interval] 1.57 [1.26 - 1.95], p < 0.00001),
which was conrmed by a Kaplan Meier plot (Figure 4.3). In multivariate regression
analysis, the minor allele of rs4809957 remained an independent predictor of mortality
after adjustment for donor and recipient age and gender, cold ischemia time, rst and
second warm ischemia times, total number of HLA mismatches, and the highest PRA
percentage (1.45 [1.15 - 1.84], p = 0.002) (Table 4.4). None of the other SNPs in recipients
or donors predicted mortality or graft failure. The risk score, calculated with donor or
recipient SNPs, was not associated with graft loss or mortality in the longitudinal analysis.
Discussion
We identied seven SNPs in three vitamin D-related genes (CYP24A1, VDR and GC) that
were associated with ESRD, since their risk allele frequencies were signicantly dierent
between kidney transplant donors and recipients. These seven SNPs contributed to the
risk of ESRD independently of each other and of donor and recipient age and gender and
of the type of transplantation. When all risk alleles of these seven SNPs were considered
together, a risk score was obtained that was associated with an increased risk of ESRD
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Table 4.1: Population characteristics.
Donor characteristics (n = 1186)
Age (years) 44  14
Gender (males (percentage)) 603 (51%)
Type of donation
living 282 (24%)
heartbeating 717 (60%)
non heartbeating 187 (16%)
Recipient characteristics (n = 1142)
Age (years) 48  14
Gender (males (percentage)) 662 (58%)
Highest PRA percentage (median (IQR)) 0 (0 - 0)
Primary disease Number (percentage)
Chronic renal failure, unknown etiology 155 (14)
Glomerulonephritis 292 (26)
Interstitial nephritis 150 (13)
Cystic kidney diseases 188 (16)
Other congenital and hereditary kidney diseases 46 (4)
Renal vascular disease, excluding vasculitis 112 (10)
Diabetes 47 (4)
Other multisystem diseases 70 (6)
Others / missing 82 (7)
Transplantation characteristics (n = 1068)
Follow-up (years, median (IQR)) 5.4 (3.0 - 8.8)
Cold ischemia time (minutes, median (IQR)) 1020 (523 - 1380)
Warm ischemia time 1 (minutes, median (IQR)) 0 (0 - 3)
Warm ischemia time 2 (minutes, median (IQR)) 31 (37 - 45)
Total number of HLA mismatches (median
(IQR))
2 (1 - 3)
Graft failure 170 (16%)
Death with functioning graft 185 (17%)
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Figure 4.2: Sum of risk alleles of the signicant SNPs for predicting donor or recip-
ient status and the odds ratio with 95% condence interval for recipient status.
Table 4.3: Interaction of rs757343 and rs11574143 in VDR described by distribution
of the alleles and odds ratios.
VDR SNPs rs757343
N of the minor
allele copies
0 1 2
r
s
1
1
5
7
4
1
4
3 0
Reference OR 1.78 OR 1.80
OR=1.00 p=4.5  10
-4 p=0.009
n=1552 n=169 n=25
1
OR 0.52 OR 1.00 OR 15.6
p=0.44 p=1.00 p=1.3  10
-13
n=7 n=365 n=110
2
OR 0.91
p=0.87
n=0 n=0 n=12
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Figure 4.3: Mortality curves by recipient rs4809957 genotype.
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Table 4.4: Cox multivariate regression analysis for mortality after kidney transplan-
tation.
Variable Hazard ratio 95% condence interval p
Lower Upper
rs4809957 (minor allele count) 1.451 1.148 1.836 0.002
Donor age 1.009 0.999 1.020 0.081
Donor gender 0.917 0.659 1.276 0.607
Recipient age 1.079 1.062 1.096 < 0.001
Recipient gender 1.022 0.733 1.424 0.898
Cold ischemia time 1.000 1.000 1.000 0.772
First warm ischemia time 0.981 0.953 1.009 0.182
Second warm ischemia time 1.005 0.993 1.018 0.420
Total number of HLA mismatches 1.180 1.047 1.329 0.007
Highest PRA percentage 0.999 0.993 1.006 0.883
by about 1.5 times per risk allele present (p = 9  10-28). This means that a person
with 4 risk alleles is four times more likely to be a renal transplant recipient than a donor
compared to someone with 1 risk allele. In survival analysis, another SNP (rs4809957
in CYP24A1) in recipients predicted mortality after renal transplantation. Our ndings
imply that genetic variation in CYP24A1, VDR and GC is associated with ESRD, which
is well in line with accumulating evidence linking genetic variants in vitamin D-related
genes to circulating vitamin D levels (14, 15) and lower vitamin D levels to progression of
renal disease (10, 11).
CYP24A1
CYP24A1 encodes the enzyme 24-hydroxylase, which is able to hydroxylate both 25-
hydroxyvitamin D and 1,25-dihydroxyvitamin D at the 24 position to inactive metabo-
lites. CYP24A1 is upregulated by 1,25-dihydroxyvitamin D, providing a feedback loop
to regulate vitamin D levels (19). Increased CYP24A1 activity has been implicated in
reduced vitamin D levels, possibly contributing to kidney disease progression. In 30 aged
mouse strains, albuminuria was associated with a quantitative trait locus that includes
CYP24A1 (20). Transgenic rats constitutively expressing the CYP24 gene develop albu-
minuria and hyperlipidemia shortly after weaning (21); both are important risk factors
for kidney disease progression. SNP rs8124792, in our study associated with ESRD, is
located downstream of the coding region, as well as a closely linked SNP (rs2762934).
Another closely linked SNP (rs6097809) is intronic. The rs4809957 SNP, which predicted
mortality in our study, is located downstream of the coding region, similar to the closely
related SNPs rs6097801 and rs2762932.
VDR
Vitamin D receptor is the receptor for the most bioactive vitamin D metabolite (1,25-
dihydroxyvitamin D). VDR comes in homodimers or heterodimers with amongst others
the retinoid X receptor. The VDR is a nuclear receptor interacting with vitamin D
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response elements (VDREs) in regulatory regions of target genes (22). About 6% of all
genes in the human genome contain one or more VDREs, and many cells in the human
body, including many renal cell types, express the VDR (23).
rs757343 in VDR is intronic and has also been described as a nonsense mediated
decay (NMD) transcript which may cause the transcripts of the gene to degrade. It is
closely associated with rs731236, which is a synonymous coding SNP. rs11574143 in VDR
is located within 5kb downstream of the gene and has also been described as an NMD
transcript. When analyzed without rs757343, the minor allele of rs11574143 appears to
be harmful. When both SNPs are analyzed together, the minor allele of rs11574143 is
associated with protection. This can be explained by the high linkage disequilibrium (LD)
between the two SNPs. All subjects who are homozygous for the minor allele of rs11574143
also carry two minor alleles for rs757343, suggesting that the minor allele of rs11574143
developed in a subject who already carried the minor allele for rs757343. Therefore, when
analyzed by itself, rs11574143 acts as a proxy for the harmful rs757343. The protective
eect of rs11574143 is apparently smaller than the harmful eect of rs757343.
The functional eects of genetic variability in VDR with regard to: 1) mRNA expres-
sion levels; 2) stability in in vitro studies; and to 3) response to vitamin D treatment in in
vivo studies have been analyzed extensively, but are unequivocal (24). In hypertensives
the Fok1 (rs10735810) polymorphism in VDR is associated with lower plasma renin activ-
ity (25). Allele frequencies of Apa1 (a) (rs7975232), Fok1 (f), and Bsm1 (B) (rs1544410)
were signicantly dierent between 258 ESRD patients and 569 healthy controls (26). The
latter is in close LD with rs757343, which diered between ESRD patients and donors in
our study. The eect of genetic variability in VDR on development of ESRD may be
through lower vitamin D levels or through the renin angiotensin aldosterone system.
GC
GC (vitamin D binding protein) is an albumin-like protein to which the lipophilic vitamin
D binds in the circulation. Variability in this gene is high; polymorphisms have been
studied for decades (27).
rs3755967 in GC is located in an intron and is an NMD transcript. It is closely
associated with three other intronic SNPs (rs705117, rs2282679, rs2298850) which give
rise to an NMD transcript, and to the non-synonymous coding rs4588. Intronic SNP
rs4364228 and closely linked rs222049 and rs222046 can cause NMD transcripts. rs222017
is also intronic, can cause NMD transcripts and is also upstream of a retained intron,
which is an intron that under some circumstances remains part of the mRNA when other
introns are removed. rs3733359 in GC is an intronic SNP close to a splice site. rs3733359
and the closely linked rs6817912 can both cause NMD transcripts.
Genetic variability in GC predicts 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D
levels in postmenopausal women (28), determines response to vitamin D supplementation
in healthy adults (29) and determines the vitamin D requirements in dialysis patients (30).
In two independent genome-wide association studies in 4,501 (15) and 16,125 individuals
(14) the strongest predictor of vitamin D levels was rs2282679. This SNP is in perfect LD
with rs3755967, of which the minor allele frequency was signicantly dierent between
donors and recipients in our study. Taken together, these studies suggest that the rela-
tionship between genetic variation in the GC gene and the increased risk of ESRD may
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be mediated by lower vitamin D levels and a dierent response to vitamin D in carriers
of the minor allele compared to the carriers of the major allele.
Possible implications of our study
Our results suggest that common genetic variants in the vitamin D pathway can be used
to identify subjects at increased risk of developing ESRD. Previous studies in both hu-
mans and animals suggest a causative relation between the vitamin D pathway and renal
disease, but do not unequivocally prove it. Recently published results from clinical trials
disappointingly suggested that vitamin D analogues had only marginal eects on albu-
minuria (12) and no eects at all on left ventricular mass or diastolic dysfunction (13).
These studies were preceded by consistently positive preclinical studies showing additive
protective eects of vitamin D analogues on top of RAAS blockers, the current corner-
stone of renoprotection. Our study may provide an explanation for this discrepancy, as
common genetic variations in the vitamin D pathway may in
uence development and pro-
gression of renal disease through their eects on vitamin D levels and vitamin D handling.
Future studies should address whether the genetic variants we identied can be a target
for intervention in order to prevent end-stage renal disease.
Conclusion
In a large cohort of renal transplant recipients we identied seven SNPs in the vita-
min D pathway that independently contributed to the risk of ESRD. Another SNP in
the CYP24A1 gene was independently associated with all-cause mortality when present
in graft recipients. This study connects previous work linking genetic variations in the
vitamin D pathway to vitamin D deciency, and studies linking vitamin D deciency to
progression of renal disease by showing an association between genetic variation and ESRD
risk. Conrmation of our ndings is warranted, since these SNPs can be used to identify
subjects with an increased risk of developing ESRD and renal transplant recipients with
an increased risk of mortality.
68Vitamin D pathway SNPs in renal transplantation
Table 4.5: Genotyped tagSNPs in vitamin D pathway related genes. Per gene SNP
name (major allele/minor allele) are given.
CYP27B1 CYP24A1 VDR GC
rs4646536 (A/G) rs4809957 (A/G) rs12721364 (G/A) rs1491711 (C/G)
rs1048691 (C/T) rs4809955 (A/G) rs7968585 (A/G) rs3755967 (C/T)
rs6097807 (A/G) rs11574143 (C/T) rs12640179 (C/G)
rs4809958 (T/G) rs7963776 (T/C) rs7041 (G/T)
rs8124792 (G/A) rs11168268 (T/C) rs4364228 (A/G)
rs2245153 (T/C) rs757343 (C/T) rs222014 (C/T)
rs3787555 (C/A) rs2107301 (G/A) rs222017 (T/A)
rs1570669 (G/A) rs3819545 (A/G) rs222020 (T/C)
rs2585428 (C/T) rs2248098 (C/T) rs1155563 (T/C)
rs2248461 (G/A) rs2239182 (G/A) rs2298849 (A/G)
rs2181874 (G/A) rs2189480 (G/T) rs3733359 (G/A)
rs3787557 (T/C) rs2239179 (A/G)
rs2762929 (T/C) rs886441 (A/G)
rs6022999 (A/G)
rs6068810 (G/T)
rs4809959 (T/C)
rs2762941 (C/T)
rs4809960 (T/C)
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Abstract
Creatinine-based equations are available to estimate GFR. After renal transplan-
tation body composition usually changes, thus specic validation is required for
transplant recipients. Nine equations were compared with iothalamate glomerular
ltration rate (GFR) at 1 year after transplantation in 798 recipients. Equations were
analyzed for precision, bias and accuracy. Sources of bias were analyzed by univariate
and multivariate analysis, with body mass index (BMI), age and sex as independent
variables and bias as dependent variable. Four hundred and seventy-eight patients were
studied to assess whether the equations can be used to monitor renal function over
time. Predictive performance was modest for all equations. MDRD and Jellie 2 were
the best predictors of GFR. Bias was signicantly related to BMI, age and gender in
most equations. Multivariate analysis conrmed their independent contribution to the
bias of MDRD, Jellie 2 and most other equations. Over time, bias was relatively stable
at group level, but predictive performance in individuals was modest. The predictive
performance of renal function equations is modest in renal transplants, which hampers
their use for accurate assessment of renal function in the individual. The role of patient
factors in the systematic error suggests that development of better equations should be
feasible by better incorporation of these factors.
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Introduction
Glomerular ltration rate (GFR) can be precisely measured by specic ltration markers
such as inulin, 125I-iothalamate, 51Cr-EDTA, 99mTc-DTPA and iohexol. These measure-
ments, however, are laborious and expensive, and therefore, in clinical practice GFR
is usually estimated from serum creatinine, using renal function equations that include
antropometric indices such as age, weight and gender to account for between-individual
dierences in muscle mass and the consequent dierences in creatinine generation. Many
equations are available, most of which were developed in populations with native kidney
disease (1{18). The predictive performance as well as the shortcomings of creatinine-based
renal function equations has been subject of several recent reviews (19, 20).
After renal transplantation body composition often changes, with a high prevalence
of obesity and loss of muscle mass due to steroid use-which could violate the assumptions
underlying the creatinine-based renal function equations. Thus, for renal transplant re-
cipients specic validation of renal function equations would be required. Several studies
addressed this issue (21{25), indicating a relatively poor predictive performance of renal
function equations in the transplant population. However, these studies included only rel-
atively small populations, and only evaluated a small number of equations. Furthermore,
in these studies the factors underlying the poor predictive performance, and the conse-
quences for the clinical monitoring of individual patients over time were not analyzed. In
the present study, therefore, we studied the predictive performance of nine renal function
equations in a large single center population of renal transplant recipients, and analyzed
for determinants of the systematic error. Moreover, to assess the suitability of equations
to monitor renal function over time, the stability of bias over time and the accuracy of
the equations to predict the change in GFR over time were studied in 478 patients with
a follow-up to 5 years after transplantation.
Materials and Methods
Patients
The study group consisted of 798 renal transplant recipients (722 from cadaveric and 77
from living donors; 453 males, 345 females; mean age at transplantation: 44  13 years)
in whom renal hemodynamic measurements had been routinely performed in our depart-
ment 1 year after transplantation. The patients were transplanted between 1984 and 2002.
The study group was selected out of 1798 patients-the total number transplanted from
1968 until 2002. Of 997 patients, renal hemodynamic measurements at 1 year after trans-
plantation were available. Of these patients, 199 could not be included because relevant
data on certain hemodynamic parameters were missing. The routine immunosuppressive
regimen is described in detail elsewhere (26).
Methods
Renal hemodynamic measurements| GFR was measured by constant infusion of 125I-
iothalamate, with correction for voiding errors by simultaneous measurement of the clear-
ance of 131I-Hippuran as described by Donker et al. and Apperloo et al. (27, 28). Brie
y,
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an intravenous cannula was inserted for tracer infusion at 8 AM. The infusion 
uid con-
sisted of 4 MBq 131I-Hippuran and 3 MBq 125I-iothalamate per 100 mL saline. First,
a priming solution of 0.4 mL/kg body weight was administered plus an extra 0.6 MBq
125I-iothalamate to ensure steady state of the plasma tracers within the time frame of the
measurement. Thereafter, a continuous infusion was started. After a stabilization period
of 2 h, two 2-h clearance periods followed. GFR was measured as the urinary clearance of
125I-iothalamate (UV/P) and corrected for voiding errors by multiplying UV/Piothal by
the ratio of plasma clearance of 131I-Hippuran to urinary clearance of 131I-Hippuran. This
correction method is based on the fact that, during steady state, the plasma clearance
of 131I-Hippuran equals its urinary clearance when urine collection is perfect. Thus, the
voiding error can be calculated from the ratio of urinary clearance and plasma clearance of
131I-Hippuran. This GFR measurement has a day-to-day coecient of variation of 2.2%.
Serum creatinine levels were determined by an alkaline picrate creatinine assay (Ja e),
which has a day-to-day variability of 4% in our laboratory.
Renal function equations| As a rst, screening, step, 18 equations (Cockcroft, Ed-
wards, Mawer, Bjornsson, Hull, Salazar, Nankivell 1 (developed for kidney transplant
recipients), Nankivell 2 (developed for combined kidney/pancreas transplant recipients),
Baracskay, Walser, Jellie 1 and 2,Gates, Agarwal, Toto, Nguyen, simplied MDRD
and the recently published equation developed by Rule et al. (1{18) were analyzed for
predictive performance from the data obtained at 1 year after transplantation. These
equations are given in Appendix. Equations were analyzed for precision (R2, dened as
the scatter of the series of observations), accuracy (dened as the percentage of subjects
within 30% of true GFR, i.e. 125I-iothalamate clearance) and bias (calculated as the mean
prediction error (ME), dened as ME = 1/N  (predicted value - true value). All equa-
tions were tested against true GFR, including equations predicting creatinine clearance.
Equations predicting GFR per BSA (indicated by ) were tested against GFR per BSA.
Walser and Hull were tested against GFR per 3 m2 and GFR per 70 kg, respectively.
Selection of equations for detailed analysis| A selection of the equations was used for
further analysis. The MDRD, Jellie 2, Jellie 1, Gates, Cockcroft, Hull and Mawer were
selected because they are reviewed in six papers or more (a criterion also used in the DOQI
guidelines review on the use of renal function equations (19)) and in our population had an
overall predictive performance (30% accuracy) above 70%. Nankivell 1 was chosen because
it was especially developed for the renal transplant population. Finally, we included the
recently published equation of Rule et al. (15), as this equation is anticipated to provide a
better renal function estimate in subjects with mild renal function impairment. The 10%
and 30% accuracy of the nonselected equations was: Salazar: 31% and 71%; Bjornsson:
33% and 70%; Agarwal: 17% and 51%; Toto: 18% and 50%; Baracskay: 15% and 39%;
Nguyen: 4% and 13%; Edwards: 36% and 85%; Walser: 30% and 82% and Nankivell 2:
30% and 80%, respectively. The sources of systematic error in these nonselected equations
were comparable to those of the selected ones, but for the sake of conciseness these data
are not presented in the paper.
Predictive performance over time| The suitability of equations to monitor renal func-
tion over time was tested in all 478 subjects in whom data were available at 2 and 5 years
as well, in addition to data at 1 year after transplantation. First, the mean bias at years
1, 2 and 5 was calculated and tested for changes over time. Second, to test the suitability
for follow-up we assessed the predictive performance of the equations to detect a change
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in true GFR over time (R2, bias, accuracy).
Statistical analysis
Statistical computations were performed using SPSS, version 12.0 software (SPSS, Inc.,
Chicago, IL). To test for the sources of the systematic error univariate and multivariate
analyses were performed. For univariate analysis the population was divided in tertiles of
BMI, age and GFR, respectively. The dierence in bias between the tertiles was assessed
by analysis of variance (ANOVA). The dierence in bias between men and women was
tested by ANOVA as well. Multivariate analysis was used to identify patient character-
istics that were independent determinants of the systematic error. This was analyzed by
multilinear regression analysis, with bias as the dependent variable and BMI, age and
sex as independent variables. To test whether bias changed over time, repeated measures
analysis by general linear modeling was performed in the subgroup with a follow-up to 5
years after transplantation, with bias as the dependent variable. A two-sided p-value less
than 0.05 was considered statistically signicant.
Results
Overall predictive performance
Patient characteristics are given in Table 5.1. Mean body mass index (BMI) was 25.6
( 4.0) kg/m2. Obesity (BMI > 27.0 kg/m2) was present in 32% of the patients (n =
252). Table 5.2 presents the overall predictive performance of the nine selected equations,
calculated from the data at 1 year after transplantation. Predictive performance is ex-
pressed as precision (R2, depicted for individual patients in Figure 5.1), bias (the mean
prediction error) and 10% and 30% accuracy (the % of values within 10% and 30% of the
true value, respectively), ranked by 30% accuracy. It shows, rst, that the nonsystematic
error, as re
ected by the precision, is relatively large for all equations. Second, the average
systematic error, i.e. bias or prediction error, appears small for most formula, with small
condence intervals as well, probably due to the large number Patient characteristics are
given in Table 5.1. Mean body mass index (BMI) was 25.6 ( 4.0) kg/m2. Obesity (BMI
>27.0 kg/m2) was present in 32% of the patients (n = 252). Table 5.2 presents the overall
predictive performance of the nine selected equations, calculated from the data at 1 year
after transplantation. Predictive performance is expressed as precision (R2, depicted for
individual patients in Figure 5.1), bias (the mean prediction error) and 10% and 30%
accuracy (the % of values within 10% and 30% of the true value, respectively), ranked by
30% accuracy. It shows, rst, that the nonsystematic error, as re
ected by the precision,
is relatively large for all equations. Second, the average systematic error, i.e. bias or
prediction error, appears small for most formula, with small condence intervals as well,
probably due to the large number
Sources of systematic error
As apparent from Figure 5.1, for most equations the prediction error is not stable over
the dierent levels of true GFR. We quantied this by comparing the prediction errors
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Table 5.1: Population characteristics (n = 798).
Mean  SD Range
Male/female (453/345)
Age (years) 44  13 14-77
BMI (kg/m
2) 25.6  4.0 15.8-46.6
MAP (mmHg) 108  12 73-167
GFR (mL/min) 55  18 18-115
Serum creatinine (mol/L) 145  40 68-267
Creatinine clearance (mL/min) 64  21 16-146
Table 5.2: Overall predictive performance, ranked by 30% accuracy.
Formula Precision Bias 95% CI Range
Accuracy
10% 30%
MDRD 0.63 -3.2 -3.9/-2.5 -30.4/35.5 38% 88%
Jellie 2 0.6 -1.4 -2.1/-0.7 -37.7/30.9 36% 88%
Jellie 1 0.63 -0.9 -1.6/-0.2 -33.2/38.0 37% 87%
Gates 0.6 -1.6 -2.4/-0.9 -34.6/44.8 40% 87%
Nankivell 1 0.64 5.8 5.1/6.8 -28.0/39.8 35% 76%
Cockcroft-Gault 0.61 6.3 5.4/7.1 -34.6/50.3 36% 76%
Hull 0.63 6.5 5.7/7.2 -39.5/45.0 35% 74%
Mawer 0.63 7.4 6.6/8.2 -33.6/50.0 35% 73%
Rule 0.65 7.4 6.5/8.3 -4.7/68.5 29% 72%
Creatinine clearance 0.55 9.3 8.3/10.3 -37.0/83.0 23% 66%
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Figure 5.1: Scatter plots, showing the correlations between the selected equations
and the measured GFR. The dashed lines represent the lines of identity.
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for tertiles of true GFR for all equations as shown in Figure 5.2. Bias was signicantly
and considerably dierent for the dierent tertiles of GFR for all equations. Remarkably,
for the Rule equation the impact of the level of GFR on bias was opposite to that of all
other equations.
The impact of BMI, age and gender, respectively, on the systematic error is shown in
Figure 5.3 A-C. Figure 5.3 A shows mean values for bias for all equations (ranked by 30%
accuracy) by a breakup according to tertiles of BMI. Mean BMI for the increasing tertiles
was: 21.7 (range: 15.8-23.7), 25.3 (range: 23.7-26.8) and 30.0 (range: 26.8-46.6) kg/m2.
It shows that BMI signicantly aects bias in all but three equations. It is also apparent
that the eect of BMI on bias for the two most widely used equations, the MDRD equation
and the Cockcroft-Gault equation, is opposite, with underestimation of GFR at high BMI
by the MDRD, and overestimation of GFR at high BMI by the Cockcroft-Gault equation.
Figure 5.3 B shows bias by a break-up according to age. Mean age per tertile was 28.4
(range: 14-38) years, 45.3 (range: 39-51) years and 58.8 (range: 52-77) years, respectively.
Again, in all but one equation the systematic error is signicantly aected by age. Finally,
Figure 5.3 C gives mean bias by a break-up according to gender, showing that gender has
a signicant eect on bias in most equations. Multivariate analysis was performed to see
whether the patient characteristics BMI, age and sex were independent determinants of
the prediction error, or whether there might be interdependency. An outline of the models
is given in Table 5.3, showing that BMI was an independent determinant of the model
explaining bias for most equations, age for all but two equations and gender for all but
two equations.
Predictive performance to monitor renal function over time
To test the suitability of renal function equations to monitor renal function over time, rst,
in 478 recipients in whom GFR was also measured at 2 and 5 years after transplantation,
we analyzed the course of the prediction error over time. Mean values for bias (SE) at
1, 2 and 5 years after transplantation are given in Figure 5.4 continuous lines). As the
cross-sectional analysis at year 1 had shown that GFR and the BMI were determinants of
the prediction error, we also evaluated whether the mean prediction error might be more
stable over time in the subgroups with stable GFR (less than 10% change, n = 215, broken
lines) and stable BMI (less than 5% change, n = 343, dotted lines), respectively. For the
whole patient group, generally, the mean bias was fairly stable over time, not exceeding
an absolute value of 2-3 mL/min over the 4-year observation period. On repeated mea-
surement analysis, nevertheless, the small change in prediction error over time reached
statistical signicance for the MDRD, Jellie 1 and 2, Gates and Nankivell equations (all
p < 0.001). This was similarly true for the subgroups with stable BMI and stable GFR,
respectively (p < 0.001). For the Cockcroft-Gault, Hull, Mawer and Rule equation, bias
did not change signicantly over time.
Finally, we analyzed the accuracy of the equations in predicting the change in GFR
over time. The mean change in GFR between years 1 and 5 was -1.9  15.1 mL/min
(Table 5.4), whereas the mean changes estimated by the dierent equations ranged from
+0.5  12.1 mL/min (Jelie 1) to -2.3  12.3 mL/min (Hull), which was not signicantly
dierent from the change in true GFR. However, the precision of the equations to predict a
change in true GFR from a change in estimated GFR was relatively poor, ranging from an
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Figure 5.2: Univariate analysis showing the mean values for bias (mL/min) for the
selected equations (ranked by 30% accuracy) by a break up according to tertiles of
GFR. GFR 1: 38 (range: 18-46) mL/min. GFR 2: 54 (range: 47-61) mL/min. GFR 3: 75
(range: 62-115) mL/min. Bias signicantly dierent across the tertiles (ANOVA, p < 0.05).
Table 5.3: Multivariate analysis. Table showing the models for the dierent equations
obtained by multilinear regression analysis. All models were statistically signicant.
BMI Age Sex
R
2 Beta p Beta p Beta p
MDRD 0.073 -0.121 0.001 -0.007 0.832 0.241 < 0.001
Jellie 2 0.171 -0.102 0.002 -0.356 < 0.001 -0.134 < 0.001
Jellie 1 0.115 -0.118 0.001 0.329 < 0.001 -0.93 0.005
Gates 0.149 -0.112 0.001 0.006 0.87 0.371 < 0.001
Nankivell 1 0.101 -0.167 < 0.001 0.282 < 0.001 0.128 < 0.001
Cockcroft 0.266 0.393 < 0.001 -0.423 < 0.001 0.078 0.01
Hull 0.206 0.279 < 0.001 -0.425 < 0.001 0.032 0.318
Mawer 0.248 0.404 < 0.001 -0.396 < 0.001 0.017 0.587
Rule 0.044 -0.118 0.001 -0.108 0.003 -0.114 0.001
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Figure 5.3: (A) Univariate analysis showing the mean values for bias (mL/min) for
the selected equations (ranked by 30% accuracy) by a break up according to tertiles
of BMI. BMI 1:21.7 (range: 15.8-23.7) kg/m
2. BMI 2:25.3 (range: 23.7-26.8) kg/m
2. BMI 3:30.0
(range: 26.8-46.6) kg/m
2. *Bias signicantly dierent across the tertiles (ANOVA, p<0.05). (B)
Univariate analysis showing the mean values for bias (mL/min) for the selected equations (ranked
by 30% accuracy) by a break up according to tertiles of age. Age 1:28.4 (range: 14-38) years.
Age 2:45.3 (range: 39-51) years. Age 3:58.8 (range: 52-77) years. *Bias signicantly dierent
across the tertiles (ANOVA, p < 0.05). (C) Univariate analysis showing the mean values for
bias (mL/min) for the selected equations (ranked by 30% accuracy) by a break up according to
gender. *Bias signicantly dierent across the tertiles (ANOVA, p < 0.05).
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Table 5.4: Predictive performance of the changes between estimated GFR and true
GFR (mL/min) at years 1 and 5.
Equation Delta
(mean 
SD)
Precision Bias 95%CI Range 30% Accu-
racy
MDRD -0.5  10.9 0.49 1.1 0.2/2.0 -38.2/35.3 21%
Jellie 2 -1.9  9.8 0.5 -0.3 -1.2/0.6 -36.1/29.7 20%
Jellie 1 0.5  12.1 0.49 2.2 1.2/3.1 -39.0/38.0 21%
Gates -0.5  11.3 0.49 1.2 0.3/2.1 -40.5/35.9 22%
Nankivell 1 0.3  12.0 0.54 1.6 0.6/2.5 -41.1/33.3 22%
Cockcroft-Gault -1.4  13.4 0.54 0.4 -0.5/1.4 -47.3/42.4 22%
Hull -2.3  12.3 0.49 0.1 -0.7/1.0 -40.0/28.4 22%
Mawer -1.9  14.2 0.54 -0.1 -1.0/0.9 -49.9/43.9 24%
Rule -1.4  17.1 0.44 0.3 -0.9/1.4 -51.4/41.3 20%
Iothalamate GFR -1.9  15.1
R2 of 0.49 (MDRD, Jellie 1, Gates and Hull) to 0.54 (Nankivell 1, Cockcroft-Gault and
Mawer). Whereas mean bias was small, the condence intervals were wide, and overall
predictive performance was poor with a 30% accuracy that did not exceed 24% (Mawer).
Data for individual patients are given in Figure 5.5, providing the correlations of the %
change in true GFR with the % change in equation-estimated GFR, and with % change in
reciprocal of serum creatinine, respectively. It shows a relatively wide scatter of individual
values, with R2 values for the equations ranging from 0.49 (Rule) to 0.57 (Cockcroft-Gault
and Mawer). For the reciprocal of serum creatinine the R2 (0.51) was also within this
range.
Discussion
The overall predictive performance of renal function equations in our renal transplant
population was modest to poor. On group level, predictive performance was acceptable
for several equations, but individual assessment of renal function was relatively poor for all
equations, which hampers the use of equations in clinical practice, both for cross-sectional
assessment and for long-term follow-up. On univariate and multivariate analysis the pa-
tient characteristics age, gender and BMI were signicant determinants of the systematic
error. Moreover, the systematic error was dependent on the level of true GFR. As the
systematic error can in principle be corrected for, these data indicate that it should be
feasible to develop more accurate renal function equations.
Our study provides the largest transplant population analyzed so far. Several prior
smaller studies recently evaluated the performance of specic renal function equations in
transplant populations, with a comparable outcome as to overall predictive performance
(21{25). At variance with these prior studies, the sample size of our population allows
for analysis of the determinants of bias. This is relevant, as, in contrast to the random
error, the systematic error can in principle be corrected for. Patient characteristics were
involved in the systematic error in all equations, including those with the best predictive
83Chapter 5
Figure 5.4: Graphs showing mean bias (mL/min,  SE) for at years 1, 2 and 5.
Continuous line: mean values for all 478 patients of whom hemodynamic measurements were
available at years 1, 2 and 5. Broken lines represent the subpopulation with a stable GFR (n =
215), dotted line represents the subpopulation with a stable BMI (n = 343). The dashed line
indicates the zero value for bias, so values above the dashed line implicate that the equation
overestimates true GFR, and values below the line that the equation underestimates true GFR.
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Figure 5.5: Graphs showing correlations between % change in true GFR (X-axes)
between years 1 and 5 and the % change in equation-estimated GFR, and the %
change in reciprocal of serum creatinine over that period for the 478 patients of
whom iothalamate clearances were available at years 1, 2 and 5.
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performance. The patient characteristics age and gender are components of all equations,
representing factors that modify muscle mass and hence creatinine generation and serum
creatinine for a given renal function. Our analysis suggests, however, that the available
equations do not adequately account for this relationship in the transplant population.
BMI aected predictive performance as well. We analyzed for its impact as body weight
is used in most equations to re
ect muscle mass, without however, taking into account
the impact of obesity on the estimation of muscle mass for a given body weight. The
role of BMI as a determinant of the systematic error, therefore, was anticipated. It may
be of clinical relevance that the two most widely used equations, the MDRD and the
Cockcroft-Gault, had opposite eects on the BMI-related error in renal function estimate,
with progressive underestimation at higher BMI by the MDRD, as compared to progres-
sive overestimation of renal function at higher BMI by the Cockcroft-Gault equation. The
systematic error was also dependent on the level of GFR. These data in transplant recipi-
ents are well in line with a recent analysis in a large population of European renal patients
(without transplant recipients) showing that the biases of the MDRD and Cockcroft-Gault
equations were signicantly dierent for subgroups of age, gender, BMI and level of GFR
(29).
Taken together, the impact of simple and generally available patient factors on the
systematic error indicates that it should be feasible to develop a renal function equation
with better predictive performance, by more adequately incorporating these demographic
factors into the equation. This should be the subject of future analysis, with probably an
even larger number of measurements.
Our data derive from a single academic center and were obtained from the routine
renal hemodynamic measurements in our transplant population. GFR was measured as
the clearance of 125I-iothalamate, with correction for voiding errors by the clearance of
simultaneously infused 131I-Hippuran. This method has a day-to-day variability of only
2.2% (27). The single center setup has the additional advantage of a uniform method for
creatinine assessment, for which the day-to-day variability is 4%. We did not attempt
to calibrate our creatinine measurements against that of other laboratories, as, in order
to be valid, this should have been done for all dierent laboratories where the equations
were originally developed, which was not feasible. Nevertheless, whereas the nominal
values of estimated GFR might be somewhat modied by a dierent creatinine assessment,
our data allow a comparative assessment of the equations in single center setting, and
a solid assessment of the predictive performance over time. The impact of calibration
of serum creatinine measurements was recently re-emphasized by data by Hallan et al.
(30). In their study the MDRD equation underestimated GFR in a population with
mild renal insuciency, however, after recalibrating their serum creatinine values the
systematic error was reduced and accuracy improved. This suggests that calibration of
serum creatinine provides another possibility for better performance of renal function
equations. It moreover illustrates a possible pitfall when the performance of an equation
that has been developed in a specic population is tested in another one. In our analysis,
for instance, the predictive performance of the MDRD equation, as well as of the Rule
equation, lagged behind their performance in the original publications. This may be due
to calibration factors, but also to dierences in population characteristics (such as the
ones identied here as confounders, but possible also unidentied ones). The need to test
even well-validated equations in other, large populations in order to be able to assess their
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generalizability has therefore been emphasized (19).
As to the clinical applicability of renal function equations, a distinction can be made
between the assessment of group data and individual renal function assessment. In clinical
epidemiology and clinical trials, the random error can be compensated for by larger patient
numbers. The systematic error unfortunately cannot be accounted for by larger numbers.
However, as to the bias induced by patient factors such as age and gender, the error can
hopefully be distributed equally over the dierent patient groups, as randomization of
patients usually takes into account age and gender. Our data indicate that for studies
using renal function equations it would be useful to ensure that also BMI and level of GFR
are equally distributed over the patient groups. For epidemiological purposes, recent
data from our group, obtained in the general population, illustrate the impact of the
error inherent to patient characteristics for the outcome of renal epidemiological studies
using dierent renal function equations (31). For individual renal function assessment the
problem of an accurate estimate was stated to be even larger, as underlined by several
recent studies in dierent populations (32, 33). Accordingly, these authors recommend
not to rely on renal function equations for individual assessment, but to perform a true
GFR instead, which is fully in line with our data in the transplant population.
We also evaluated the performance of the equations over time. At group level the mean
change in GFR over a period of 4 years was well re
ected by all tested equations. This is
somewhat at variance with recent data by Gaspari (25). In a population of 81 transplant
recipients they found that the rate of GFR decline between 6 and 21 months after trans-
plantation was signicantly higher for the tested equations than for the reference method,
iohexol clearance. The reasons for the discrepancy with our ndings are not immediately
apparent, but may relate to dierences in reference method, time elapsed after transplan-
tation or dierences in patient population. Our data suggest that, within the time frame
tested, renal function equations can be of use for follow-up of renal function in transplant
recipients on the level of group data, provided that the sample size is suciently large.
Obviously, for longer follow-up additional validation would be needed. Unfortunately, for
individual follow-up of renal function over time the performance of renal function equa-
tions was disappointing. This could raise the question whether, for individual monitoring
of renal function, the equations have any added value over serum creatinine only. In this
respect our data showed that the correlation between % change in reciprocal of serum
creatinine with the % change in GFR was more or less similar to that of most tested
equations, refuting an added value of the equations for individual monitoring.
We conclude that the predictive performance of renal function equations is modest in
the transplant population as a whole. For the best performing equations, the observed
accuracy can be considered acceptable for, for instance, comparative clinical trials, pro-
vided that sample size and randomization allow for an equal distribution of the sources
of systematic error (age, sex, BMI and GFR) over the groups. For individual patients
however, the relatively low accuracy hampers accurate assessment of renal function by
the tested equations, also for individual follow-up. Finally, the role of the systematic
error indicates that better incorporation of body dimensions, age and gender will allow to
develop better renal function equations with a better predictive performance in the renal
transplant population.
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Equations Used in the Article
Screat = serum creatinine (mg/dL)
Pcreat = serum creatinine (mol/L)
Urea = serum urea (mmol/L)
BW = body weight (kg)
Ht = height (m)
Height = height (cm)
BMI = kg/m
2
Baracskay et al. (mL/min)
4;420=pcreat + 88   age
Bjornsson (mL/min)
Male: f[27   (0:173  age)]  BW  0:07g=screat
Female: f[25   (0:175  age)]  BW  0:07g=screat
Cockcroft-Gault (mL/min)
Male: [(140   age)  BW]=72  screat
Female: correction factor 0.85
Edwards and Whyte (mL/min)
Male: (94:3=screat)   1:8
Female: (69:9=screat) + 2:2
Hull (mL/min/70 kg)
Male: [(145   age)=screat]   3
Female: correction factor 0.85
Mawer (mL/min)
Male: fweight  [29:3   (0:203  age)]  [1   (0:03  screat)]g=(14:4  screat)
Female: fweight  [25:3   (0:175  age)]  [1   (0:03  screat)]g=(14:4  screat)
Nankivell 1 (mL/min)
Male: 35 + 6700=pcreat + BW=4 + urea=2   100=height(m)
2
Female: 25 + 6700=pcreat + BW=4 + urea=2   100=height(m)
2
Nankivell 2 (mL/min)
Male: 71:4 + (5;520=pcreat) + (0:27  BW)   (age=2)   (0:29  height)
Female: 50:4 + (5;520=pcreat) + (0:27  BW)   (age=2)   (0:29  height)
Salazar and Corcoran (mL/min)
Male: f(137   age)  [(0:285  BW) + (12:1  Ht  Ht)]g=(51  screat)
Female: f(146   age)  [(0:287  BW) + (9:74  Ht  Ht)]g=(60  screat)
Walser (mL/min/3 m
2)
Male: 7;570=pcreat   (0:103  age) + (0:096  BW)   6:66
Female: 6;050=pcreat   (0:08  age) + (0:08  BW)   4:81
Agarwal and Nicar (mL/min/1.73 m
2)
Male: [(163:95   age)  BW  1:057]=pcreat
Female: [(190:43   age)  BW  0:707]=pcreat
Gates (mL/min/1.73 m
2)
Male: [89:4 + (55   age)  (0:005  89:4)]=screat
1.2
Female: [60 + (56   age)  (0:005  60)]=screat
1.2
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Jellie 1 (mL/min/1.73 m
2)
Male: (100=screat)   12
Female: (80=screat)   7
Jellie 2 (mL/min/1.73 m
2)
Male: f98   [16  [(age   20)=20]]g=screat
Female: correction factor 0.85
Simplied MDRD (Levey et al.) (mL/min/1.73 m
2)
Male: 186  pcreat
-1.154  age
-0.203
Female: correction factor 0.742
Nguyen (mL/min/1.73 m
2)
218:1   0:916  age   0:635  pcreat
Toto (mL/min/1.73 m
2)
Male:  0:30  (age   52) + (9;282=pcreat) + BW   86
Female:  0:29  (age   52) + (7;780=pcreat)   0:77  (BMI   30)
Rule (mL/min/1.73 m
2)
Male : exp(1:911 + 5249=screat   2114=screat
2   0:00686  age)
Female : exp(1:911 + 5249=screat   2114=screat
2   0:00686  age   0:205)
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Abstract
Vitamin D deciency is common in chronic kidney disease (CKD). Increased urinary loss
of vitamin D binding protein (VDBP), the main transporter of 25-hydroxyvitamin D3
in the circulation, has been postulated to contribute to vitamin D deciency in
proteinuria. To test this hypothesis we analyzed urinary and plasma levels of VDBP,
25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 from proteinuric patients, before
and after antiproteinuric interventions. We performed a post-hoc analysis of a clinical
trial in CKD patients (n = 13, creatinine clearance median 60 (range 25-177) ml/min)
subjected to the following study periods: washout (no antiproteinuric treatment, 4
weeks), lisinopril 40 mg QD (ACEi, 6 weeks), or indomethacin 75 mg BID (NSAID,
4 weeks) in randomized sequence. Healthy subjects screened for donation (n =
10) served as controls. Plasma and urine VDBP levels were measured by ELISA,
25-hydroxyvitamin D3 levels by LC-MS and 1,25-dihydroxyvitamin D3 levels by ra-
dioimmunoassay. In CKD patients urinary VDBP excretion was strongly increased
(median (range) 5413 (155-211,027) g/24 h) as compared to healthy controls (64 (23-
111) g/24 h, p < 0.001). Both NSAID and ACEi signicantly decreased urinary VDBP
excretion, in proportion to proteinuria reduction. Plasma VDBP, 25-hydroxyvitamin D3
and 1,25-dihydroxyvitamin D3 levels, however, were similar between patients and
controls and not aected by antiproteinuric intervention. Urinary VDBP excretion is
markedly increased in proteinuria and responds to antiproteinuric treatment. Urinary
VDBP loss is not associated with plasma VDBP or vitamin D3 levels, suggesting that
urinary loss of VDBP does not aect vitamin D status.
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Introduction
Vitamin D deciency is common in chronic kidney disease (CKD). Beside contributing
to deregulation of calcium/phosphate metabolism in CKD, more recently vitamin D de-
ciency has been associated with progression of CKD and mortality in CKD patients as well
(1, 2). Reduced activity of the enzyme 1-hydroxylase in damaged tubular epithelial cells
is considered the main cause of 1,25-dihydroxyvitamin D3 (active vitamin D) deciency
in CKD patients, although induction of the vitamin D-degrading enzyme 24-hydroxylase
may also contribute (3, 4). However also 25-hydroxyvitamin D3 deciency is relatively
common in CKD (5), suggesting that additional mechanisms contribute to vitamin D de-
ciency in CKD. Increased urinary loss of vitamin D-binding protein (VDBP), the main
transporter of vitamin D3 in the circulation, has been postulated to contribute to vitamin
D deciency in proteinuric conditions (6).
In the circulation, 25-hydroxyvitamin D3 is bound to the albumin-like protein VDBP.
The VDBP-25-hydroxyvitamin D3 complex is ltered by the glomerulus, followed by
receptor-mediated re-uptake at the brush border of tubular epithelial cells (7) involv-
ing megalin (8) and cubulin (9). Under normal conditions urinary VDBP excretion is
therefore minimal. In proteinuria, on the other hand, loss of receptor-mediated uptake
at the tubular brush border may result in urinary excretion of the VDBP-vitamin D3
complex, possibly contributing to vitamin D deciency.
To investigate whether urinary loss of VDBP might contribute to vitamin D de-
ciency in proteinuric patients, we measured urinary and plasma levels of VDBP, 25-
hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 of patients with overt proteinuria, and
tested the eects of proteinuria reduction by dierent modes of pharmacological interven-
tion, i.e. blockade of the renin-angiotensin-aldosterone system (RAAS) or prostaglandin
inhibition, respectively.
Material and methods
Patients
The current study is a post-hoc analysis of a previously performed clinical trial (10).
The original study by Vogt et al. was performed in Caucasian patients (n = 16) who
fullled the following inclusion criteria after a six week washout period without RAAS
intervention: proteinuria  2 g/day, diastolic blood pressure (BP) < 90 mmHg, creatinine
clearance  30 mL/min and age 18-70 years. During the washout period BP was titrated
with hydrochlorothiazide 12.5 mg QD combined with amlodipine or doxazosine if neces-
sary; this regimen remained unchanged during the study period. One patient received
calcitriol during the study period, none of the other patients received vitamin D supple-
ments or analogues. Participants were asked to adhere to a restricted sodium intake (<
100 mmol/day) and standardized protein intake (1 g/kg body weight/day). The study
was approved by our local medical ethics committee, was performed in adherence to the
declaration of Helsinki, and all participants provided written informed consent.
Patients were subsequently treated in random order with indomethacin 75 mg BID
(retard formula; Indocidﬁ Merck & Co., Inc., Whitehouse Station, NJ, USA) and ro-
fecoxib (VIOXXﬁ), both for four weeks. A subset of the original 16 patients (n = 11)
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underwent an extension study consisting of another washout period (six weeks) followed
by lisinopril (40 mg QD) treatment for six weeks. Blood and urine samples were collected
at the end of each study period.
Since non-specic COX inhibition would be suciently suitable as a non-RAAS-related
antiproteinuric intervention, we did not analyze the rofecoxib study period. From the 16
patients in the original study, urine and plasma samples were available from 13 patients
with the following disorders: membranous glomerulopathy (n = 2), primary focal seg-
mental glomerular sclerosis (n = 2), IgA nephropathy (n = 2), non-conclusive diagnosis
(n = 2) and (type 2) diabetic nephropathy (n = 5). Baseline characteristics of these
patients were similar to the original population. Plasma and urine samples were avail-
able of 13 patients for the washout period, of 13 patients for the indomethacin treatment
period (NSAID), and of 10 patients for the extension study with lisinopril (ACEi). Age-
and gender-matched healthy Caucasian subjects (n = 10) who were screened for kidney
donation were included as controls. None of the controls used a vitamin D supplement.
Measurements
VDBP was measured in EDTA-plasma or urine with a VDBP sandwich ELISA (Im-
mundiagnostik, catalog # K2314, Bensheim, Germany), according to the manufacturer's
instructions. Brie
y, plasma (diluted 1:40,000) or urine (diluted 1:2-1:5 for controls and
1:10-1:30,000 for the other groups depending on the concentration of VDBP) was incu-
bated in a microtiter plate coated with polyclonal anti-VDBP antibodies for 1 h. Subse-
quently, a polyclonal peroxidase-labeled rabbit-anti-VDBP detection antibody was added
and incubated for 1 h. After washing, tetramethylbenzidine was added as substrate for 15
min. After adding a stop solution, absorbance at 450 nm was measured by a spectropho-
tometer (BenchMark Plus, Bio-Rad Laboratories, Veenendaal, The Netherlands). Using
a standard curve generated with VDBP protein as provided by the manufacturer, nal
VDBP concentrations were calculated. VDBP excretion was calculated from the VDBP
concentration in urine collected over a 24-h period. The detection limit of this ELISA is
1.23 ng/ml; intra-assay CV < 5.0% for 16 replicate determinations at concentrations of
24.2 and 42.9 mg/dl and inter-assay CV < 12.7% for a concentration of 19.3 mg/dl in 14
dierent assays on two dierent lots; recovery ranges from 85 to 116% and linearity was
acceptable (r2 = 0.998).
Plasma and urine 25-hydroxyvitamin D3 levels were determined using isotope dilution-
online solid phase extraction liquid chromatography-tandem mass spectrometry (ID-XLC-
MS/MS). K2-EDTA plasma was prepared immediately after collection and stored until
analysis at -80 ￿C. Patient samples were analyzed in one run. First, plasma was pre-
treated by proteolysis to disrupt 25-hydroxyvitamin D3-VDBP interactions. Subsequently
deuterated internal standard (IS: 25-hydroxyvitamin D3-d6), was added and samples were
mixed. Samples were extracted and analyzed by XLC-MS/MS (system described previ-
ously (11)). Quantication of plasma 25-hydroxyvitamin D3 was done relating analyte/IS
peak area ratios in patient plasma to analyte/IS peak area ratios in blanc (pre-treated
and dialysed) plasma spiked with 25-hydroxyvitamin D3 at concentrations ranging from
0 to 280 nmol/l and IS at a xed concentration. Method characteristics: LOQ 4.0 nmol/l;
intra-assay CV < 7.2% and inter-assay CV < 14.1% for 3 concentrations between 20 and
150 nmol/L; recovery ranges from 93 to 98% and linearity was acceptable (r2 = 0.9972).
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The accuracy of 25-hydroxyvitamin D3 results was established using NIST (National In-
stitute of Standards & Technology, Gaithersburg, MD) reference material to establish true
values for calibration standards. Calibration standards, QC-samples and patient samples
were stable for 6 days at 6 ￿C (CV < 11%). Samples are stable for 3 freeze-thaw cy-
cles (CV < 3%). Levels of 1,25-dihydroxyvitamin D3 in plasma and urine were measured
by radioimmunoassay. Standard laboratory measurements were performed as described
previously (10).
Statistical analysis
Results are expressed as median (range). Statistical dierences between groups were
assessed using the Wilcoxon non-parametric test for paired observations or the Mann-
Whitney non-parametric test for unpaired observations. Non-parametric testing was used
given the small sample size and the fact that urinary VDBP was not normally distributed.
Data in graphs are presented as mean  SEM. Spearman's correlation was used for corre-
lations between continuous variables. All calculations and analyses were performed using
SPSS 16.0 for Windows (SPSS Inc., Chicago, Illinois, USA).
Results
Patient characteristics
Baseline patient characteristics are presented in Table 6.1. At baseline, systolic BP and
serum creatinine concentration were slightly elevated in CKD patients, and creatinine
clearance was lower as compared to healthy controls. CKD patients were in K/DOQI
stages I-III. Both ACEi and NSAID eectively reduced proteinuria as compared to the
period without antiproteinuric treatment (Figure 6.1 A).
Urine and plasma VDBP levels
In CKD patients without antiproteinuric treatment, urinary VDBP excretion was strongly
increased as compared to healthy controls (5413 (155-211,027) vs. 64 (23-111) g/24 h, p <
0.001, Figure 6.1 B). Urinary VDBP excretion was signicantly reduced by antiproteinuric
therapy, either with ACEi (4276 (50-35,800) g/24 h, p < 0.05), or with NSAID (1653
(97-129,854) g/24 h, p < 0.05). Urinary VDBP excretion was strongly associated with
proteinuria across treated and untreated CKD patients (Figure 6.2). The decline of urinary
VDBP excretion was signicantly associated with the antiproteinuric response (NSAID:
r = 0.776, p < 0.01, ACEi: r = 0.771, p < 0.05). Plasma VDBP levels of proteinuric
patients showed a trend to reduction as compared to healthy controls, but this dierence
did not reach statistical signicance. Antiproteinuric treatment did not aect plasma
VDBP levels (Figure 6.1 C). When data from both antiproteinuric interventions were
pooled to increase statistical power, plasma VDBP levels remained similar to controls.
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Table 6.1: Baseline characteristics of CKD patients with proteinuria and age- and
gender-matched healthy controls.
Healthy controls Proteinuric CKD patients
No treatment ACEi NSAID
n 10 13 10 13
Age (years) 57 (41-68) 56 (41-67) 55 (41-67) 55 (41-67)
Male (%) 7 (70%) 9 (69%) 8 (80%) 8 (67%)
DM (n) 0 4 4 4
BMI
(kg/m
2)
27 (23-29) 27 (23-38) 30 (23-38) 30 (24-38)
Systolic
BP
(mmHg)
119 (105-151) 143 (124-197)
* 123 (107-169) 151 (122-188)
*
Diastolic
BP
(mmHg)
70 (55-84) 83 (69-95)
* 72 (60-81)
# 79 (65-95)
*
Proteinuria
(g/24 h)
0.0 (0.0-0.2) 2.9 (1.3-13.1)
* 2.0 (0.2-7.9)
*,# 1.2 (0.3-12.5)
*,#
Serum
creatinine
(mol/l)
74 (60-92) 107 (53-292)
* 142 (59-358)
* 120 (59-346)
*
Creatinine
clearance
(ml/min)
113 (59-187) 74 (31-134)
* 64 (23-112)
* 61 (22-134)
*
Serum
phosphate
(mmol/l)
1.10 (0.79-1.22) 1.09 (0.84-1.41) 1.00 (0.97-1.03) 1.14 (0.78-1.48)
Serum
calcium
(mmol/l)
2.30 (2.16-2.43) 2.38 (2.29-2.52)
* 2.42 (2.41-2.43) 2.46 (2.29-2.65)
*
Serum
albumin
(g/l)
44 (42-47) 35 (25-38)
* 36 (27-38)
* 37 (32-40)
*,#
Serum
cholesterol
(mmol/l)
5.1 (4.4-7.1) 6.6 (5.5-11.1)
* 6.5 (4.0-8.4) 5.7 (4.8-8.8)
*
Serum
triglyc-
erides
(mmol/l)
1.1 (0.8-3.0) 2.9 (1.4-7.0)
* 3.5 (1.1-6.7)
* 3.0 (1.5-6.4)
*
Serum
PTH
(pmol/l)
3.20 (3.10-3.58) 8.29 (1.19-22.50)
* 8.8 (2.90-39.90) 9.51 (2.16-51.30)
*
DM = number of patients with diabetes mellitus, BMI = body mass index, BP = blood pressure.
* p < 0.05 vs. healthy controls.
# p < 0.05 vs. untreated patients.
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Figure 6.1: Urinary VDBP excretion per 24 h and plasma VDBP levels. (A) Pro-
teinuria (mg/24 h) in healthy controls, CKD patients without antiproteinuric treat-
ment, with NSAID treatment and with ACE inhibitor treatment. In CKD patients
without antiproteinuric treatment, proteinuria was strongly increased as compared to healthy
controls. Antiproteinuric treatment (both ACEi and NSAID) signicantly reduced proteinuria.
(B) Urinary VDBP excretion (g/24 h) in healthy controls, proteinuric CKD patients without
antiproteinuric treatment, with NSAID treatment and with ACE inhibitor treatment. In pro-
teinuric CKD patients, 24 h-urinary VDBP excretion was strongly increased as compared to
healthy controls. Antiproteinuric treatment (both ACEi and NSAID) signicantly reduced uri-
nary VDBP excretion. (C) Plasma VDBP levels (mg/dl) in healthy controls, proteinuric CKD
patients without antiproteinuric treatment, with NSAID treatment and with ACE inhibitor treat-
ment. Antiproteinuric treatment did not aect plasma VDBP levels.
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Figure 6.2: Association between proteinuria and 24 h-urinary VDBP excretion.
ssociation between proteinuria (g/24 h) and urinary VDBP excretion (g/24 h) in treated (open
circles) and untreated (closed circles) proteinuric CKD patients.
Urine and plasma levels of 25-hydroxyvitamin D3 and 1,25-di-
hydroxyvitamin D3
Plasma 25-hydroxyvitamin D3 levels (Figure 6.3 A) were not signicantly dierent be-
tween CKD patients without antiproteinuric treatment (40 (16-72) nmol/l) and healthy
controls (40 (28-51) nmol/l). Antiproteinuric treatment did not aect 25-hydroxyvitamin
D3 levels (NSAID 42 (19-63), ACEi 38 (28-43) nmol/l). Similarly, 1,25-dihydroxyvitamin
D3 levels (Figure 6.3 B) were not dierent among CKD patients and healthy controls, and
not aected by antiproteinuric treatment. Urinary 25-hydroxyvitamin D3 was detectable
in only one CKD patient (8.0 nmol/l), namely the patient with highest proteinuria during
the period without antiproteinuric treatment (proteinuria 13.1 g/24 h), and was reduced to
5.5 nmol/l by NSAID treatment, and to 2.6 nmol/l by ACEi. Although the plasma VDBP
of this patient (27 mg/dL) was below the median, 25-hydroxyvitamin D3 (74.7 nmol/l)
and 1,25-dihydroxyvitamin D3 (79.7 pmol/l) were normal. Urinary 1,25-dihydroxyvitamin
D was not detectable in any patient.
Discussion
In line with prior studies (12) we found that in proteinuric patients urinary VDBP excre-
tion was strongly increased, in proportion to proteinuria. However, urinary VDBP loss was
not associated with signicantly reduced plasma levels of VDBP, 25-hydroxyvitamin D3
or 1,25-dihydroxyvitamin D3, although a trend towards lower plasma VDBP was observed
100Antiproteinuric treatment reduces urinary loss of vitamin D
Figure 6.3: Plasma 25(OH) and 1,25(OH)2 vitamin D3 levels. Plasma 25(OH) vitamin
D3 (A) and 1,25(OH)2 vitamin D3 (B) levels in healthy controls and in proteinuric CKD patients
without antiproteinuric treatment, with NSAID treatment and with ACE inhibitor treatment.
Antiproteinuric treatment did not aect plasma levels of 25(OH) or 1,25(OH)2 vitamin D3.
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in CKD. Urinary loss of VDBP was substantially and signicantly reduced by antipro-
teinuric intervention, in proportion to proteinuria reduction, irrespective of the mode
of treatment. This large change in urinary VDBP was not associated with signicant
changes in plasma VDBP, 25-hydroxyvitamin D3 or 1,25-dihydroxyvitamin D3. Taken
together these data do not support the assumption that urinary loss of VDBP contributes
to vitamin D deciency in proteinuric patients.
Our ndings seem to be in contrast with a previous paper by Thrailkill et al., who sug-
gested that enhanced excretion of VDBP may play a role in vitamin D deciency (12). Al-
though the sample size of that study was higher, no dierence in serum 25-hydroxyvitamin
D3 levels was found between type 1 diabetic patients with or without albuminuria and
healthy controls either. Several factors may account for the absence of an association
between changes in urinary VDBP and circulating vitamin D. Urinary VDBP loss is nor-
mally compensated for by synthesis in the liver which is estimated at 10 mg/kg (13).
In patients with liver disease, lower plasma levels of VDBP and 25-hydroxyvitamin D3
have been measured (14), implicating that normal liver function is required to maintain
normal plasma VDBP levels. Although plasma levels of albumin were reduced in CKD
patients as compared to controls, cholesterol and triglycerides were increased (Table 6.1),
suggesting that liver function was not compromised in these patients. In addition, the
occupancy of circulating VDBP by vitamin D3 metabolites is generally lower than 5%
(15), implying that only massive VDBP loss could result in 25-hydroxyvitamin D3 de-
ciency. Accordingly, there was no association between plasma VDBP and vitamin D3
levels. Only in one severely nephrotic patient, plasma VDBP was relatively low and uri-
nary loss of 25-hydroxyvitamin D3 could be detected. This suggests that only in severe
nephrotic syndrome (i.e. proteinuria > 10 g/24 h), urinary VDBP loss may contribute to
lower plasma VDBP levels, although it remains very unlikely that this will aect plasma
vitamin D3 levels.
It could be argued that in our study follow-up was too short to detect signicant
changes in plasma VDBP and/or 25-hydroxyvitamin D3 levels. However, the plasma
half-life of VDBP is 2.5-3.0 days (16), so steady state is assumed to have been reached be-
fore the end of the treatment periods. As the plasma half-life for 25-hydroxyvitamin D3
is longer (12 days, 15 days and even longer half-lives have been reported), it is di-
cult to draw conclusions on a possible treatment eect on 25-hydroxyvitamin D3 levels.
However, not even a trend to lower vitamin D levels was present within the time frame
studied here, i.e. 4 and 6 week treatment periods. We cannot exclude the possibility
that confounding factors such as sun exposure and dietary vitamin D intake may have
been dierent between the study groups. Further limitations of this study are the limited
group sizes, warranting cautious interpretation of our results and requiring conrmation
in larger cohorts, and the post-hoc nature of our study. The strength however, is the
intervention design, and the use of dierent modes of intervention that enhances the ro-
bustness of our ndings. In conclusion, proteinuric CKD is associated with abundant
urinary VDBP loss which can be reduced by antiproteinuric therapy. Urinary VDBP loss
was not associated with signicantly lower plasma levels of VDBP, 25-hydroxyvitamin D3
or 1,25-dihydroxyvitamin D3 in CKD patients. Antiproteinuric therapy did not aect
plasma levels of VDBP, 25-hydroxyvitamin D3 or 1,25-dihydroxyvitamin D3. Together,
these ndings suggest that other factors controlling the vitamin D pathway, such as low
sunlight exposure, impaired vitamin D synthesis in the skin of CKD patients or low nu-
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tritional vitamin D intake, may contribute to the more prevalent 25-hydroxyvitamin D3
deciency in CKD as documented in previous studies (5). A recent review also dis-
cusses the plausible explanation that in CKD, decreased GFR reduces the amount of
25-hydroxyvitamin D3 bound to VDBP ltered that is available for renal uptake (17).
Together, these explanations may play a more important role to the deregulation of vita-
min D homeostasis in CKD patients than urinary VDBP loss.
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Abstract
Non-invasive tubulointerstitial damage markers may allow better titration and
monitoring of renoprotective therapy. We investigated the value of urinary vitamin D
binding protein excretion (uVDBP) as a tubulointerstitial in
ammation and brosis
marker in adriamycin rats, and tested whether uVDBP parallels renal damage and
responds to therapy intensication in humans. In adriamycin (ADR) rats, uVDBP
was strongly elevated vs. controls (CON) already at 6 wks after induction of nephrosis
(ADR: 727  674 [mean  SD] vs. CON: 9  12 g/d, p < 0.01), i.e. before onset
of pre-brotic and in
ammatory tubulointerstitial damage, and at all following 6-wk
timepoints until end of followup at 30 wks (ADR: 1403  1026 vs. CON: 206  132
g/d, p < 0.01). In multivariate regression analysis, uVDBP was associated with
tubulointerstitial macrophage accumulation (standardized beta=0.47, p=0.01) and
collagen III expression (standardized beta=0.44, p=0.02) independently of albuminuria.
In humans, uVDBP was increased in 100 microalbuminuric subjects (44  93 g/d)
and in 47 CKD patients with overt proteinuria (9.2  13.0 mg/d) compared to 100
normoalbuminuric subjects (12  12 g/d, p < 0.001). In CKD patients, uVDBP
responded to intensication of renoprotective therapy (ACEi+liberal sodium: 9.2 
13.0 mg/d vs. dual RAAS blockade+low sodium: 2747  4013 g/d, p < 0.001), but
remained still > 100-fold increased during maximal therapy vs. normoalbuminurics (p
< 0.001), consistent with persisting tubulointerstitial damage. uVDBP was associated
with tubular and in
ammatory damage markers KIM-1 (standardized beta=0.52, p <
0.001), beta-2-microglobuline (st.beta=0.45, p < 0.001), cystatin C (st.beta=0.40, p <
0.001) and MCP-1 (st.beta=0.31, p < 0.001) independently of albuminuria. uVDBP
may be a novel urinary biomarker of tubulointerstitial damage. Prospectively designed
studies are required to validate our ndings and conrm its relevance in the clinical
setting.
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Introduction
The severity of renal interstitial brosis has consistently been identied as the strongest
predictor of subsequent progressive renal function loss (1). Early probrotic changes,
on the other hand, might still be reversible (2). Reliable, non-invasive assessment of
tubulointerstitial damage would therefore be of great value in development and moni-
toring of renoprotective therapy (3). Vitamin D binding protein (VDBP), also known
as group-specic component (GC), is a glycosylated alpha-globulin of 58 kDa (4). Its
main function is to transport vitamin D metabolites through the circulation. VDBP is
ltered by the glomerulus and subsequently reabsorbed by proximal tubular cells through
receptor-mediated uptake. This process is crucial for retrieval of vitamin D for activation
by 1-alpha hydroxylase, which is abundantly present in proximal tubular cells (5). Tubu-
lar reabsorption of VDBP is mediated by megalin and cubulin receptors (6, 7). Since
receptor-mediated uptake of proteins such as VDBP is energy-consuming, tubular injury
would be expected to result in urinary VDBP (uVDBP) loss (8). Indeed, a previous small
study suggested that uVDBP is grossly elevated in CKD patients and can be reversed
by antiproteinuric treatment (9). In diabetic subjects, uVDBP is increased compared
to non-diabetics, especially when albuminuria is present (10). Whether uVDBP is re-
lated to the extent of tubulointerstitial damage has not specically been addressed. We
therefore explored the potential role of uVDBP as a marker of tubulointerstitial damage
in two independent settings. First we studied the time course of uVDBP in relation to
the development of interstitial brosis and in
ammation in the rat model of adriamycin-
induced nephropathy at several time points after induction of nephrosis. Subsequently,
in human subjects we addressed the relation between uVDBP and established tubular
damage markers in patients with various stages of renal damage, i.e microalbuminuria
and overt proteinuria, respectively, as compared to normoalbuminuric controls. We also
studied whether intensication of anti-proteinuric therapy would reduce urinary VDBP
excretion.
Materials and Methods
Animal model
Male Wistar rats (n = 90) were housed in a temperature and light controlled room, with
free access to food and water. Twentyfour hour urine was collected every two weeks by
housing in metabolic cages. Surgical procedures took place under iso
urane anesthesia.
At the end of the study, the abdominal aorta was cannulated and kidneys were perfused
in situ with saline during removal. Proteinuria was measured on a BNII third-generation
nephelometer (Dade Behring, Mannheim, Germany). The protocols were approved by the
Animal Experiments Committee of the University of Groningen, the Netherlands.
Rats were assigned to two groups: unilateral adriamycin proteinuric (UAP) nephropa-
thy (n = 60), or controls (n = 30). Unilateral adriamycin nephrosis was induced by
temporarily clipping the left renal artery through a midline abdominal incision, followed
by adriamycin (1.5 mg/kg) injection via the tail vein, as described previously (11). Af-
ter 12 min, when adriamycin has been cleared from the circulation (12), the clamp was
removed. Control rats underwent the same procedure but were injected with saline. To
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study renal damage over time, groups of 12 UAP and six control rats were sacriced at
weeks 6, 12, 18, 24, and 30 after surgery. Kidneys were xed in formalin and embedded
into paran.
Patients
For clinical studies, 100 normoalbuminuric and 100 microalbuminuric subjects were ran-
domly selected from Prevention of REnal and Vascular ENd stage Disease (PREVEND),
a prospective cohort study investigating the association of albuminuria with renal and
cardiovascular disease progression in the general population (13). In short, between 1997
and 1998, participants of the PREVEND cohort were recruited from 40,856 inhabitants
of the city of Groningen, the Netherlands. To obtain a cohort enriched for the presence of
elevated albuminuria levels, selection was based on the albumin concentration in a spot
morning urine sample. The baseline screening round was completed in by 8,592 partic-
ipants. Thereafter, participants were invited to visit an outpatient clinic for a medical
examination at approximately 3-year intervals. For the present study, data obtained at
baseline were used. The PREVEND study was approved by the medical ethics committee
of our institution and conducted in accordance with the guidelines of the Declaration of
Helsinki. All participants gave written informed consent. Anthropometrical, clinical and
biochemical data were collected as reported previously (13). Glomerular ltration rate
was estimated (eGFR) with the modied Modication of Diet in Renal Disease (MDRD)
formula, taking into account gender, age, race, and serum creatinine concentration. At
each screening round two 24-h urine samples were collected after thorough oral and written
instructions on how to collect these samples. Urinary albumin concentration was deter-
mined in fresh urine samples by nephelometry with a threshold of 2.3 mg/L and intra-
and inter-assay coecients of variation (CV) of 2.2 and 2.6%, respectively (BNII; Dade
Behring Diagnostic, Marburg, Germany). Albuminuria is given as the mean of the two
24-hour urine albumin excretion measurements. Urine samples for biomarker measure-
ments were stored at -20￿C. VDBP was measured in urine samples collected at baseline
from 100 randomly selected normo- and microalbuminuric subjects.
Furthermore, urine samples and clinical data were used from a previously performed
randomized controlled trial in patients with established non-diabetic chronic kidney dis-
ease (14). Brie
y, in this study, 52 patients were subjected to a protocol including a 6-week
study period with standard anti-proteinuric therapy (i.e. the ACE inhibitor lisinopril 40
mg/day and a regular sodium diet of 200 mmol Na+ per day), and another 6-week study
period with intensied anti-proteinuric therapy (lisinopril 40 mg/day combined with the
AT1 receptor blocker valsartan 320 mg/day and a low sodium diet, target 50 mmol Na+
per day). At the end of each study period, clinical data were recorded and blood and urine
samples were collected for analysis. Data and urine samples from both study periods were
available for 47 patients for the current post-hoc analyses (14).
Measurement of urinary VDBP and other biomarkers
After thawing urine and plasma samples were vortexed and subsequently centrifuged
(14.000 rpm). The supernatant was used for measurements. Human VDBP was measured
with a commercially available sandwich ELISA (Immundiagnostik, catalog # K2314, Ben-
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sheim, Germany), according to the manufacturer's instructions. Brie
y, plasma (diluted
1:40000) or urine (diluted 1:2 - 1:5 for controls and 1:10 - 1:3000 for the other groups de-
pending on the concentration of VDBP) was incubated in a microtiter plate coated with
polyclonal anti-VDBP antibodies for one hour. Subsequently, a polyclonal peroxidase-
labeled rabbit-anti-VDBP detection antibody was added and incubated for one hour.
After washing, tetramethylbenzidine was added as substrate for 15 minutes. After adding
a stop solution, absorbance at 450 nm was measured by a spectrophotometer (BenchMark
Plus, Bio-Rad Laboratories, Veenendaal, The Netherlands). Using a standard curve gen-
erated with VDBP protein as provided by the manufacturer, nal VDBP concentrations
were calculated. The detection limit of this ELISA is 1.23 ng/ml; intra-assay CV < 5.0%
for 16 replicate determinations at concentrations of 24.2 and 42.9 mg/dl and inter-assay
CV < 12.7% for a concentration of 19.3 mg/dl in 14 dierent assays on two dierent
lots; recovery ranges from 85-116% and linearity was acceptable (r2 =0.998). Rat VDBP
was measured using another commercially available ELISA kit (Alpco, Salem, NH), ac-
cording to the manufacturer's instructions. Detection limit as provided by manufacturer:
3.125 ng/ml, range 3.125-100 ng/ml. VDBP excretion was calculated from the VDBP
concentration in urine collected over a 24-hour period. The established proximal tubular
damage markers KIM-1, beta-2-microglobulin and cystatin C as well as the in
ammation
marker MCP-1 were determined as described previously (15, 16). Brie
y, we developed
direct sandwich-enzyme-linked immunosorbent assays using monoclonal coating antibod-
ies and labeled polyclonal detection antibodies on a Maxisorp plate (Nunc, Denmark).
The concentration of the analyte was determined spectrophotometrically by conversion of
o-phenylenediamine by a horseradish peroxidase label. KIM-1, beta-2-microglobulin, and
MCP-1 antibodies were obtained from R&D systems (Minneapolis, USA). The intra-assay
coecients of variation (CV) of these ELISAs were 7.4%, 9.7%, and 6.8% respectively.
Cystatin C was measured by nephelometry (reagents obtained from Siemens [Marburg,
Germany]). Samples were diluted to obtain optimal concentration for measurement. All
samples were measured in duplicate.
Immunohistochemistry
Paran sections were stained with periodic acid-Schi to evaluate focal glomerulosclero-
sis (FGS). Immunostaining for collagen type III (Biogenesis, Poole, UK), -SMA (clone
1A4; Sigma), or macrophages (ED1; Serotec, Oxford, UK) was performed as previously
described (17). An automated staining system (DAKO Autostainer, Carpinteria, CA,
USA) was used to obtain comparable staining results for all slides. Immunostaining was
quantied by computerized morphometry as described previously (17).
Statistical analyses
Analyses were performed with PASW Statistics 18.0.3 (SPSS, Armonk, NY). Parametric
variables are expressed as mean  standard deviation (SD), whereas non-parametric vari-
ables are given as median (interquartile range). Dierences between groups were tested
using student's t-test or Mann-Whitney test where appropriate. Linear regression analysis
was performed to address the association between uVDBP and parameters of tubuloin-
terstitial damage, both at the time point of sacrice. These associations were studied
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in univariate models as well as in multivariate models adjusting for albuminuria to ad-
dress whether the relation between uVDBP and parameters of structural renal damage
depended on albuminuria. In these analyses, all adriamycin animals were considered to-
gether in a regression model adjusted for the timepoint after induction of nephrosis. This
allowed us to study the relation between uVDBP and renal damage parameters across
the spectrum of renal damage. Distribution of the variables was veried by Q-Q plots
and histograms. Non-normally distributed variables were transformed to the natural log
before entering the regression model. For all analyses a two-sided p < 0.05 was considered
statistically signicant.
Results
Rat unilateral adriamycin model
The relation between urinary VDBP excretion and structural renal abnormalities in
chronic kidney disease was addressed in the rat unilateral adriamycin nephropathy model.
This model is characterized by relatively mild albuminuria as only one kidney is aected,
followed by the development of renal in
ammation, focal glomerulosclerosis (FGS), and
tubulointerstitial brosis in the aected kidney, as described in detail previously (18).
Massive urinary VDBP excretion was already present at 6 weeks after adriamycin injec-
tion (Figure 7.1 A, (adriamycin: 727  674 g/d vs. controls: 9  12 g/d, p < 0.01),
when interstitial alpha-smooth muscle actin (-SMA) and collagen III expression as well
as interstitial macrophage accumulation were still similar to control kidneys (Figure 7.1
B). Also at all other time points until end of followup at 30 wks (ADR: 1403  1026 vs.
CON: 206  132 g/d, p < 0.01), VDBP remained elevated in adriamycin rats compared
to controls at the same time point after start of the experiment.
The relation between uVDBP and renal damage markers were subsequently addressed
in multivariate regression analysis where all adriamycin rats were analyzed together and
data were adjusted for the timepoint of sacrice. This approach allowed us to address the
relation between uVDBP and renal damage markers across the spectrum of renal dam-
age, analyzing each animal once (at the time of sacrice). uVDBP was strongly associated
with interstitial expression of the pre-brotic marker -SMA and with collagen III expres-
sion, as well as with interstitial macrophage accumulation (Table 7.1). uVDBP was also
associated with albuminuria and FGS. Subsequently the associations between uVBDP
and the parameters of renal damage were adjusted for albuminuria in multivariate regres-
sion analysis. uVDBP remained signicantly associated with -SMA and collagen III as
well as with interstitial macrophage accumulation, independently of albuminuria. The
association between uVDBP and FGS, however, did depend on albuminuria (Table 7.1).
Together, these data suggest that uVDBP is already increased before the onset of (early)
tubulointerstitial brosis and in
ammation, and uVDBP increases further in association
with increasing tubulointerstitial damage severity.
Clinical studies
We further characterized urinary VDBP excretion in the clinical setting. Table 7.2 shows
baseline parameters at inclusion for the study groups: subjects with microalbuminuria
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Figure 7.1: A. Graphs illustrating the development of albuminuria (orange) and
uVDBP (purple) over time in the unilateral adriamycin nephropathy model and in
sham-operated control animals. B. Development of tubulointerstitial damage as re-

ected by interstitial alpha-smooth muscle actin (blue bars) and collagen III staining
(green bars), and interstitial macrophage accumulation (red bars) in adriamycin rats
(dark bars) and controls (light bars).
113Chapter 7
Table 7.1: Associations of urinary VDBP with renal histological parameters in the
aected kidney in the rat unilateral adriamycin nephropathy model.
Univariate analysis Adjusted for albuminuria
Damage marker Standardized beta P Standardized beta P
FGS score 0.56 < 0.001 0.28 0.52
Interstitial collagen III 0.32 0.005 0.44 0.02
Interstitial macrophage
count
0.46 < 0.001 0.47 0.01
Interstitial SMA protein
expression
0.46 < 0.001 0.43 0.01
(n=100) and normoalbuminuric controls (n=100), both derived from a general popu-
lation cohort study, and subjects with non-diabetic chronic kidney disease (CKD) with
overt proteinuria (n=47). The CKD group was studied during two dierent treatment
periods of 6 weeks, one period with an ACE inhibitor under a liberal sodium diet, and
one period with intensied renoprotective therapy: dual RAAS blockade (ACE inhibitor
and AT1 receptor blocker) under dietary sodium restriction. As shown in Figure 7.2,
uVDBP was low in normoalbuminuric subjects, higher in microalbuminurics, and high-
est in patients with established CKD (p < 0.001). In CKD patients, intensication of
anti-proteinuric therapy (dual RAAS blockade and dietary sodium restriction) reduced
uVDBP from median 4 mg/day to 1 mg/24h (p < 0.001); however urinary VDBP was
still > 100-fold increased as compared to normoalbuminuric subjects (median 7 g/24h; p
< 0.001 vs. CKD+ACEi+ARB+low sodium), consistent with persistent tubulointerstitial
damage despite maximal therapy.
VDBP is associated with established renal damage markers
The relation between uVDBP and established markers of proximal tubular damage and re-
nal in
ammation was further addressed in normo- and microalbuminuric subjects (n=200).
uVDBP was strongly associated with urinary kidney injury molecule-1 (KIM-1), beta-2-
microglobulin and cystatin C (Table 7.3 and Figure 7.3). Of interest, urinary VDBP was
also associated with urinary excretion of the in
ammation marker monocyte chemoattrac-
tant protein-1 (MCP-1). These associations were independent of albuminuria (Table 7.3,
Figure 7.3).
Discussion
To our knowledge this study is the rst to demonstrate that urinary VDBP is a biomarker
of tubulointerstitial damage, independent of albuminuria, in an animal model of renal dam-
age. In humans, urinary VDBP increased along with the severity of renal damage, was
associated with tubular and in
ammatory markers independently of albuminuria, and
responded to intensication of renoprotective therapy. Yet, the current cornerstone of
renoprotective therapy (maximal RAAS blockade combined with dietary sodium restric-
tion) did not achieve normalization of uVDBP, suggesting persistent tubulointerstitial
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Figure 7.2: Box-whisker plots indicating the median, interquartile range, and range
of 24-h uVDBP per patient category. general population with normoalbuminuria, general
population with microalbuminuria, chronic kidney disease with overt proteinuria treated with
ACE inhibitor and liberal sodium diet, and chronic kidney disease with overt proteinuria treated
with ACE inhibitor + ARB + low sodium diet. uVDBP increased with albuminuria (rst three
groups, p < 0.001) and responded to intensication of anti-proteinuric treatment (two last groups,
p < 0.001).
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Figure 7.3: Box-whisker plots illustrating the relation between uVDBP and estab-
lished renal tubular damage markers kidney injury molecule-1 (KIM-1) (A), beta-
2-microglobulin (B2M) (B), Cystatin C (CysC) (C) and monocyte chemoattractant
protein-1 (MCP-1) (D) in normo- and microalbuminuric subjects (both n=100). The
uVDBP is presented per quartile of the established renal damage marker studied. In all pan-
els (A-D), the left four box whisker plots represent the unadjusted VDBP excretion, and the
right four box whisker plots represent the uVDBP adjusted for albuminuria. All biomarkers are
positively associated with uVDBP, also when uVDBP was adjusted for albuminuria (p < 0.001,
Kruskal Wallis).
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Table 7.3: Associations of VDBP with renal damage markers across the clinical
cohorts.
Association with uVDBP
Univariate Adjusted for albuminuria
Damage marker Standardized beta P Standardized beta P
KIM-1 0.77 < 0.001 0.52 < 0.001
Beta-2-microglobulin 0.54 < 0.001 0.45 < 0.001
Cystatin C 0.49 < 0.001 0.4 < 0.001
MCP-1 0.28 < 0.001 0.31 0.001
KIM-1 = kidney injury molecule-1, MCP-1 = monocyte chemoattractant protein-1
damage in CKD patients. These ndings suggest that uVDBP could be developed into a
non-invasive urinary marker to monitor tubulointerstitial in
ammation and brosis.
The urinary loss of VDBP in the setting of renal damage has been reported previously
in a rat nephrotoxicity model using urinary proteomics analysis (19), as well as in the
setting of chronic kidney disease (9, 10), but its mechanism has not been documented.
Interestingly, we found that uVDBP was strongly and consistently elevated in a very
early stage of adriamycin-induced nephropathy, even before a detectable increase in the
early pre-brotic marker -SMA. uVDBP was also strongly associated with markers of
both early and late tubulointerstitial brosis (-SMA and collagen III, respectively) in
linear regression analysis adjusted for the time after induction of nephrosis. Of interest,
VDBP excretion was also associated with interstitial in
ammation, even independent of
albuminuria. Its potential as a marker of interstitial in
ammation renders VDBP an even
more interesting candidate biomarker. The fact that these associations persisted after
adjustment for albuminuria suggests that not only protein overload of the megalin/cubulin
complex plays a role in urinary VDBP loss. Rather, damaged tubular epithelial cells in
areas of tubulointerstitial brosis may no longer be able to handle VDBP, resulting in gross
VDBP loss into the urine. Indeed, major factors involved in tubulointerstitial brosis and
in
ammation (e.g. TGF-beta and angiotensin II) negatively regulate receptor-mediated
endocytosis (20, 21).
We and others reported previously that uVDBP is increased in patients with chronic
kidney disease (9, 10), and that it can be modulated by anti-proteinuric treatment in
patients (9), although our previous study was of limited sample size. Our study is in line
with previous work showing that uVDBP increases with increasing severity of diabetic
nephropathy (10). Although the combination of optimal RAAS blockade and dietary
sodium restriction, an intervention considered optimal for renoprotection, considerably
reduced VDBP excretion, it remained > 100-fold increased as compared to healthy nor-
moalbuminuric subjects. This suggests that tubulointerstitial damage, considered the nal
common pathway towards end-stage renal disease (ESRD), persists to a considerable ex-
tent despite current best available therapy. This is in line with previous preclinical studies
showing progression of pre-brotic tubulointerstitial lesions - in spite of optimal reduction
of proteinuria - by ACE inhibition and (very strict) dietary sodium restriction (22). This
may explain at least partly why many patients progress to ESRD despite optimal RAAS
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blockade and dietary sodium restriction - although progression to ESRD is more common
in those with high sodium intake (23).
Limitations of our study include the lack of histopathological data in humans to which
uVDBP could be related, and the largely cross-sectional design. Although in the animal
studies uVDBP was tracked over time, this study does not contain prospective data al-
lowing validation of uVDBP as a biomarker. Strengths of our study, on the other hand,
include the use of 24h-urine samples in both human and the animal studies, and the
equivocal ndings in patients and animals, using two dierent ELISA systems to detect
urinary VDBP. Therefore we believe that our observations can be considered hypothesis-
generating and warrant further studies on the predictive value of urinary VDBP in a
well-characterized cohort with longitudinal follow-up, as well as studies addressing the
associations between uVDBP and histopathological ndings in the clinical setting.
In conclusion, we demonstrated that urinary VDBP excretion is increased early after
renal injury, and is associated with tubulointerstitial in
ammation and brosis indepen-
dently of albuminuria in a rat model of proteinuric nephropathy. In humans, uVDBP
increased with increasing severity of renal damage, and responded to renoprotective ther-
apy. Yet, persisting uVDBP at > 100 times above normal suggested persistent tubuloin-
terstitial damage despite optimal renoprotective therapy. Future studies should address
whether urinary VDBP has predictive value for progression of renal function loss and is
a more suitable early marker of tubulointerstitial damage than those currently available,
to better guide therapy in chronic kidney disease patients.
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A translational approach to the genetics of renal disease
Over the past decades the eld of genetics has evolved rapidly. New tools have become
available to study the genome in increasing detail. Genome-wide screening for genetic
variation, a hypothesis-free approach, allows for the unbiased study of associations be-
tween genetic variants in the whole genome and the phenotype of interest. In contrast,
hypothesis-driven studies focus on a selection of genetic variants, guided by biological
plausibility or results from hypothesis-free studies. Combination of these approaches has
allowed a vast expansion of the body of knowledge on the genetic basis of disease over the
last years. This applies in particular to monogenetic, Mendelian disorders. Unraveling
the genetic basis of common complex disorders such as hypertension and renal disease
however, proved to be a substantially larger challenge. In complex disorders many genetic
and environmental factors are involved. Since each factor only has a small contribution,
the identication and establishment of the relative contribution of these factors can be
dicult. By combining data from studies with dierent discovery strategies, and dierent
sources, nevertheless, gradual progress has been made also for complex disorders. The
main challenge currently is to use the rapidly growing body of knowledge on the genetic
basis of complex disease to fuel progress in clinical medicine. In this thesis, we attempt to
do so for the genetic basis of progressive renal function loss. To this purpose, this thesis
provides an integrative approach to the genetics of renal disease by combining studies on
genetic variation in renal disease (chapters 2 and 4) with studies on the renal phenotypes
that serve the translation of novel genetic ndings towards clinical perspectives in renal
disease (chapters 3 and 5-7).
From quantitative trait locus to candidate gene: ndings from
hypothesis-free studies
Chapter 2 aims to identify genetic loci associated with the renal phenotype albuminuria
using a second generation intercross of A/J mice which spontaneously develop albuminuria
and C57BL/6J mice which do not. The presence of albuminuria was associated with
genetic markers, resulting in the discovery of three quantitative trait loci (QTL), of which
two were concordant with previously discovered QTL for renal damage in rat and human
and one with a locus found in rat. The eect of the absence of the apolipoprotein E gene
(Apoe), a model of spontaneous hypercholesterolemia, was assessed in a second intercross
between A/J mice and B6-Apoe-/- mice. In the Apoe-/- animals the previously mentioned
QTL were not found, however, two other loci were detected. This suggests that the Apoe
pathway is involved in the development of renal disease.
The QTL identied in our study contain many genes that may be involved in re-
nal disease. Using the homology between species, our QTL were mapped to previously
identied QTL for renal phenotypes in mouse, rat and human. Then single nucleotide
polymorphisms (SNPs) between A/J and B6 mice were compared and regions for which
haplotypes diered were identied. With these methods the interval region was narrowed.
However, the resulting region of interest still contained 343 genes that may be involved in
albuminuria.
A QTL that we identied in Apoe-/- mice was also found in another cross between
mouse strains in a follow-up study. In that study gene expression data were analyzed.
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Of the genes in that QTL, the expression of Toll Like Receptor 12 (Tlr12) diered
most between albuminuric and non-albuminuric animals. This dierence was conrmed
with immunohistochemical staining with an antibody against TLR12 protein: the anti-
body stained the distal convoluted tubule of albuminuric animals but not that of non-
albuminuric animals, conrming Tlr12 as the most likely candidate gene for the QTL (1).
This suggests that Tlr12 may also be the gene underlying the QTL we found.
Tlr12, a receptor involved in the innate immune response during infections, has been
associated with kidney infections as shown by the high susceptibility of Tlr12-/- mice to
kidney infections by uropathogenic bacteria (2). Another interesting aspect of Tlr12 as
a candidate gene for albuminuria is its localization in the distal tubule. Albuminuria
is traditionally linked to glomerular albumin leakage and proximal tubular reabsorption.
However, in albuminuric patients the distal tubular damage marker H-FABP is demon-
strated to be elevated in urine (Nauta FL, unpublished). Moreover, urinary H-FABP was
reduced during antiproteinuric intervention (3). Although the distal tubular localization
of TLR12 and the increased excretion of the distal tubular marker H-FABP suggest that
the distal tubule may play a role in albuminuria, we can only speculate about a potential
mechanism. Distal tubular changes may prevent reabsorption of albumin. On the other
hand, albumin in the pre-urine may also damage the distal tubule, resulting in increased
H-FABP excretion.
Since the human genome only contains a non-functional pseudogene for TLR12, the
discovery of TLR12 as a candidate gene for albuminuria in mice may not seem relevant.
However, TLRs have been associated with acute kidney injury, glomerulonephritis, lupus
nephritis, allograft rejection and ischemic renal injury (4) justifying further research into
the role of the Toll Like Receptor family in albuminuria.
Apoe plays a role in receptor-mediated uptake of triglyceride rich lipoprotein par-
ticles. Therefore the Apoe-/- mouse is commonly used as a model for atherosclerosis.
Apoe-/- mice also develop renal damage in the form of glomerular inltration with mono-
cytes/macrophages and glomerular lipid deposits. The tubulointerstitium on the other
hand, is well preserved (5). Tlr12 is upregulated in obese mice, both when obesity re-
sults from a high fat diet and when it results from leptin deciency (6). Since the QTL
which contains Tlr12 as a possible candidate gene was only identied in the atherosclerotic
Apoe-/- intercross, albuminuria resulting from an in
ammatory response in the glomerulus
as seen in atherosclerosis may be mediated by Tlr12. Together, these data demonstrate
that hypothesis-free approaches can contribute to the development of our understanding
of renal pathophysiology. Although one of their advantages is that hypothesis-free ap-
proaches can identify novel pathways in an unbiased manner, it may be more ecient to
study a pathway already suspected to be involved in the development and/or progression
of renal disease.
From genotype to phenotype: a hypothesis-driven approach
This thesis contains several studies on vitamin D as a potential novel factor involved in
the development of progression of renal disease. Classically, vitamin D has been known
as a hormone crucially involved in calcium/phosphate metabolism. Recent studies have
however revealed a broad range of action for vitamin D, with the vitamin D receptor
being expressed in over 70 dierent tissues in the human body (7). Interestingly, recent
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studies have suggested a role for vitamin D in the development and progression of renal
disease. Chapter 3 reviews these so-called non-classical eects of vitamin D, focusing on
the eects that may in
uence the course of renal disease progression. Special attention is
paid to the interaction between vitamin D and the renin-angiotensin-aldosterone system,
one of the most important hormone systems involved in regulation of sodium and volume
homeostasis. Although the interaction between vitamin D and circulating renin levels has
been rst implied in the 1970s, recent elegant studies provided mechanistic insight in the
impact of vitamin D on the regulation of renin gene expression (8). Besides its eects on
the renin-angiotensin-aldosterone system, vitamin D also has anti-in
ammatory properties
which may be benecial in chronic kidney disease. Whether intervention with vitamin D
may actually improve the prognosis of subjects with chronic kidney disease remains to be
demonstrated by (large-scale) randomized controlled trials.
In chapter 4 we report on a study driven by the hypothesis that genetic changes in
the vitamin D pathway may in
uence the course of chronic kidney disease. Low vitamin
D levels in chronic kidney disease patients have been associated with an increased risk of
disease progression and mortality (9, 10). Therefore, the vitamin D pathway has gained
much attention as a possible target for renoprotective intervention in chronic kidney dis-
ease. Furthermore, genetic variation in vitamin D related genes has been associated with
vitamin D levels in previous studies (11, 12), indicating that genetic changes can indeed
aect the intermediate phenotype of vitamin D deciency. Whether the previous two
ndings could be integrated, linking genetic changes in the vitamin D pathway to renal
disease progression, was the subject of our studies. Therefore we genotyped SNPs in
four genes in the vitamin D pathway, namely CYP27B1 or 1-hydroxylase, CYP24A1 or
24-hydroxylase, VDR or vitamin D receptor and GC or vitamin D binding protein, in a
cohort of renal transplant donors and recipients. We identied seven SNPs in CYP24A1,
VDR and GC that had a signicantly dierent prevalence between donors and recipients.
Furthermore, one SNP in CYP24A1 in recipients was associated with all-cause mortality
during follow-up. These results imply that vitamin D plays a role in the development
of end stage renal disease and that genetic variation in genes in the vitamin D pathway
may dierentiate between those who will and those who will not develop end stage renal
disease.
Renal phenotypes
In the association studies described above, the phenotypes, namely end stage renal disease
and all-cause mortality, were very crude. Whereas such crude phenotypes are relevant
because of their clinical impact, more rened phenotyping can be used to focus on specic
renal diseases or renal disease symptoms. A precise denition of the phenotype is essential
to improve the quality of the study and guide interpretation of the results. In studies
of familial diseases, the denition of the phenotype is relatively straightforward, since
familial diseases are usually associated with genetic variations with a strong eect on
phenotype, as is typical for Mendelian inheritance. Chronic kidney disease however, can
be initiated by a variety of underlying renal disorders, and progressive renal function loss,
irrespective of the initial cause, is highly multifactorial. Accordingly, genetic variants that
may be associated with chronic kidney disease are likely to have only very small eects.
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Selecting the most suitable phenotype for the study of progressive renal function loss is
not entirely straightforward either. The classication of chronic kidney disease (CKD) is
based on estimated GFR (eGFR) and albuminuria, so it would be logical to select these
for phenotyping kidney disease - as is frequently done. However, the lack of overlap of
QTL for eGFR and albuminuria points to caution in interpretation of the results. In
addition it should be noted that the phenotype of end stage renal disease is often selected
as an extreme phenotype of progressive renal function loss. Whereas this makes sense,
it should not be overlooked that the population of end stage renal disease does not only
represent those with a propensity to progressive renal function loss, but also those who
were able to survive the excessively high cardiovascular risk in the preceding stages of
renal disease. These considerations clearly demonstrate that a proper understanding of
the clinical phenotype is crucial to interpret ndings from genetic studies.
Estimated GFR: a suboptimal measure of renal function
In most large-scale studies on renal disease the phenotype of interest, chosen as a repre-
sentation of the severity of renal disease, is the estimated GFR. To circumvent expensive
gold-standard measurement of true GFR by a simpler cheaper method, many creatinine-
based renal function equations have been developed, mainly in CKD patients, of which
the equation by Cockcroft and Gault (13), and the more recent MDRD study (14) and
CKD-EPI equations (15) are probably best known. These equations use serum creatinine
and biometric data such as height, weight, gender and race to estimate either creatinine
clearance or glomerular ltration rate. In chapter 5 we found that the accuracy of renal
function equations in renal transplant recipients is relatively poor and therefore unsuitable
for evaluation of individual patients. We identied age, sex, BMI and GFR as sources
of bias in these equations. Since our publication eorts to improve the predictive per-
formance of creatinine-based renal function equations have led to standardization of the
creatinine measurement. However, despite this eort, estimating renal function by means
of a renal function equation remains just that: an estimate (16). A recent genetic study
from our department however, reveals that the degree of bias in renal function equations
is associated with a genetic variant in a gene encoding for a tubular protein (Reznichenko
A, provisionally accepted in Physiol Genomics).
However, eGFR and albuminuria do not represent all aspects of renal damage and are
therefore limited in their ability to predict progression of renal disease. Renal brosis,
in particular tubulointerstitial brosis, is the nal common pathway of most progressive
renal diseases leading to renal insuciency (17). A marker for tubulointerstitial brosis
would be promising for the prediction of end stage renal disease.
Vitamin D binding protein: a marker of brosis?
The main role of vitamin D binding protein (VDBP) is to enable transport of vitamin
D in the circulation. Both the precursor 25-hydroxyvitamin D3 and the active form
1,25-dihydroxyvitamin D3 are lipophilic and bind with high anity to VDBP, an albumin-
like protein.
25-hydroxyvitamin D3 is metabolized in proximal tubular cells of the kidney by 1-
hydroxylase to the active form 1,25-dihydroxyvitamin D3. Vitamin D binding protein
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bound 25-hydroxyvitamin D3 enters the proximal tubular cells from the intraluminal side
after being ltered by the glomerulus. Reuptake into the proximal tubular cell is facili-
tated by megalin-cubilin receptors (18, 19). These same receptors scavenge other proteins
like albumin from the pre-urine (20). Since tubular reabsorption of the VDBP-vitamin D
complex in the proximal tubuli requires active transport, tubular dysfunction would result
in urinary loss of VDBP. In chapter 7 we show that urinary VDBP is indeed a promising
marker for tubular damage in the form of tubulointerstitial brosis. In rats urinary VDBP
excretion was strongly associated with the extent of tubulointerstitial brosis; this associ-
ation remained after adjustment for albuminuria. In CKD patients urinary VDBP is also
associated with tubulointerstitial damage, supporting our hypothesis that urinary VDBP
was increased compared to subjects without albuminuria, urinary VDBP correlated with
established tubular damage markers, and responded to antiproteinuric therapy which is
considered also tubulo-protective, supporting our hypothesis that urinary VDBP can be
a marker of tubulointerstitial damage.
Since proteinuric patients lose VDBP in their urine, we hypothesized that this may
also explain lower circulating vitamin D levels frequently observed in CKD. This hy-
pothesis was tested by measuring not only urinary VDBP but also plasma VDBP and
circulating 25-hydroxy- or 1,25-dihydroxyvitamin D3 levels in patients with or without
antiproteinuric treatment, as reported in chapter 6. We found that urinary vitamin D
binding protein is increased in proteinuric patients compared to normal subjects. How-
ever, urinary vitamin D binding protein loss was not associated with signicant changes
in plasma VDBP, 25-hydroxyvitamin D3 or 1,25-dihydroxyvitamin D3 in proteinuric pa-
tients. Urinary loss of VDBP was substantially reduced by antiproteinuric intervention, in
proportion to proteinuria reduction, by two dierent modes of antiproteinuric treatment.
Yet antiproteinuric treatment did also not aect circulating levels of VDBP or vitamin
D metabolites. Our data therefore do not support the assumption that urinary loss of
VDBP contributes to vitamin D deciency in proteinuric patients, in line with another
study (21).
Future perspectives
Of many common complex disorders like most forms of renal disease genetic components
are largely unknown. Variants in many genes may in
uence the risk of renal disease and
its progression. A part of the results presented in this thesis have been replicated in
other, similar cohorts. In only a fraction of cases, however, a causal mutation is pin-
pointed. What could then be the clinical implications of genetic variations? First, in a
general sense, identied genetic risk proles could help in risk stratication. However,
the risk alleles identied so far explain just a low percentage of the risk variation, and
moreover, of the heritable risk, so obviously, to this purpose, the clinical benet is negligi-
ble. However, for target nding, genetic studies might be of some use. Given the positive
association studies linking vitamin D deciency with CKD progression as summarized
above, as well as consistently positive animal studies (22) on renoprotection by vitamin
D analogues, a growing number of randomized controlled trials with vitamin D has been
initiated. Surprisingly, results have been to some extent disappointing. The VITAL study
demonstrated a borderline signicant 20% reduction of albuminuria on top of standard
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treatment (RAAS blockade) in subjects with diabetic nephropathy (23). The recently
published PRIMO study addressing cardiovascular outcomes after vitamin D analogue
treatment in CKD has been disappointingly negative, as the vitamin D analogue did not
reduce left ventricular mass (24). The discrepancy between the strikingly positive preclin-
ical studies on the one hand, and the disappointing results from randomized controlled
trials on the other hand may be attributed for an important part to inter-individual ge-
netic dierences. Particularly for the vitamin D pathway, the potential clinical impact of
genetic variations has been demonstrated recently. Genetic variation in GC, the gene en-
coding for VDBP, determined the response to vitamin D therapy in healthy subjects (25)
and determined vitamin D requirements in dialysis patients (26). The genetic make-up
of an individual thus determines the potential treatment eect and is therefore clinically
relevant. Using genetic screening, individualized therapy can be prescribed based on the
expected treatment benet given a subjects genetic prole.
Our data illustrate a template for the application of genetic ndings in a translational
perspective aimed at improving understanding and treatment of progressive renal function
loss. Whereas it is obvious that much further study is required to substantiate clinical
benet, nevertheless our data illustrate that further integration of genetic and clinical
tools can provide a strategy to optimize personalized evidence-based medicine.
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133Een translationele benadering van de genetische basis
van nierziekten
In de afgelopen decennia hebben de nieuwe inzichten binnen de genetica elkaar snel op-
gevolgd. Nieuwe manieren om het genoom, alle erfelijke informatie van een organisme,
te bestuderen, zijn beschikbaar gekomen. Een van die manieren is het bestuderen van
het gehele genoom om te zoeken naar genetische varianten die geassocieerd zijn met een
bepaald fenotype. Het fenotype is het totaal aan waarneembare eigenschappen van een
organisme. Deze aanpak van onderzoek is een voorbeeld van een verkennend onderzoek,
ofwel een onderzoek zonder hypothese. Daar staan onderzoeksmethoden tegenover die wel
gebaseerd zijn op een hypothese. Binnen de genetica houdt dat in dat slechts een selec-
tie van genetische varianten wordt bestudeerd, geleid door biologische waarschijnlijkheid.
Door deze twee benaderingen te combineren, is de kennis over het genetische aandeel in
het ontstaan van ziekten enorm toegenomen. Vooral bij aandoeningen die worden ver-
oorzaakt door een variant in  e en speciek gen is op dit gebied voortgang geboekt. Veel
aandoeningen worden echter veroorzaakt door een veelheid aan zowel genetische factoren
als omgevingsfactoren. Omdat elk van die factoren slechts een kleine bijdrage aan het
geheel levert, zijn die niet eenvoudig te identiceren. Door verschillende manieren van on-
derzoek te combineren, wordt langzamerhand ook over deze veel voorkomende, complexe
aandoeningen steeds meer bekend. De grote uitdaging is om het klinische onderzoek te
laten proteren van de groeiende hoeveelheid kennis over de genetische basis van ziekten.
In dit proefschrift wordt getracht dit te bereiken voor de genetische factoren die een rol
spelen bij progressieve achteruitgang van nierfunctie. Dit proefschrift laat een integratie
zien van genetica en klinisch onderzoek door studies naar genetische varianten bij nier-
ziekten (hoofdstuk 2 en 4) te combineren met studies naar een aantal eigenschappen van
de nier teneinde een vertaling van nieuwe genetische ontdekkingen naar klinische inzichten
mogelijk te maken.
Van quantitative trait locus tot kandidaatgen: bevindingen van
verkennende onderzoeken
De nieren zorgen ervoor dat de hoeveelheid water en opgeloste stoen in het bloed constant
blijft en dat afvalstoen uitgescheiden worden in de urine. Een nier bestaat uit 800.000 tot
1,5 miljoen nefronen. Een nefron is de kleinste functionele eenheid van de nier en bestaat
uit een glomerulus en een tubulus. De glomerulus is een soort lter dat grote eiwitten zoals
rode bloedcellen tegenhoudt en dat water, zouten en kleine eiwitten doorlaat. Op deze
manier wordt dagelijks ongeveer 180 liter voorurine geproduceerd. De tubuli zorgen ervoor
dat waardevolle stoen actief of passief teruggeresorbeerd worden en dat afvalstoen extra
uitgescheiden kunnen worden.
Een van de uitingen van een nierziekte is het verlies van eiwit in de urine. In een ge-
zonde nier wordt praktisch al het eiwit dat uit het bloed gelterd wordt en in de voorurine
terecht komt, teruggeresorbeerd door de tubuli. Wanneer in de urine het eiwit albumine
gevonden wordt (albuminurie), duidt dit op nierschade. Dit kan veroorzaakt worden door
een toenemende doorlaatbaarheid van het glomerulaire lter of door onvermogen van de
tubuli om eiwit uit de voorurine te resorberen.
Hoofdstuk 2 heeft tot doel plekken op het genoom, loci, te identiceren die geassocieerd
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zijn met albuminurie. Hiertoe werden A/J-muizen, die spontaan albuminurie ontwikkelen,
gekruist met C57BL/6J-muizen, die gezonde nieren hebben. Door inteelt zijn deze twee
muizenstammen homozygoot; dit betekent dat van elke genetische variant twee identieke
kopie en aanwezig zijn. De eerste generatie nageslacht van de hierboven beschreven kruising
is heterozygoot voor alle genetische varianten. Van de ene ouder kregen ze genetisch
materiaal van de A/J-stam en van de andere ouder van de C57BL/6J-stam. Doordat
muizen van deze generatie dezelfde combinatie van genen hebben, zal er weinig variatie
zijn in hun fenotype. Interessanter is de tweede generatie. De tweede generatie kan van
elke ouder zowel genetisch materiaal erven dat van de ene muizenstam afkomstig is als van
de andere. Deze overerving is willekeurig. Bij de ene muis zal daardoor een groot deel van
zijn genen oorspronkelijk afkomstig zijn uit de A/J-stam, bij de andere muis maar een klein
deel. De grote variatie in genen in deze muizen zorgt voor grote variatie in het fenotype.
In hoofdstuk 2 bleek slechts een klein deel van de tweede generatie muizen albuminurie te
ontwikkelen. De genetische varianten van de muizen met albuminurie werden vergeleken
met de genetische varianten van muizen die geen albuminurie ontwikkelden. Genetische
varianten op drie chromosomen bleken bij muizen met albuminurie signicant vaker voor
te komen dan bij gezonde muizen. Een gebied op een chromosoom dat geassocieerd is
met een kwantitatieve eigenschap zoals albuminurie wordt quantitative trait locus (QTL)
genoemd.
Deze onderzoeksopzet werd opnieuw gebruikt met muizen die geen Apolipoprotein E
(Apoe) kunnen aanmaken. Deze muizen krijgen een te hoog cholesterolgehalte in het
bloed en ontwikkelen daardoor atherosclerose, ofwel aderverkalking. In deze muizen wa-
ren de bovenbeschreven drie plaatsen op het genoom niet geassocieerd met albuminurie.
Wel werden twee andere QTL ge denticeerd. Dit suggereert dat de werking van het
cholesterolmetabolisme invloed heeft op de manier waarop nierschade met albuminurie
ontstaat.
De QTL die in dit onderzoek ge denticeerd zijn, zijn zo groot, dat ze honderden genen
omvatten. Om een aangrijpingspunt te hebben voor behandeling van de albuminurie, is
het noodzakelijk te weten welk van die honderden genen albuminurie veroorzaakt. Hiertoe
werden de QTL vergeleken met QTL uit eerder onderzoek, met andere muizenstammen
of in ratten of mensen. Hierdoor werd het aantal kandidaatgenen teruggebracht tot 343.
Dit aantal is erg groot om per gen te onderzoeken.
Anderen hebben met dezelfde onderzoeksopzet een gebied ge denticeerd dat overlapt
met een QTL die we hebben gevonden in muizen zonder Apoe. Bij het meten van de
eiwitexpressie van alle genen die in het gebied liggen dat geassocieerd is met albuminurie,
sprong er een eiwit uit. Dit eiwit, Toll Like Receptor 12 (TLR12), speelt een rol in
het immuunsysteem wanneer er een infectie is. Aangezien dit gebied op het genoom
alleen geassocieerd was met albuminurie in muizen die geen Apoe kunnen aanmaken,
wordt albuminurie bij deze muizen mogelijk veroorzaakt door een ontstekingsreactie op
atherosclerose in de glomeruli.
De mens heeft geen functionele equivalent van het TLR12-gen. Men zou kunnen den-
ken dat de ontdekking dat het TLR12-gen bij muizen geassocieerd is met albuminurie niet
relevant is voor het onderzoek bij mensen. Bij mensen zijn echter in diverse onderzoeken
andere TLRs ge denticeerd die geassocieerd zijn met nierziekten zoals glomerulonefritis,
waarbij de glomeruli van de nieren zijn aangedaan, en afstoting van een getransplanteerde
nier, waardoor nader onderzoek naar de rol van de Toll Like Receptor-familie gerecht-
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onbevooroordeelde aanpak kan leiden tot de identicatie van nieuwe reactiepaden die be-
trokken kunnen zijn bij het ontstaan van een ziekte. Wanneer mogelijk, kan het eci enter
zijn om gerichter onderzoek te doen naar reactiepaden waarvan al vermoed wordt dat ze
betrokken zijn bij het ontstaan dan wel bij de progressie van nierziekten.
Van genotype naar fenotype: bevindingen van op een hypothese
gebaseerde onderzoeken
Dit proefschrift bevat een aantal onderzoeken naar vitamine D als factor in de ontwikke-
ling van nierziekte. Van oudsher is vitamine D bekend uit de calciumfosfaathuishouding.
De laatste jaren worden steeds meer functies van vitamine D ontdekt. De vitamine D
receptor is in meer dan 70 verschillende weefsels in het menselijk lichaam aangetoond.
Ook bij de ontwikkeling en progressie van nierziekten lijkt vitamine D een rol te spe-
len. In hoofdstuk 3 wordt een overzicht gegeven van wat er in de literatuur bekend is
over de zogenaamde niet-klassieke eecten van vitamine D, vanuit het oogpunt van de
invloed van vitamine D op de progressie van nierziekte. Beschreven wordt onder andere
de interactie tussen vitamine D en het renine-angiotensine-aldosteronsysteem, een van de
belangrijkste hormonale systemen in de water- en zouthuishouding. Al in de jaren '70
werd gesuggereerd dat vitamine D invloed had op de reninespiegels in het bloed. Het
onderliggende mechanisme, namelijk dat vitamine D door binding aan het reninegen de
eiwitexpressie van renine reguleert, is veel minder lang bekend. Naast de eecten op het
renine-angiotensine-aldosteronsysteem heeft vitamine D ook ontstekingsremmende eigen-
schappen. Dit zou gunstige eecten kunnen hebben bij chronische nierinsuci entie. Of
behandeling met vitamine D daadwerkelijk de prognose van chronische nierpati enten kan
verbeteren, moet nog aangetoond worden in grote klinische studies.
In twee grote onderzoeken is ontdekt dat er varianten zijn in genen die onderdeel zijn
van het vitamine-D-metabolisme die geassocieerd zijn met lage vitamine-D-spiegels in het
bloed. Lage vitamine-D-spiegels in het bloed bij pati enten met chronische nierinsuci entie
zijn geassocieerd met een grotere kans op progressie van de ziekte en met sterfte. In hoofd-
stuk 4 wordt daarom onderzocht of er genetische varianten in het vitamine-D-metabolisme
zijn die invloed hebben op het ontstaan en beloop van chronische nierinsuci entie. Daar-
toe richtten we ons op single nucleotide polymorphisms (SNPs) - dit zijn variaties in het
DNA van  e en nucleotide lang - in enkele genen uit het vitamine-D-metabolisme, namelijk
CYP27B1, het gen dat codeert voor het eiwit 1alfa-hydroxylase, CYP24A1, dat codeert
voor 24-hydroxylase, VDR dat codeert voor vitamine D receptor en GC dat codeert voor
vitamine-D-bindend eiwit. Deze genen zorgen respectievelijk voor het omzetten van vi-
tamine D naar de actieve vorm, het afbreken van de actieve vorm van vitamine D of de
voorloper ervan naar een inactieve vorm, het binden van vitamine D waardoor vitamine D
in dat weefsel zijn invloed kan uitoefenen en het binden van vitamine D wanneer het zich
in de bloedsomloop bevindt. In een cohort niertransplantaatontvangers en nierdonoren
hebben we deze SNPs gegenotypeerd. We hebben zeven SNPs gevonden die niet even
vaak voorkomen in ontvangers en donoren. Bovendien hebben we in het gen voor 24-
hydroxylase een SNP ge denticeerd die geassocieerd is met sterfte, ongeacht de oorzaak,
gedurende het vervolgen van de niertransplantaatontvangers. Deze resultaten suggereren
dat het vitamine-D-metabolisme een rol speelt in de ontwikkeling van terminale nierin-
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suci entie. Mogelijk kunnen aan de hand van deze bevindingen mensen die terminale
nierinsuci entie zullen krijgen, onderscheiden worden van de mensen die dit niet krijgen.
Renale fenotypes
Renale fenotypes zijn waarneembare eigenschappen van een organisme die betrekking
hebben op de nier, zoals de grootte van de nier, albuminurie of de nierfunctie. In de as-
sociatiestudies die hierboven beschreven zijn, waren de fenotypes nogal algemeen. Zowel
albuminurie als terminale nierinsuci entie kunnen het gevolg zijn van een grote verschei-
denheid aan oorzaken. Hoewel onderzoek naar zulke algemene fenotypes van belang is
vanwege de grote klinische betekenis, kan het nauwkeuriger deni eren van het fenotype
gebruikt worden voor onderzoek naar specieke nierziekten of symptomen. Een nauwkeu-
rige denitie van het fenotype is essentieel voor de kwaliteit van de studie en de inter-
pretatie van de resultaten. In studies naar erfelijke aandoeningen is de denitie relatief
duidelijk, bijvoorbeeld het wel of niet hebben van de aandoening. Dit kan bij erfelijke aan-
doeningen vertaald worden naar de aan- of afwezigheid van dezelfde genetische variant.
Chronische nierinsuci entie daarentegen, kan het gevolg zijn van een heleboel verschil-
lende onderliggende aandoeningen. Iedere pati ent zal een eigen combinatie van factoren
hebben die hebben geleid tot het ontstaan van de chronische nierinsuci entie. Ook de
ziekteprogressie hangt van veel factoren af.
De selectie van het meest geschikte fenotype voor progressieve nierziekte is niet een-
duidig. De classicatie van chronische nierinsuci entie is gebaseerd op de geschatte glo-
merulaire ltratiesnelheid en albuminurie. Het ligt voor de hand om het fenotype nier-
ziekte aan de hand daarvan te deni eren. Uit het onderzoek naar QTL voor de geschatte
glomerulaire ltratiesnelheid en albuminurie is bekend dat er weinig overlap is tussen
beide. Bij interpretatie van studieresultaten zal rekening gehouden moeten worden dat de
genetische factoren die de geschatte glomerulaire ltratiesnelheid en albuminurie bepalen,
waarschijnlijk niet dezelfde zijn. Terminale nierinsuci entie wordt vaak als extreem feno-
type van progressieve nierziekte gekozen. Hoewel dit logisch lijkt, moet men niet vergeten
dat deze pati entengroep naast de aanleg om een ernstige nierziekte te ontwikkelen, ook
de aanleg heeft om het sterk verhoogde cardiovasculaire risico dat gepaard gaat met nier-
ziekte, te overleven. Deze overwegingen illustreren dat een goed begrip van het klinische
fenotype cruciaal is voor de interpretatie van resultaten van klinische onderzoeken.
Geschatte glomerulaire ltratiesnelheid: een suboptimale maat
voor de nierfunctie
In veel grootschalige studies naar nierziekte wordt als maat van de ernst van nierziekte de
geschatte glomerulaire ltratiesnelheid genomen. Een gouden standaard voor het bepalen
van de glomerulaire ltratiesnelheid (GFR) betreft de klaring van 125I-iothalamaat. De
GFR wordt gemeten door constante toediening van dit radioactief gelabelde molecuul via
een infuus, waardoor deze bepaling alleen tijdens een dagopname in het ziekenhuis kan
plaatsvinden. Omdat het bepalen van de nierfunctie met deze methode niet mogelijk is
bij grote groepen pati enten, zijn vergelijkingen ontwikkeld om op basis van serum cre-
atinine en biometrische gegevens als geslacht, leeftijd, lengte en gewicht de nierfunctie
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Tegenwoordig worden de MDRD en CKD-EPI-vergelijkingen veelvuldig gebruikt. Deze
vergelijkingen hebben echter hun beperkingen. In hoofdstuk 5 vonden we dat de nauw-
keurigheid van deze vergelijkingen in niertransplantaatontvangers te wensen over laat,
waardoor de betekenis ervan voor de individuele pati ent gering is. Leeftijd, geslacht,
body mass index en GFR dragen bij aan de systematische fout in deze vergelijkingen.
Sinds de publicatie van dit artikel is getracht de voorspellende waarde te verbeteren door
de creatininebepaling te standaardiseren. Desondanks blijft de geschatte GFR precies dat:
een schatting. Een recente studie in ons centrum heeft aangetoond dat een genetische va-
riant in een gen coderend voor een tubulair eiwit geassocieerd is met de grootte van de
systematische fout in nierfunctievergelijkingen.
De geschatte glomerulaire ltratiesnelheid en albuminurie vertegenwoordigen echter
niet alle aspecten van nierschade en hebben daardoor een beperkte waarde bij de voor-
spelling van progressie van nierziekte. Onafhankelijk van de onderliggende nierziekte
wordt vergaande progressie gekenmerkt door brose, en met name tubulo-interstiti ele -
brose. Dit is verbindweefseling van de ruimte tussen de tubuluscellen, met als gevolg dat
de tubuli minder goed functioneren. Een marker voor tubulo-interstiti ele brose zou een
veelbelovende marker voor terminale nierinsuci entie kunnen zijn.
Vitamine-D-bindend eiwit: een marker voor brose?
De belangrijkste rol van het vitamine-D-bindend eiwit is om transport van vitamine D in
de circulatie mogelijk te maken. Zowel de inactieve als de actieve vorm van vitamine D
zijn lipoel en lossen slecht op in waterige oplossingen, zoals bloed. Bijna alle vitamine
D in de bloedsomloop is gebonden aan eiwitten, voornamelijk aan vitamine-D-bindend
eiwit.
De inactieve vorm van vitamine D wordt in de proximale tubuluscellen van de nier
omgezet onder invloed van 1alfahydroxylase tot actief vitamine D. Vitamine-D-bindend
eiwit met daaraan gebonden inactief vitamine D wordt in de glomerulus van de nier
gelterd. Dit vitamine-D-bindend eiwit-vitamine D-complex wordt actief opgenomen in
de proximale tubulus via de megaline- en cubilinereceptoren. Deze twee receptoren nemen
ook andere eiwitten zoals albumine op uit de voorurine, zodat er geen eiwit in de urine
terecht komt. Aangezien er energie nodig is voor deze actieve opname in de cel, zal de
opname van vitamine-D-bindend eiwit-vitamine D-complex in de proximale tubuluscel
onder druk komen te staan wanneer de tubulus beschadigd is en niet goed functioneert.
Dit resulteert in verlies van vitamine-D-bindend eiwit in de urine. In hoofdstuk 7 laten we
zien dat vitamine-D-bindend eiwit in de urine een veelbelovende marker is voor tubulaire
schade in de vorm van tubulo-intersiti ele brose. Bij ratten was uitscheiding van vitamine-
D-bindend eiwit in de urine sterk geassocieerd met de mate van tubulo-interstiti ele brose,
zelfs nadat rekening was gehouden met de mate van albuminurie. Ook bij pati enten
met chronische nierinsuci entie was de uitscheiding van vitamine-D-bindend eiwit in de
urine geassocierd met tubulo-interstiti ele schade, wat de hypothese ondersteunt dat de
uitscheiding van vitamine-D-bindend eiwit hoger is bij pati enten met albuminurie dan
bij met pati enten zonder albuminurie. De uitscheiding van vitamine-D-bindend eiwit
correleert met andere markers van tubulaire schade en verminderde bij anti-prote nurische
behandeling, die gezien wordt als beschermend voor de tubulus. Vitamine-D-bindend eiwit
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in de urine kan dus een marker zijn voor tubulo-interstiti ele schade.
Aangezien pati enten met prote nurie ook vitamine-D-bindend eiwit verliezen in de
urine, hebben we de hypothese onderzocht dat het verlies van vitamine-D-bindend eiwit
in de urine de verklaring is voor lage vitamine-D-spiegels die vaak worden gezien bij
pati enten met chronische nierinsuci entie. Hiertoe hebben we vitamine-D-bindend eiwit
in de urine en het plasma gemeten en ook spiegels van inactief en actief vitamine D bepaald
bij pati enten met en zonder antiprote nurische behandeling, zoals beschreven in hoofdstuk
6. In vergelijking met gezonde mensen scheiden pati enten met prote nurie meer vitamine-
D-bindend eiwit uit in de urine. De mate van verlies van vitamine-D-bindend eiwit in de
urine was niet geassocieerd met verschillen in de plasmaspiegels van vitamine-D-bindend
eiwit, en evenmin met plasmaspiegels van inactief en actief vitamine D bij pati enten met
prote nurie. Het verlies van vitamine-D-bindend eiwit in de urine werd signicant verlaagd
wanneer pati enten antiprote nurische behandeling kregen; in proportie met de reductie in
prote nurie. Dit werd met twee verschillende vormen van antiprote nurische behandeling
bereikt. Toch had antiprote nurische behandeling geen eect op de spiegels van vitamine-
D-bindend eiwit, inactief of actief vitamine D. Deze resultaten kunnen de hypothese dat de
lage vitamine-D-spiegels bij pati enten met chronische nierinsuci entie worden verklaard
door een verlies van vitamine D gebonden aan vitamine-D-bindend eiwit in de urine dus
niet bevestigen, zoals in een andere studie ook werd gevonden.
Toekomstperspectief
Van een groot aantal veel voorkomende complexe aandoeningen zoals de meeste vormen
van nierziekte is de genetische basis grotendeels onbekend. Varianten in veel verschillende
genen kunnen de kans op het krijgen van een nierziekte en de progressie ervan be nvloeden.
Een deel van de resultaten die in dit proefschrift gepresenteerd worden, zijn gerepliceerd
in andere vergelijkbare pati entengroepen. In slechts een klein deel van de gevallen is dui-
delijk geworden welke genetische variatie oorzakelijk is. Wat kunnen dan de klinische
implicaties zijn van genetische variaties? Ten eerste kan met behulp van genetische varia-
ties een risicoproel worden samengesteld, waarmee voorspeld zou kunnen worden hoeveel
risico iemand heeft op een nierziekte en hoe groot de kans op progressie van de nierziekte
is. Op dit moment verklaren de ge denticeerde risicodragende genetische variaties slechts
een klein percentage van de variatie in risico en daarmee de erfelijke component van het
risico. Het klinische belang is daardoor op dit moment verwaarloosbaar. Genetische stu-
dies kunnen wel van nut zijn bij de identicatie van aangrijpingspunten voor interventie.
Gezien de positieve studies die een lage vitamine-D-spiegels in het bloed associ eren met
progressie van nierziekte zoals hierboven is samengevat en consistent positieve resultaten
in dierstudies waarbij behandeling met vitamine-D-analogen beschermend werkt voor de
nier wordt een toenemend aantal klinische studies gestart. Helaas zijn de resultaten tot nu
toe enigszins teleurstellend. De VITAL-studie, waarbij het eect van vitamine-D-analoog
paricalcitol op albuminurie bij pati enten met type II diabetes werd onderzocht, was op
de grens van signicant. Bij de PRIMO-studie, die het eect van een vitamine-D-analoog
op structuur en functie van het hart testte, kon geen positief eect op de massa van
de linkerkamer van het hart aantonen. De discrepantie tussen de positieve pre-klinische
studies aan de ene kant en teleurstellende resultaten van klinische studies aan de andere
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genetische verschillen. Juist voor het vitamine-D-metabolisme is de potenti ele klinische
impact van genetische variaties aangetoond. Genetische variaties in het gen dat codeert
voor het vitamine-D-bindend eiwit bepalen hoe goed gezonde mensen reageren op vita-
mine D behandeling en bepalen de vitamine D behoefte bij dialysepati enten. Het totaal
aan genetische variaties dat iemand bij zich draagt, bepaalt dus potentieel het eect dat
behandeling met vitamine D heeft en is daarmee klinisch relevant. Met behulp van gene-
tisch screenen kan in de toekomst ge ndividualiseerde behandeling worden voorgeschreven
die past bij het gevonden specieke genetische proel.
Onze resultaten tonen een model voor de toepassing van genetische bevindingen van-
uit een translationeel perspectief gericht op kennisverwerving over en verbetering van de
behandeling van progressieve achteruitgang van nierfunctie. Hoewel er nog veel onderzoek
nodig is voordat genetische inzichten werkelijk hun klinische toepassing zullen vinden in de
dagelijkse praktijk van de behandeling van pati enten met een nierziekte, illustreren onze
resultaten dat een verdere integratie van genetische en klinische onderzoeksmethoden een
strategie bieden voor het optimaliseren van personalized evidence-based medicine.
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een scala aan nieuwe briljante plannen. Bedankt voor je geduld en vertrouwen, het boekje
is nu af.
En mijn co-promotor dr. M.H. de Borst, beste Martin, ongeloo
ijk, hoe je het onder-
zoek kan combineren met je opleiding tot internist-nefroloog en een geweldig jong gezin.
Mailtjes om 4 uur 's nachts wanneer je nachtdienst had, zijn mogelijk deel van de verkla-
ring. Je kennis van en belangstelling voor vitamine D in zowel experimenteel als klinisch
onderzoek waren enorm waardevol. Hopelijk ziet iedereen binnenkort het licht: behande-
ling met vitamine D is de toekomst!
Prof. dr. T.P. Links, prof. dr. H. Snieder en prof. dr. P. Heeringa, de leden van de
leescommissie, wil ik graag bedanken voor de tijd en energie die zij hebben willen steken
in het beoordelen van mijn proefschrift. Prof. dr. H. Snieder wil ik bovendien bedanken
voor de waardevolle adviezen, aanvullingen en correcties op hoofdstuk 2.
Dr. J. van den Born, beste Jaap, je ervaring met experimenteel onderzoek was voor
mij als medicus erg waardevol. Met een kritische blik wist je bij elke bespreking nuttige
suggesties te doen. Je aanstekelijke enthousiasme bij het bekijken van een kleuring werkt
motiverend.
Prof. dr. H. van Goor, beste Harry, je snelle en pragmatische feedback op protocollen
en bijbehorende kleuringen heb ik zeer gewaardeerd.
Dr. R. Korstanje, beste Ron, tijdens mijn wetenschappelijke stage heb ik veel van je
geleerd over de genetica. Ik ben blij dat je in het Jackson Lab je ideale werkplek gevonden
hebt.
Experimenteel onderzoek is niet mogelijk zonder de hulp, kennis en ervaring van ana-
listen. Jelleke, als eerste analist in een nieuw lab zijn je organisatorische talenten on-
misbaar gebleken. Daarnaast werd het lab een leukere plek om te werken. Wendy, jouw
komst in het lab bracht meer structuur. Bedankt voor je ondersteuning van het vitamine
D-onderzoek. Anita, hoewel je niet direct bij mijn projecten betrokken was, wil ik je
bedanken voor de goede sfeer in het lab en daarbuiten.
Ook Linda en Germaine van de experimentele cardiologie wil ik graag bedanken voor
hun belangeloze adviezen en uitleg over celkweek en het opzetten van PCR in de tijd dat
de experimentele nefrologie nog geen analist had.
Bij de afdeling Pathologie gaat mijn dank uit naar Marian. Marian, hoe je bijhoudt
142Dankwoord
waar welke blokjes liggen, is me een raadsel. Ik ben blij dat jij er was om me te helpen
met zoeken naar de juiste materialen. Beste Winie, je deur staat altijd open voor een
belangstellend praatje. Bedankt daarvoor en voor je hulp.
Onderzoek doen zou een stuk saaier zijn geweest zonder collega's. Kiran, we've sat
next to each other for years. I enjoy your positivity and wish you a great time in Georgia
with Shruti. Pramod, ik waardeer je oplossingsgerichte benadering van problemen en je
humor. Fijn dat Meena en jij nog een jaar in Nederland kunnen blijven. Giuseppe, ik
bewonder de manier waarop je allerlei zaken gedaan wist te krijgen. Daar moet je Italiaan
voor zijn denk ik. Je wordt gemist. Azi, je hebt me geleerd dat zaken die in Nederland
vanzelfsprekend zijn, dat in andere landen niet altijd zijn. Ik ben blij dat je nog een jaar
in Nederland kan blijven. Anna, genetisch expert van het lab, bedankt voor je hulp bij
mijn SNP-analyses. Het lezen van Russische e-mails was erg gezellig, ook al begrijp ik
nog steeds niet waar ze over gaan. Veel succes in het Jackson lab. Saritha, thank you for
being such a cheerful roommate and thanks for taking over the experimental nephrology
e-mails. Shanthi, thank you for your positivity, even when things were not as they should
be. Saleh, the changing backgrounds on your computer were a welcome distraction from
work. I enjoyed our very ecient trip to Croatia. I think we could not have seen more in
the few days we were there. Katarina, I valued our talks about vitamin D, research and
other things. Thank you for the opportunity to be present at your wedding. You'll get
the pictures, I promise. Leandro, I really enjoyed the salsa dancing, maybe you should
teach me some more! Maaike, eindelijk iemand om in snel tempo Nederlands mee te
praten! Bedankt voor je initiatieven voor gezellige dingen. Ook de vele studenten die
stage hebben gelopen in het lab wil ik bedanken: Milton, Ditmer, Edwin, Menno, Kim,
Willemien, Eva, Bernardo, Willem, Julian, Leo thank you for the good times. I really
enjoyed our multinational multilingual group of colleagues with Indian dinners, drinks and
the gezellige atmosphere. And honestly: four years was not enough: Meri Hindi kooch
khas nahi hai. :)
Ook de collega-onderzoekers in de Kidney Alley, bij Prevend, bij de pathologie en bij
aanverwante afdelingen wil ik bedanken voor de gezelligheid (in willekeurige volgorde):
Else, Hilde, Dorien, Arjan, Alaa, Tjitske, Solmaz, Maartje, Jan, Folkert, Steef, Hiddo,
Leendert, Rutger, Jerey, Jelena, Mirjan, Auke, Gemma, Wynand, Eelke, Paulien, Jaco-
line, Sasha, Rutger, Martine, Maria, Astrid, Marije, Akin, Nynke, Inge, Mieneke, Titia,
Femke, Andrea, Judith, Aiko, Sasha, Ferdau, Esther, Wendy, Lieneke, Laura, Hanneke,
Heleen, Miriam, Sander, Michel, Merel en vele anderen.
Mijn nieuwe collega's bij Cardio Research wil ik graag bedanken voor hun steun bij de
laatste loodjes van dit proefschrift.
Waar de dagen besteed werden aan onderzoek, vulden de avonden zich met Toesactivi-
teiten. Ik ben blij deel uit te maken van zo'n leuke vereniging. Ik wil alle (oud-)leden van
Studenten Stijldansvereniging The Blue Toes graag bedanken voor de gezelige tijd, met
name Jan Willem (hoe houd je het al meer dan zeven jaar uit als mijn danspartner?) en
Sandra (succes met de bruidsjurk!), Joke (ik ben blij zo'n zorgzame vriendin te hebben)
en Willem, Jarno en Marije (bedankt voor de vele spelletjesmiddagen), Maarten (zullen
we gaan zeilen als het mooi weer is?), Jan Willem, Boy, Marten, Thomas en Marije, Els,
Hans en Laura, Tina, Carlijn en Erik, Petra, Alex (Keep on playing your music, I'm sure
143you'll nd a way), Ingeborg en Andr e (dat dit boekje is gelay-out in L ATEX is jouw invloed,
veel succes in Canberra!). Annechien, jn dat je mijn paranimf wil zijn.
Daarnaast wil ik de Carla, Dinet, Jaap, Jet, Loukie, Karline, Carolien, Hanneke,
Annemieke, Jos, Sigi, Mirjam en natuurlijk Jankees van barokensembles 1 en 2 bedanken
voor het gezellig samen spelen op woensdagavond.
Woensdagavond is ook de avond van de pubquiz. In wisselende samenstellingen worden
wisselende resultaten behaald. Bas, David, Sandra, Annechien, Sander, Marije, Jarno,
Boy en Reeuwerd, bedankt voor de gezelligheid en op naar de volgende 
es wijn (of de
derde plaats, dat mag ook).
Ooms, tantes, neven en nichten, leden van de clique en anderen, bedankt voor jullie
belangstelling voor mijn onderzoek.
Lieve oma's, ik ben blij dat jullie er op deze bijzondere dag bij kunnen zijn. Lieve
Jeroen, bedankt dat je er altijd voor me bent en ervoor weet te zorgen dat alles goed
komt. Bedankt voor het maken van de voorkant van dit boekje. Met jou als paranimf
komt de organisatie zeker goed. Lieve Marianne, ik heb genoten van onze reizen naar
Barcelona, de Azoren en Botswana. Waar zullen we heen in je volgende roostervrije
periode? Lieve ouders, bedankt dat jullie me in de gelegenheid hebben gesteld om mijn
studie en promotieonderzoek af te ronden. Zonder jullie liefde en steun was dit boekje er
niet geweest.
144List of publications
1. Doorenbos CRC, Navis GJ, van den Born J, Damman J, Snieder H, Leuvenink
HGD, van Goor H, Hillebrands JL, van Dijk MCRF, Hepkema BG, Reznichenko A,
Bakker SJL, Ploeg RJ, Seelen MA, de Borst MH. Genetic variants in the vitamin
D pathway are associated with end-stage renal disease and outcome after human
kidney transplantation. In preparation.
2. Mirkovic K*, Doorenbos CRC*, Dam WA, Lambers Heerspink HJ, Slagman MCJ,
Nauta FL, Kramer AB, Gansevoort RT, van den Born J, Navis GJ, de Borst MH.
Urinary vitamin D binding protein: a potential novel marker of interstitial in
am-
mation and brosis. PLoS One. Provisionally accepted. * authors contributed
equally
3. Doorenbos CRC, de Cuba MM, Vogt L, Kema IP, van den Born J, Gans ROB,
Navis GJ, de Borst MH. Antiproteinuric treatment reduces urinary loss of vitamin
D-binding protein but does not aect vitamin D status in patients with chronic
kidney disease. J Steroid Biochem Mol Biol. 2012 Jan;128(1-2):56-61.
4. Doorenbos CRC, Van den Born J, Navis GJ, De Borst MH. Possible renopro-
tective eects of vitamin D: beyond mineral metabolism. Nat Rev Nephrol 2009
Dec;5(12):691-700.
5. Doorenbos CRC, Bruin EJ, Tsaih S, Ishimori N, Navis GJ, Churchill GA, Paigen
BJ, DiPetrillo KJ, Korstanje R. Quantitative trait loci for urinary albumin in crosses
between C57BL/6J and A/J inbred mice in the presence and absence of Apoe Ge-
netics. 2008 May;179(1):693-9.
6. Bosma RJ, Doorenbos CRC, Stegeman CA, van der Heide JJ, Navis GJ. Predictive
performance of renal function equations in renal transplant recipients: an analysis
of patient factors in bias. Am J Transplant. 2005 Sep;5(9):2193-203.
7. Doorenbos CRC, Vogt L. Onduidelijke betekenis van natriuretisch-peptidespiegels
bij overgewicht in relatie tot hypertensie en cardiovasculair risico. Ned Tijdschr
Geneeskd. 2005;149:550-1.
145